<SEC-DOCUMENT>0000856982-20-000041.txt : 20201016
<SEC-HEADER>0000856982-20-000041.hdr.sgml : 20201016
<ACCEPTANCE-DATETIME>20201016172833
ACCESSION NUMBER:		0000856982-20-000041
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20201013
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201016
DATE AS OF CHANGE:		20201016

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MERIT MEDICAL SYSTEMS INC
		CENTRAL INDEX KEY:			0000856982
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				870447695
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-18592
		FILM NUMBER:		201244756

	BUSINESS ADDRESS:	
		STREET 1:		1600 WEST MERIT PARK WAY
		CITY:			SOUTH JORDAN
		STATE:			UT
		ZIP:			84095
		BUSINESS PHONE:		8012531600

	MAIL ADDRESS:	
		STREET 1:		1600 WEST MERIT PARKWAY
		CITY:			SOUTH JORDAN
		STATE:			UT
		ZIP:			84095
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mmsi-20201013x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7556.35618 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 10/16/2020 9:26:25 PM -->
      <!-- iXBRL Library version: 1.0.7556.35625 -->
      <!-- iXBRL Service Job ID: 6cb683e1-eb88-4b2e-88c5-72c8b460edda -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mmsi="http://www.merit.com/20201013" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig" name="dei:EntityCentralIndexKey" id="Tc_D7TGQShzE0KPqd7DFPj_hA_2_1">0000856982</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig" name="dei:AmendmentFlag" id="Tc_NwLtxPWj8EeTZuqig3pmrw_3_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig" name="dei:EntityRegistrantName" id="Hidden__CX5Zu6a-US0rFDjN6L4cQ">MERIT MEDICAL SYSTEMS INC</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="mmsi-20201013.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000856982</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-13</xbrli:startDate><xbrli:endDate>2020-10-13</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:50.24pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_acea19b6_f380_437e_9344_e805d8ad182f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C.&#160; 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig" name="dei:DocumentType" id="Narr_pK-JLRrmJEWcRHTAyM7XcA"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Date of Report (date of earliest event reported): </span><ix:nonNumeric contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_3rrz0JuCXUe9IAbH9R7eJg"><span style="font-size:9pt;">October 13, 2020</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="mmsi-20201013x8k001.jpg" alt="Graphic" style="display:inline-block;height:50.24pt;width:279.71pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden__CX5Zu6a-US0rFDjN6L4cQ"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:17pt;font-style:normal;font-weight:bold;text-align:center;">Merit Medical Systems,&#160;Inc.</b></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_a9f42b70_becf_4065_9163_18d812720dc3"></a><a id="Tc_S8UX4NQgQkqVlxt3VPOFtg_2_0"></a><a id="Tc_y96c9ItFpUaOOhn3_lW4Rg_2_2"></a><a id="Tc_l9JtmNTuGkOaI0jK50tQGQ_2_4"></a><a id="Tc_faZZvJl1aUSWrWtT6k1ngw_3_0"></a><a id="Tc_nevMvLnXMkGCyg2FJco8SQ_3_2"></a><a id="Tc_PZhWHpFA60KwcGa_uIDIEQ_3_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.04%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:23.6%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:33.19%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.04%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_jmdvAA8hKEWPCPjakEbWng_1_0"><b style="font-size:9pt;font-weight:bold;">Utah</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:23.6%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig" name="dei:EntityFileNumber" id="Tc_gMjSD8NizEWWYBQbPtD_dQ_1_2"><b style="font-size:9pt;font-weight:bold;">0-18592</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:33.19%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig" name="dei:EntityTaxIdentificationNumber" id="Tc_uLz39PH8jUeEVBGTMwkcPw_1_4"><b style="font-size:9pt;font-weight:bold;">87-0447695</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:38.04%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(State or other jurisdiction of</p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.6%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Commission</p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.19%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(I.R.S. Employer</p></td></tr><tr><td style="vertical-align:bottom;width:38.04%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">incorporation or organization)</p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.6%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">File Number)</p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.19%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_a46fc64f_fd15_4263_b177_c3932843b5d7"></a><a id="Tc__OGV0Yrrd0mNyCQidV_Qlw_2_0"></a><a id="Tc_saLPPGwVkEuLydcC3ya5dw_3_0"></a><a id="Tc_kDqVpg8OtE2lh9QJxUrriw_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.97%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:46.96%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.97%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig" name="dei:EntityAddressAddressLine1" id="Tc_lSccnRLs10SmsfLQYbfFzQ_1_0"><b style="font-size:9pt;font-weight:bold;">1600 West Merit Parkway</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:46.96%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.97%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig" name="dei:EntityAddressCityOrTown" id="Narr_qPB3st1P10us2Igu94NBBQ"><b style="font-size:9pt;font-weight:bold;">South Jordan</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="Narr_phkVjhK5Vk6tGlkhNNaaYw"><b style="font-size:9pt;font-weight:bold;">Utah</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.96%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig" name="dei:EntityAddressPostalZipCode" id="Tc_3v8P_MD2nkeNEPtMsdHgGg_2_2"><b style="font-size:9pt;font-weight:bold;">84095</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:50.97%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.96%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig" name="dei:CityAreaCode" id="Narr_o316idkVX0uNXZaBMDwATA"><b style="font-size:9pt;font-weight:bold;">801</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig" name="dei:LocalPhoneNumber" id="Narr_D98cUfVJ-EGW-Cirm9APGQ"><b style="font-size:9pt;font-weight:bold;">253-1600</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Registrant&#39;s telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Former name or former address, if changed since last report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_fRB_wH2WZ0OmXVlIDHUMYA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;&#160;Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr__2fVXgeczkCus8551t9ILA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_LjtltwS_50OGoYVKSXVqrw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_nHH52VZTWEaGB45QTjhSag"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_6100c6e9_d517_497c_a55b_abb2322aab5e"></a><a id="Tc_YZr1xNijXk69XPNgBS9uVQ_0_0"></a><a id="Tc_Y5p5Ysazb0qJJbjJKHHIEg_0_2"></a><a id="Tc_U338S7W_cEeNoAWVd1zwXw_0_4"></a><a id="Tc_CxUzUiMy6kqaEio05viUOQ_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:bottom;width:31.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Title&#160;of&#160;each&#160;class</p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:20.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Trading&#160;Symbol(s)</p></td><td style="vertical-align:bottom;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered</p></td></tr><tr><td style="vertical-align:top;width:31.7%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig" name="dei:Security12bTitle" id="Tc_pzwSR8gahk2DW_PxaK2dXQ_1_0"><span style="font-size:9pt;">Common Stock, no par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.06%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig" name="dei:TradingSymbol" id="Tc_7au7S0PGrUW23r--sC0AjA_1_2"><span style="font-size:9pt;">MMSI</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.39%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Narr_W3M6L5J4dUKalXdStigoJw"><span style="font-size:9pt;">NASDAQ</span></ix:nonNumeric><span style="font-size:9pt;"> Global Select Market System</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;">Emerging growth company&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_K6YZ9WfSYkOJuas5En_EYQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.59%;padding-right:10.59%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><b style="background-color:#ffffff;color:#212529;font-weight:bold;white-space:pre-wrap;">Item 1.01.  </b><b style="background-color:#ffffff;color:#212529;font-weight:bold;text-decoration:underline;text-decoration-color:#212529;">Entry into a Material Definitive Agreement</b><b style="background-color:#ffffff;color:#212529;font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="background-color:#ffffff;color:#212529;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;color:#212529;">On October 13, 2020, Merit Medical Systems, Inc. (the &quot;Company) entered into agreements with the United States Department of Justice&#160;(&#8220;DOJ&#8221;) and others to fully resolve the DOJ&#8217;s investigation of certain marketing and promotional practices of the Company. The Company denies the DOJ&#8217;s allegations, but has determined that avoiding protracted litigation and its associated costs will enable it to focus on its mission of being the most customer-focused company in healthcare. These agreements memorialize the agreement in principle that the Company previously disclosed in its press release on July 15, 2020 (a copy of the press release was also filed in a Form 8-K that same day). </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;color:#212529;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;color:#212529;">Specifically, the Company entered into:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;color:#212529;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="color:#212529;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">a Settlement Agreement, a copy of which is attached hereto as </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#212529;">Exhibit 10.1</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">, effective October 13, 2020, with the DOJ, and on behalf of the Inspector General of the Department of Health and Human Services (the &#8220;OIG&#8221;), the Defense Health Agency (&#8220;DHA&#8221;), acting on behalf of the TRICARE Program, and the relator named therein; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><span style="background-color:#ffffff;color:#212529;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="color:#212529;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">a Corporate Integrity Agreement, a copy of which is attached hereto as </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#212529;">Exhibit 10.2</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">, effective October 13, 2020, with the DOJ and OIG. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="background-color:#ffffff;color:#212529;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;color:#212529;">The DOJ asserted that the Company provided benefits, allegedly in the form of patient referrals advertising assistance, practice development, practice support, and educational grants to induce healthcare providers to purchase and use the Company&#8217;s products in medical procedures performed on federal healthcare program beneficiaries, in violation of the Anti-Kickback Statute, 42 U.S.C. &#167;1320a-7b(b), and caused the submission of false claims under the False Claims Act, 31 U.S.C. &#167;3729 (as further described in the Settlement Agreement, the &#8220;Covered Conduct&#8221;). This settlement is neither an admission of fault or liability on the part of the Company nor a concession by the DOJ that its claims are unfounded. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;color:#212529;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background-color:#ffffff;color:#212529;text-decoration:underline;text-decoration-color:#212529;">Settlement Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;color:#212529;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;color:#212529;">Under the terms of the Settlement Agreement, the Company will pay a total of $18,000,000 plus accrued interest from July 8, 2020 at a rate of 0.75% per annum (the &#8220;Settlement Payment&#8221;). The Settlement Payment consists of $15,210,000 (plus interest) paid to the United States no later than October 27, 2020, and $2,790,000 (plus interest) to be paid under the terms of separate agreements the Company will enter into with participating states to settle claims related to the Covered Conduct. </span><span style="background-color:#ffffff;">The Company expects to make the portion of the Settlement Payment to the United States prior to its due date and the portion of the Settlement Payment to the states as those payments become due. Upon reaching an agreement in principle with the DOJ, the Company previously recorded a legal settlement expense of $18.2 million in the second quarter of 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;color:#212529;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;color:#212529;">Conditioned upon payment of the Settlement Payment, and dismissal of certain actions against the government, the DOJ, OIG, DHA and the relator have agreed to release the Company and its subsidiaries from any civil or administrative monetary liability arising from the Covered Conduct;</span><span style="background-color:#ffffff;"> the DOJ and the relator have agreed to dismiss the civil action filed by the relator; and in consideration of the Company&#8217;s obligations under the Corporate Integrity Agreement (as described below), the OIG has agreed to waive its permissive exclusion authority and refrain from instituting any administrative action seeking to exclude the Company from participating in Medicare, Medicaid or other Federal health care programs as a result of the Covered Conduct.</span><span style="background-color:#ffffff;color:#212529;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;color:#212529;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background-color:#ffffff;color:#212529;text-decoration:underline;text-decoration-color:#212529;">Corporate Integrity Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;color:#212529;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;">In connection with the resolution of the investigated matters, and in exchange for the OIG&#8217;s agreement not to exclude the Company from participating in federal health care programs, on October 13, 2020, the Company entered into a five-year Corporate Integrity Agreement with the OIG. The Corporate Integrity Agreement imposes compliance, monitoring, reporting, certification, oversight and training obligations on the Company, certain of which have previously been implemented. The Corporate Integrity Agreement requires, among other matters, that the Company (i) maintain a Compliance Officer, a Compliance Committee, board review and oversight of certain federal healthcare compliance matters, compliance programs, and disclosure programs; (ii) establish robust compliance policies and procedures to meet federal health care program and FDA requirements; (iii) provide management certifications and compliance training and education; (iv) engage an independent review organization to conduct a thorough review of the Company&#8217;s systems, </span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.82%;border:0;margin:30pt 10.59% 30pt 10.59%;"></div><div style="max-width:100%;padding-left:10.59%;padding-right:10.59%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background-color:#ffffff;">policies, processes and procedures related to promotional materials, product evaluations, consulting agreements, trainings provided to healthcare professionals, sponsorships, grants and charitable contributions; (v) implement a risk assessment and internal review process; (vi) establish a disclosure program for whistleblowers; (vii) increase oversight of the interactions between its sales personnel and healthcare providers; and (viii) report or disclose certain events and physician payments.</span><i style="background-color:#ffffff;font-style:italic;">&#160;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;">The Company&#8217;s failure to comply with its obligations under the Corporate Integrity Agreement could result in monetary penalties and the Company being excluded from participating in federal health care programs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;">The foregoing descriptions of the Settlement Agreement&#160;and the Corporate Integrity Agreement are qualified in their entirety by the full terms of the&#160;Settlement Agreement and the&#160;Corporate Integrity Agreement, which are attached as&#160;</span><span style="background-color:#ffffff;text-decoration:underline;text-decoration-color:#000000;">Exhibit 10.1</span><span style="background-color:#ffffff;">&#160;and&#160;</span><span style="background-color:#ffffff;text-decoration:underline;text-decoration-color:#000000;">Exhibit 10.2</span><span style="background-color:#ffffff;">&#160;hereto, respectively, and incorporated herein by reference.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="background-color:#ffffff;color:#212529;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><b style="background-color:#ffffff;color:#212529;font-weight:bold;white-space:pre-wrap;">Item 2.03.  </b><b style="background-color:#ffffff;color:#212529;font-weight:bold;text-decoration:underline;text-decoration-color:#212529;">Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant</b><b style="background-color:#ffffff;color:#212529;font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="background-color:#ffffff;color:#212529;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;">The information set forth above under Item&#160;1.01 regarding the Settlement Agreement and Settlement Payment is incorporated by reference into this Item&#160;2.03.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;color:#212529;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><b style="background-color:#ffffff;color:#212529;font-weight:bold;white-space:pre-wrap;">Item 8.01.  </b><b style="background-color:#ffffff;color:#212529;font-weight:bold;text-decoration:underline;text-decoration-color:#212529;">Other Events</b><b style="background-color:#ffffff;color:#212529;font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="background-color:#ffffff;color:#212529;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;color:#212529;">On October 13, 2020, the Company issued a press release announcing that it had finalized a settlement with the DOJ to fully resolve the DOJ&#8217;s investigation of certain marketing and promotional practices. &#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background-color:#ffffff;color:#212529;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;color:#212529;">A copy of the Company&#8217;s press release is attached hereto as </span><span style="background-color:#ffffff;color:#212529;text-decoration:underline;text-decoration-color:#212529;">Exhibit 99.1</span><span style="background-color:#ffffff;color:#212529;"> hereto and is incorporated herein by reference. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.82%;border:0;margin:30pt 10.59% 30pt 10.59%;"></div><div style="max-width:100%;padding-left:10.59%;padding-right:10.59%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:10pt;font-weight:bold;white-space:pre-wrap;">Item 9.01.  </b><b style="font-size:10pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Financial Statements and Exhibits</b><b style="font-size:10pt;font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;"> (d)</span></span>Exhibits</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.25%;"><tr style="height:1pt;"><td style="vertical-align:top;width:16.16%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:83.83%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:12.15pt;"><td style="vertical-align:top;width:16.16%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;border-bottom:1.0pt solid #000000;margin:0pt;">Exhibit No. </p></td><td style="vertical-align:top;width:83.83%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;border-bottom:1.0pt solid #000000;margin:0pt;">Exhibit</p></td></tr><tr style="height:36.9pt;"><td style="vertical-align:top;width:16.16%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:83.83%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="mmsi-20201013ex1017cba2a.htm"><span style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Settlement Agreement, dated October 13, 2020, by and among the United States of America, acting through the United States Department of Justice and on behalf of the Office of Inspector General (&#8220;OIG-HHS&#8221;) of the Department of Health and Human Services (&#8220;HHS&#8221;), and the Defense Health Agency (&#8220;DHA&#8221;), acting on behalf of the TRICARE Program (collectively, the &#8220;United States&#8221;); the Company; and Charles J. Wolf, M.D. (&#8220;Relator&#8221;), through their authorized representatives.</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:36.9pt;"><td style="vertical-align:top;width:16.16%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:83.83%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="mmsi-20201013ex102809a99.htm"><span style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Corporate Integrity Agreement, dated October 13, 2020, by and between the OIG-HHS and the Company</span></a><span style="background-color:#ffffff;">.</span></p></td></tr><tr style="height:36.9pt;"><td style="vertical-align:top;width:16.16%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;">99.1</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.83%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri Light';font-size:10pt;font-weight:bold;margin:0pt;"><a style="-sec-extract:exhibit;" href="mmsi-20201013ex991f93af4.htm"><span style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Press Release, dated October 13, 2020, entitled &#8220;Merit Medical Finalizes Resolution with the Government.&#8221;</span></a></p></td></tr><tr><td style="vertical-align:top;width:16.16%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;">101</p></td><td style="vertical-align:top;width:83.83%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffffff;color:#212529;">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL and incorporated as Exhibit 101</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:16.16%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:top;width:83.83%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffffff;color:#212529;">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.82%;border:0;margin:30pt 10.59% 30pt 10.59%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49.8%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">MERIT MEDICAL SYSTEMS,&#160;INC.</p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: October 16, 2020</p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Brian G. Lloyd</p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.7%;border-top:1px solid #000000;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Brian G. Lloyd</p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.7%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Legal Officer and Corporate Secretary</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>mmsi-20201013ex1017cba2a.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.7.0.58--><!--Created on: 10/16/2020 09:25:58 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:0pt;"></font><b style="font-weight:bold;">Exhibit 10.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SETTLEMENT AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>This Settlement Agreement (&#8220;Agreement&#8221;) is entered into among the United States of America, acting through the United States Department of Justice and on behalf of the Office of Inspector General (&#8220;OIG-HHS&#8221;) of the Department of Health and Human Services (&#8220;HHS&#8221;), and the Defense Health Agency (&#8220;DHA&#8221;), acting on behalf of the TRICARE Program (collectively, the &#8220;United States&#8221;); Merit Medical Systems, Inc. (&#8220;Merit&#8221; or &#8220;Defendant&#8221;); and Charles J. Wolf, M.D. (&#8220;Relator&#8221;), through their authorized representatives.<b style="font-weight:bold;"> </b>Collectively, all of the above will be referred to as &#8220;the Parties.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">RECITALS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>A.<font style="display:inline-block;width:24.33pt;"></font>Merit, a publicly-held corporation with its principal place of business in South Jordan, Utah, is a medical device manufacturer that markets and sells its products throughout the United States. Among other things, Merit markets and sells embolotherapeutic devices used to <font style="color:#333333;">treat arteriovenous malformations, symptomatic uterine fibroids, and hypervascular tumors. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>B.<font style="display:inline-block;width:25pt;"></font>In April 2016, Relator filed a <i style="font-style:italic;">qui tam</i> action in the United States District Court for the District of New Jersey captioned <i style="font-style:italic;">United States ex rel. Wolf v. Merit Medical Systems, Inc.</i>, Civ. A. No. 16-1855 (D.N.J.), pursuant to the provisions of the False Claims Act, 31 U.S.C. &#167; 3730(b) (the &#8220;<i style="font-style:italic;">Qui Tam</i> Action&#8221;). The United States intervened in the <i style="font-style:italic;">Qui Tam</i> Action on June 12, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>C.<font style="display:inline-block;width:25pt;"></font>The United States contends that Merit caused to be submitted claims for payment to the Medicare Program, Title XVIII of the Social Security Act, 42 U.S.C. &#167;&#167; 1395-1395lll (&#8220;Medicare&#8221;); the Medicaid Program, 42 U.S.C. &#167;&#167; 1396&#8211;1396w-5 (&#8220;Medicaid&#8221;); and the TRICARE Program, 10 U.S.C. &#167;&#167; 1071&#8211;1110b (&#8220;TRICARE&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>D.<font style="display:inline-block;width:24.33pt;"></font>The United States contends that it has certain civil claims against Merit arising from the following conduct from September 1, 2010, to March 31, 2017, by which Merit caused the submission of false or fraudulent claims to Medicare, Medicaid, and TRICARE: </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>The United States contends that under an internal program known as the Local Advertising Program, Merit offered and paid physicians, medical practices, and hospitals (collectively, &#8220;Healthcare Providers&#8221;) millions of dollars in free advertising assistance, practice development, practice support, and purported unrestricted &#8220;educational&#8221; grants to induce the Healthcare Providers to purchase and use Merit products in medical procedures performed on federal healthcare program beneficiaries, in violation of the Anti-Kickback Statute (&#8220;AKS&#8221;), 42 U.S.C. &#167;&#160;1320a-7b(b). </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>The United States further contends that Merit executives and sales personnel selected which Healthcare Providers would benefit from Merit&#8217;s Local Advertising Program payments, as reward for past sales, to induce future sales, and to steer business to Merit and away from Merit&#8217;s competitors. In its subsidized advertising, Merit promoted the targeted Healthcare Providers by name, provided contact information for those Healthcare Providers, and did not mention Merit or Merit products. The United States contends that before agreeing to make the Local Advertising Program payments to benefit a targeted Healthcare Provider, Merit often estimated the &#8220;projected revenue&#8221; that it expected to receive from the Healthcare Provider&#8217;s purchase of Merit products, and after making the payments, Merit often tracked the return on investment (ROI) based on the Healthcare Provider&#8217;s purchase of Merit products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>Merit and its executives claimed that the purpose of the Local Advertising Program was to increase patient awareness of uterine fibroid embolization. In fact, the United States contends, Merit used the Local Advertising Program payments to induce its targeted Healthcare Providers to use Merit products by providing them financial support and patient referrals. In internal communications, Merit described using the Local Advertising Program payments as &#8220;leverage,&#8221; a &#8220;bargaining chip,&#8221; or as part of a &#8220;deal&#8221; to secure Merit business from Healthcare Providers. &#160;The </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:14.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">2</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;">United States contends that Merit disregarded warnings that its conduct may violate the AKS, including from its Chief Compliance Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;text-indent:36pt;margin:0pt;">The conduct set forth in Paragraph D is referred to below as the &#8220;Covered Conduct.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>E.<font style="display:inline-block;width:25.67pt;"></font>Merit denies the allegations and contentions of the United States and the Relator. &#160;This Settlement Agreement is neither an admission of liability by Merit nor a concession by the United States that its claims are not well founded. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>F.<font style="display:inline-block;width:26.33pt;"></font>Relator claims entitlement under 31 U.S.C. &#167; 3730(d) to a share of the proceeds of this Settlement Agreement and to Relator&#8217;s reasonable expenses, attorneys&#8217; fees, and costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>G.<font style="display:inline-block;width:24.33pt;"></font>Merit has entered into, or will be entering into, separate settlement agreements described below in Paragraph 1(b) (&#8220;Medicaid State Settlement Agreements&#8221;) with the states (&#8220;Medicaid Participating States&#8221;) in settlement of the conduct released in those separate Medicaid State Settlement Agreements. &#160;Relator claims entitlement under 31 U.S.C. &#167; 3730(d), and State equivalents, to a share of the proceeds of the Medicaid State Settlement Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>To avoid the delay, uncertainty, inconvenience, and expense of protracted litigation of the above claims, and in consideration of the mutual promises and obligations of this Settlement Agreement, the Parties agree and covenant as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">TERMS AND CONDITIONS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>1.<font style="display:inline-block;width:27pt;"></font>Merit shall pay to the United States and the Medicaid Participating States the sum of Eighteen Million Dollars ($18,000,000.00) plus interest at the rate of 0.75% per annum, calculated monthly, from July 8, 2020, and continuing until and including the date of payment (&#8220;Total Settlement Amount&#8221;). &#160;The Total Settlement Amount shall be paid, subject to the provisions of Paragraph 14 below, as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>a.<font style="display:inline-block;width:27.67pt;"></font>Merit shall pay to the United States the sum of Fifteen Million Two Hundred Ten Thousand Dollars ($15,210,000.00), of which Seven Million Six Hundred Five Thousand </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:14.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">3</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;">Dollars ($7,605,000.00) is restitution, plus accrued interest as set forth above (&#8220;Federal Settlement Amount&#8221;), no later than fourteen (14) calendar days after the Effective Date of this Agreement by electronic funds transfer pursuant to written instructions to be provided by the United States Attorney&#8217;s Office for the District of New Jersey.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>b.<font style="display:inline-block;width:27pt;"></font>Merit shall collectively pay to the Medicaid Participating States the total sum of Two Million Seven Hundred Ninety Thousand Dollars ($2,790,000.00), of which One Million Three Hundred Ninety-Five Thousand Dollars ($1,395,000.00) is restitution, plus accrued interest as set forth above (&#8220;State Settlement Amount&#8221;), pursuant to written instructions from the National Association of Medicaid Fraud Control Units (&#8220;NAMFCU&#8221;) State Team and under the terms and conditions of the separate agreements that Merit has entered into, or will enter into, with the Medicaid Participating States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>2.<font style="display:inline-block;width:27pt;"></font>Conditioned upon the United States receiving the Federal Settlement Amount from Merit and as soon as feasible after receipt, the United States shall pay Two Million Six Hundred Fifty Thousand Dollars ($2,650,000.00) to Relator by electronic funds transfer to the trust account of Joseph Greenwald &amp; Laake, P.A.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>3.<font style="display:inline-block;width:27pt;"></font>The Defendant and Relator and their heirs, successors, attorneys, agents, and assigns each retain all of their rights pursuant to 31 U.S.C. &#167; 3730(d) on the issue of Relator&#8217;s expenses, fees, and costs, and have not reached agreement on those issues to date. Relator and Defendant further agree that, should the Parties be unable to reach an agreement on amounts, Relator may file a motion for attorney&#8217;s fees, costs and expenses in the District Court within sixty (60) days of the date of dismissal of the Civil Action. The Parties agree that the United States District Court for the District of New Jersey shall retain and have continuing jurisdiction with regard to any disputes over the amounts for expenses, attorney&#8217;s fees and costs.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:14.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">4</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>4.<font style="display:inline-block;width:27pt;"></font>Subject to the exceptions in Paragraph 8 (concerning excluded claims) below, and conditioned upon Merit&#8217;s full payment of the Total Settlement Amount and Merit&#8217;s full and timely compliance with Paragraph 17 below, the United States releases Merit and Merit&#8217;s current and former parent corporations, direct and indirect subsidiaries, and brother and sister corporations (collectively, the &#8220;Released Parties&#8221;) from any civil or administrative monetary claim the United States has for the Covered Conduct under the False Claims Act, 31 U.S.C. &#167;&#167; 3729-3733; the Civil Monetary Penalties Law, 42 U.S.C. &#167; 1320a-7a; the Program Fraud Civil Remedies Act, 31 U.S.C. &#167;&#167; 3801-3812; or the common law theories of payment by mistake, unjust enrichment, and fraud. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>5.<font style="display:inline-block;width:27pt;"></font>Subject to Paragraph 3 and conditioned upon Merit&#8217;s full payment of the Total Settlement Amount, Relator, for himself and for his heirs, successors, attorneys, agents, and assigns, releases, remises, and forever discharges Merit, together with its current and former employees, officers, owners, directors, shareholders, attorneys, agents, insurers, parents, subsidiaries, predecessors, successors, assigns, and affiliated and related entities (collectively, the &#8220;Merit Releasees&#8221;) from any claims, rights, demands, controversies, allegations, causes of action, suits, obligations, judgments, debts, duties, and all other liabilities of any kind or nature whatsoever, known or unknown, suspected or unsuspected, accrued or not accrued, fixed or contingent, in law or in equity, in contract or in tort, under common law, under any federal or state statute or regulation (including without limitation any civil monetary claim the Relator has on behalf of the United States for the Covered Conduct under the False Claims Act, 31 U.S.C. &#167;&#167;&#160;3729-33), and whether or not asserted, that Relator or his respective heirs, successors, attorneys, agents, affiliates, and assigns otherwise would have standing to bring, have asserted, could have asserted, or may assert in the future against Merit or any of the Merit Releasees, from the beginning of time to the Effective Date of this Agreement.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:14.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">5</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>6.<font style="display:inline-block;width:27pt;"></font>The Relator covenants and warrants that the Relator and his attorneys and agents will within thirty (30) days of the Effective Date of this Agreement return to Merit and provide written certification that the Relator and his attorneys and agents have returned to Merit (a) all documents, records, files, data and other information that Relator obtained from Merit during his employment, or otherwise constitutes or contains the property of Merit, including but not limited to confidential or proprietary information, (b) all electronic equipment and electronic information storage devices (e.g., computers, cellular phones, PDAs, zip drives, thumb drives, disks, etc.) that constitutes or contains property of Merit, and (c) Merit credit cards, office keys, and any other property of Merit that the Relator and his attorneys and agents obtained or that were made available to the Relator as a consequence of the Relator&#8217;s employment with Merit and/or that constitute or contain the rightful property of Merit, and that all electronic copies of the above have been permanently deleted from Relator&#8217;s computers, electronic equipment, storage devices, and cloud-storage accounts. &#160;Merit agrees to retain all material returned under this paragraph until the Relator&#8217;s claims pursuant to 31 U.S.C. &#167; 3730(d) for expenses, fees, and costs, as described in paragraph 3, have been fully resolved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>7.<font style="display:inline-block;width:27pt;"></font>In consideration of the obligations of Merit in this Agreement and the Corporate Integrity Agreement (CIA) entered into between OIG-HHS and Merit, and conditioned upon Merit&#8217;s full payment of the Total Settlement Amount and Merit&#8217;s full and timely compliance with Paragraph 17 below, the OIG-HHS agrees to release and refrain from instituting, directing, or maintaining any administrative action seeking exclusion from Medicare, Medicaid, and other Federal healthcare programs (as defined in 42 U.S.C. &#167; 1320a-7b(f)) against Merit under 42 U.S.C. &#167; 1320a-7a (Civil Monetary Penalties Law) or 42 U.S.C. &#167; 1320a-7(b)(7) (permissive exclusion for fraud, kickbacks, and other prohibited activities) for the Covered Conduct, except as reserved in this Paragraph and in Paragraph 8 (concerning excluded claims), below. &#160;The OIG-HHS </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:14.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">6</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;">expressly reserves all rights to comply with any statutory obligations to exclude Merit from Medicare, Medicaid, and other Federal healthcare programs under 42 U.S.C. &#167; 1320a-7(a) (mandatory exclusion) based upon the Covered Conduct. &#160;Nothing in this Paragraph precludes the OIG-HHS from taking action against entities or persons, or for conduct and practices, for which claims have been reserved in Paragraph 8, below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>8.<font style="display:inline-block;width:27pt;"></font>Notwithstanding the releases given in paragraphs 4 and 5 of this Agreement, or any other term of this Agreement, the following claims of the United States are specifically reserved and are not released: </p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Any liability arising under Title 26, U.S. Code (Internal Revenue Code);</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Any criminal liability;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Except as explicitly stated in this Agreement, any administrative liability, including mandatory exclusion from Federal healthcare programs;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;">d.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Any liability to the United States (or its agencies) for any conduct other than the Covered Conduct;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;">e.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Any liability based upon obligations created by this Agreement; </p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;">f.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Any liability of individuals;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;">g. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Any liability for express or implied warranty claims or other claims for defective or deficient products or services, including quality of goods and services;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;">h. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Any liability for failure to deliver goods or services due; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;">i. </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Any liability for personal injury or property damage or for other consequential damages arising from the Covered Conduct.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>9.<font style="display:inline-block;width:27pt;"></font>Relator and his heirs, successors, attorneys, agents, and assigns shall not object to this Agreement but agree and confirm that this Agreement is fair, adequate, and reasonable under </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:14.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">7</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;">all the circumstances, pursuant to 31 U.S.C. &#167; 3730(c)(2)(B). Conditioned upon Relator&#8217;s receipt of the payment described in Paragraph 2, Relator and his heirs, successors, attorneys, agents, and assigns fully and finally release, waive, and forever discharge the United States, its agencies, officers, agents, employees, and servants, from any claims arising from the filing of the <i style="font-style:italic;">Qui Tam</i> Action or under 31 U.S.C. &#167; 3730, and from any claims to a share of the proceeds of this Agreement and/or the <i style="font-style:italic;">Qui Tam</i> Action. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>10.<font style="display:inline-block;width:21pt;"></font>Merit waives and shall not assert any defenses that Merit may have to any criminal prosecution or administrative action relating to the Covered Conduct that may be based in whole or in part on a contention that, under the Double Jeopardy Clause in the Fifth Amendment of the Constitution, or under the Excessive Fines Clause in the Eighth Amendment of the Constitution, this Agreement bars a remedy sought in such criminal prosecution or administrative action. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>11.<font style="display:inline-block;width:21pt;"></font>Each Released Party, listed in Paragraph 4, fully and finally releases the United States, its agencies, officers, agents, employees, and servants, from any claims (including attorneys&#8217; fees, costs, and expenses of every kind and however denominated) that the Released Party has asserted, could have asserted, or may assert in the future against the United States, its agencies, officers, agents, employees, and servants, related to the Covered Conduct and the United States&#8217; investigation and prosecution thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:2.38;text-align:justify;">12.</font></font><font style="font-family:'TimesNewRomanPSMT','Bold';">Merit</font><b style="font-family:'TimesNewRomanPSMT','Bold';font-weight:bold;"> </b><font style="font-family:'TimesNewRomanPSMT';">fully and finally releases the Relator from any claims (including attorneys&#8217; fees, costs, and expenses of every kind and however denominated) that Merit</font><b style="font-family:'TimesNewRomanPSMT','Bold';font-weight:bold;"> </b><font style="font-family:'TimesNewRomanPSMT';">has asserted, could have asserted, or may assert in the future against the Relator, related to the Covered Conduct and the Relator&#8217;s investigation and prosecution thereof, the pursuit and filing of the Civil Action, and any all claims brought pursuant to the </font><i style="font-family:'TimesNewRomanPSMT';font-style:italic;">qui tam</i><font style="font-family:'TimesNewRomanPSMT';"> complaint, and amended complaint.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>13.<font style="display:inline-block;width:21pt;"></font>The Total Settlement Amount shall not be decreased as a result of the denial of claims for payment now being withheld from payment by any Medicare contractor (e.g., Medicare </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:14.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">8</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;">Administrative Contractor, fiscal intermediary, carrier), TRICARE carrier or payer, or any state payer, related to the Covered Conduct; and Merit agrees not to resubmit to any Medicare contractor, TRICARE carrier or payer, or any state payer any previously denied claims related to the Covered Conduct, agrees not to appeal any such denials of claims, and agrees to withdraw any such pending appeals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font>14.<font style="display:inline-block;width:21pt;"></font>Merit agrees to the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>a.<font style="display:inline-block;width:27.67pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;">Unallowable Costs Defined</u>: All costs (as defined in the Federal Acquisition Regulation, 48 C.F.R. &#167; 31.205-47; and in Titles XVIII and XIX of the Social Security Act, 42 U.S.C. &#167;&#167; 1395-1395lll-1 and 1396-1396w-5; and the regulations and official program directives promulgated thereunder) incurred by or on behalf of Merit, its present or former officers, directors, employees, shareholders, and agents in connection with:<font style="display:inline-block;width:17.41pt;"></font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;">the matters covered by this Agreement;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;">the United States&#8217; audit(s) and civil investigation(s) of the matters covered by this Agreement;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(3)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Merit&#8217;s investigation, defense, and corrective actions undertaken in response to the United States&#8217; audit(s) and civil investigation(s) in connection with the matters covered by this Agreement (including attorneys&#8217; fees);</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(4)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;">the negotiation and performance of this Agreement; </p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(5)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;">the payment Merit makes to the United States pursuant to this Agreement and any payments that Merit may make to Relator, including costs and attorneys&#8217; fees; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="white-space:pre-wrap;"> </font>(6)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-top:0pt;text-align:justify;">the negotiation of, and obligations undertaken pursuant to the CIA to: &#160;(i)&#160;retain an independent review organization to perform annual reviews as </p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:14.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">9</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt 0pt 0pt 108pt;">described in Section III of the CIA; and (ii) prepare and submit reports to the OIG-HHS;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;">are unallowable costs for government contracting purposes and under the Medicare Program, Medicaid Program, TRICARE Program, and Federal Employees Health Benefits Program (&#8220;FEHBP&#8221;) (collectively, &#8220;Unallowable Costs&#8221;). &#160;However, nothing in paragraph 14(a)(6) that may apply to the obligations undertaken pursuant to the CIA affects the status of costs that are not allowable based on any other authority applicable to Merit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>b.<font style="display:inline-block;width:27pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;">Future Treatment of Unallowable Costs</u>: Unallowable Costs shall be separately determined and accounted for by Merit, and Merit shall not charge such Unallowable Costs directly or indirectly to any contracts with the United States or any State Medicaid program, or seek payment for such Unallowable Costs through any cost report, cost statement, information statement, or payment request submitted by Merit or any of its subsidiaries or affiliates to the Medicare, Medicaid, TRICARE, or FEHBP Programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>c.<font style="display:inline-block;width:27.67pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;">Treatment of Unallowable Costs Previously Submitted for Payment</u>: Merit further agrees that within ninety (90) days of the Effective Date of this Agreement it shall identify to applicable Medicare and TRICARE fiscal intermediaries, carriers, and/or contractors, and Medicaid and FEHBP fiscal agents, any Unallowable Costs (as defined in this Paragraph) included in payments previously sought from the United States, or any State Medicaid program, including, but not limited to, payments sought in any cost reports, cost statements, information reports, or payment requests already submitted by Merit or any of its subsidiaries or affiliates, and shall request, and agree, that such cost reports, cost statements, information reports, or payment requests, even if already settled, be adjusted to account for the effect of the inclusion of the Unallowable Costs. Merit agrees that the United States, at a minimum, shall be entitled to recoup from Merit any overpayment plus applicable interest and penalties as a result of the inclusion of </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:14.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">10</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;">such Unallowable Costs on previously-submitted cost reports, information reports, cost statements, or requests for payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>Any payments due after the adjustments have been made shall be paid to the United States pursuant to the direction of the Department of Justice and/or the affected agencies. The United States reserves its rights to disagree with any calculations submitted by Merit or any of its subsidiaries or affiliates on the effect of inclusion of Unallowable Costs (as defined in this Paragraph) on Merit or any of its subsidiaries or affiliates&#8217; cost reports, cost statements, or information reports. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>d.<font style="display:inline-block;width:27pt;"></font>Nothing in this Agreement shall constitute a waiver of the rights of the United States to audit, examine, or re-examine Merit&#8217;s books and records to determine that no Unallowable Costs have been claimed in accordance with the provisions of this Paragraph.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>15.<font style="display:inline-block;width:21pt;"></font>This Agreement is intended to be for the benefit of the Parties, the Released Parties (as to Paragraph 4), and the Merit Releasees (as to Paragraph 5) only. The Parties do not release any claims against any other person or entity, except to the extent provided for in Paragraph 16 (waiver for beneficiaries paragraph), below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font> 16.<font style="display:inline-block;width:18pt;"></font>Merit agrees that it waives and shall not seek payment for any of the healthcare billings covered by this Agreement from any healthcare beneficiaries or their parents, sponsors, legally responsible individuals, or third party payors based upon the claims defined as Covered Conduct.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>17.<font style="display:inline-block;width:21pt;"></font>Within three (3) business days of the Effective Date of this Agreement:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>a.<font style="display:inline-block;width:27.67pt;"></font>The United States and Merit shall sign and file a Joint Stipulation of Dismissal with Prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1) in <i style="font-style:italic;">Merit Medical Systems, Inc. v. United States of America et al.</i>, No. 19-mc-211 (D.N.J.); </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:14.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">11</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:2.38;text-align:justify;">b.</font></font>Merit shall sign and file a Notice of Dismissal with Prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1) in <i style="font-style:italic;">Merit Medical Systems, Inc. v. Barr et al.</i>, No. 2:20-cv-6468 (D.N.J.); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>c.<font style="display:inline-block;width:27.67pt;"></font>The United States and Merit shall sign and file a Joint Motion to Dismiss with Prejudice pursuant to Federal Rule of Appellate Procedure 42(b) in <i style="font-style:italic;">Merit Medical Systems, Inc. v. United States of America</i>, No. 20-1449 (4th Cir.).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:2.38;text-align:justify;">18.</font></font>Upon receipt of the Total Settlement Amount and upon Merit&#8217;s full and timely compliance with Paragraph 17 above, the United States and Relator shall promptly sign and file in the <i style="font-style:italic;">Qui Tam</i> Action a Notice of Dismissal of the <i style="font-style:italic;">Qui Tam</i> Action pursuant to Rule 41(a)(1) as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>a.<font style="display:inline-block;width:27.67pt;"></font>The Notice of Dismissal shall be with prejudice as to the United States&#8217; and Relator&#8217;s claims in the <i style="font-style:italic;">Qui Tam</i> Action as to the Covered Conduct and consistent with the terms and conditions of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>b.<font style="display:inline-block;width:27pt;"></font>The Notice of Dismissal shall be without prejudice to the United States and with prejudice to the Relator as to any other claims in the <i style="font-style:italic;">Qui Tam</i> Action except for those reserved by Relator and his attorneys in Paragraph 3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>19.<font style="display:inline-block;width:21pt;"></font>Except for those reserved by Relator and his attorneys in Paragraph 3, each Party shall bear its own legal and other costs incurred in connection with the <i style="font-style:italic;">Qui Tam</i> Action and the three actions referenced above in Paragraph 17, including the preparation and performance of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>20.<font style="display:inline-block;width:21pt;"></font>Each party and signatory to this Agreement represents that it freely and voluntarily enters into this Agreement without any degree of duress or compulsion. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>21.<font style="display:inline-block;width:21pt;"></font>This Agreement is governed by the laws of the United States. The exclusive jurisdiction and venue for any dispute relating to this Agreement is the United States District Court </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:14.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">12</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;">for the District of New Jersey. For purposes of construing this Agreement, this Agreement shall be deemed to have been drafted by all Parties to this Agreement and shall not, therefore, be construed against any Party for that reason in any subsequent dispute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>22.<font style="display:inline-block;width:21pt;"></font>This Agreement constitutes the complete agreement between the Parties. This Agreement may not be amended except by written consent of the Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>23.<font style="display:inline-block;width:21pt;"></font>The undersigned counsel represent and warrant that they are fully authorized to execute this Agreement on behalf of the persons and entities indicated below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>24.<font style="display:inline-block;width:21pt;"></font>This Agreement may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>25.<font style="display:inline-block;width:21pt;"></font>This Agreement is binding on Merit&#8217;s successors, transferees, heirs, and assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>26.<font style="display:inline-block;width:21pt;"></font>This Agreement is binding on Relator&#8217;s successors, transferees, heirs, and assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>27.<font style="display:inline-block;width:21pt;"></font>All parties consent to the United States&#8217; disclosure of this Agreement, and information about this Agreement, to the public.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>28.<font style="display:inline-block;width:21pt;"></font>This Agreement is effective on the date of signature of the last signatory to the Agreement (Effective Date of this Agreement). Facsimiles and electronic transmissions of signatures shall constitute acceptable, binding signatures for purposes of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">[<font style="font-variant:small-caps;">Signature Pages Follow</font>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:14.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">13</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">THE UNITED STATES OF AMERICA</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">DATED: <u style="text-decoration:underline;text-decoration-color:#000000;">October 13, 2020</u><font style="display:inline-block;width:13.36pt;"></font>BY:<font style="display:inline-block;width:16pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;">/s/ Christopher Terranova</u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:20.7pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>CHRISTOPHER TERRANOVA</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>Trial Attorney</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>Commercial Litigation Branch, Civil Division</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>United States Department of Justice</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">DATED: <u style="text-decoration:underline;text-decoration-color:#000000;">October 13, 2010</u><font style="display:inline-block;width:13.36pt;"></font>BY:<font style="display:inline-block;width:16pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;">/s/ Andrew A. Caffrey, III</u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:18.71pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>ANDREW A. CAFFREY, III</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>Assistant United States Attorney</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>United States Attorney&#8217;s Office</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>District of New Jersey</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">APPROVED:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">/s/ Lee M. Cortex, Jr.</u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:5.68pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">LEE M. CORTES, JR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Chief, Health Care Fraud Unit</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">United States Attorney&#8217;s Office</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">District of New Jersey</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">APPROVED:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">/s/ Rachael A. Honig</u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:7.35pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">RACHAEL A. HONIG</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Attorney for the United States, Acting under Authority Conferred by 28 U.S.C. &#167; 515 </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">United States Attorney&#8217;s Office</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">District of New Jersey</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">DATED: <u style="text-decoration:underline;text-decoration-color:#000000;">October 13, 2020</u><font style="display:inline-block;width:13.36pt;"></font>BY:<font style="display:inline-block;width:16pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;">/s/ Lisa M. Re</u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:4pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>LISA M. RE</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>Assistant Inspector General for Legal Affairs</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>Office of Counsel to the Inspector General</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>Office of Inspector General</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>United States Department of Health and Human Services</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">DATED: <u style="text-decoration:underline;text-decoration-color:#000000;">October 13, 2020</u><font style="display:inline-block;width:13.36pt;"></font>BY:<font style="display:inline-block;width:16pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;">/s/ Salvatore M. Maida</u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:34.02pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>SALVATORE M. MAIDA</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>General Counsel</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>Defense Health Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>United States Department of Defense</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:14.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">14</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">MERIT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="white-space:pre-wrap;">DATED:  </font><u style="text-decoration:underline;text-decoration-color:#000000;">October 13, 2020</u><font style="display:inline-block;width:10.36pt;"></font>BY:<font style="display:inline-block;width:16pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;">/s/ Fred Lampropoulos</u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:34.68pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>FRED LAMPROPOULOS</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>Chairman and Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>Merit Medical Systems, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 171pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 171pt;"><font style="display:inline-block;width:9pt;"></font><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">DATED: <u style="text-decoration:underline;text-decoration-color:#000000;">October 13, 2020</u><font style="display:inline-block;width:13.36pt;"></font>BY:<font style="display:inline-block;width:16pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;">/s/ Michael R. Pauze</u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:8.69pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>MICHAEL R. PAUZ&#201;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>King &amp; Spalding LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>Counsel for Merit Medical Systems, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">DATED: <u style="text-decoration:underline;text-decoration-color:#000000;">October 13, 2020</u><font style="display:inline-block;width:13.36pt;"></font>BY:<font style="display:inline-block;width:16pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;">/s/ Lawrence S. Lustberg</u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:24.04pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>LAWRENCE S. LUSTBERG</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>Gibbons P.C.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>Counsel for Merit Medical Systems, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:14.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">15</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">RELATOR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">DATED: <u style="text-decoration:underline;text-decoration-color:#000000;">October 13, 2020</u><font style="display:inline-block;width:13.36pt;"></font>BY:<font style="display:inline-block;width:16pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;">/s/ Charles J. Wolf, M.D.</u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:23.34pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>CHARLES J. WOLF, M.D.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">DATED: <u style="text-decoration:underline;text-decoration-color:#000000;">October 13, 2002</u><font style="display:inline-block;width:13.36pt;"></font>BY:<font style="display:inline-block;width:16pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;">/s/ Jay P. Holland</u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:23.33pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;">/s/ Veronica B. Nannis</u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:34.69pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>JAY P. HOLLAND</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>VERONICA B. NANNIS</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>Joseph Greenwald &amp; Laake, PA</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>Counsel for Relator</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:14.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">16</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>mmsi-20201013ex102809a99.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.7.0.58--><!--Created on: 10/16/2020 09:26:08 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="margin-top:30pt;min-height:39pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:0pt;"></font><b style="font-weight:bold;">Exhibit 10.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;font-weight:bold;text-align:center;text-indent:0pt;margin:12.44pt 83.6pt 0pt 84.7pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"><a name="CORPORATE_INTEGRITY_AGREEMENT"></a></b><b style="font-weight:bold;text-decoration:none;text-decoration-color:#000000;">CORPORATE INTEGRITY AGREEMENT</b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"><a name="between_the"></a></b><b style="font-weight:bold;text-decoration:none;text-decoration-color:#000000;"> BETWEEN THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 130.5pt 0pt 131.4pt;"><b style="font-size:13pt;font-weight:bold;">OFFICE OF INSPECTOR GENERAL OF THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;font-weight:bold;text-align:center;text-indent:0pt;margin:0pt 75pt 0pt 75.85pt;"><b style="font-weight:bold;text-decoration:none;text-decoration-color:#000000;">DEPARTMENT OF HEALTH AND HUMAN SERVICES AND</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0.1pt 83.85pt 0pt 84.6pt;"><b style="font-size:13pt;font-weight:bold;">MERIT MEDICAL SYSTEMS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:13pt;font-weight:bold;margin-bottom:0pt;margin-left:5.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">I.</font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">PREAMBLE</b></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:4.44pt 12.5pt 0pt 5.95pt;">Merit Medical Systems, Inc. (Merit) hereby enters into this Corporate Integrity Agreement (CIA) with the Office of Inspector General (OIG) of the United States Department of Health and Human Services (HHS) to promote compliance with the statutes, regulations, and written directives of Medicare, Medicaid, and all other Federal health care programs (as defined in 42 U.S.C. &#167; 1320a-7b(f)) (Federal health care program requirements) and with the statutes, regulations, and written directives of the Food and Drug Administration (FDA requirements). Contemporaneously with this CIA, Merit is entering into a Settlement Agreement with the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:0.05pt 25.45pt 0pt 5.95pt;">Merit represents that it has an established corporate compliance program (Compliance Program) which preceded the execution of this CIA. The Compliance Program includes a Compliance Officer, Compliance Committee, written policies and procedures, education and training programs, and a disclosure program. Merit will continue to operate its Compliance Program throughout the term of this CIA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:13pt;font-weight:bold;margin-bottom:0pt;margin-left:5.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">II.</font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">TERM AND SCOPE OF THE CIA</b></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.4pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 9.95pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">A.</font><font style="font-size:13pt;">The period of the compliance obligations assumed by Merit under this CIA shall be five years from the effective date of this CIA. The &#8220;Effective Date&#8221; shall be the date on which the final signatory of this CIA executes this CIA. Each one-year period, beginning with the one-year period following the Effective Date, shall be referred to as a &#8220;Reporting</font><font style="font-size:13pt;letter-spacing:0.05pt;"> </font><font style="font-size:13pt;">Period.&#8221;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 17.8pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">B.</font><font style="font-size:13pt;">Sections VII, X, and XI shall expire no later than 120 days after OIG&#8217;s receipt of: (1) Merit&#8217;s final Annual Report; or (2) any additional materials submitted</font><font style="font-size:13pt;letter-spacing:-0.8pt;"> </font><font style="font-size:13pt;">by Merit pursuant to OIG&#8217;s request, whichever is</font><font style="font-size:13pt;letter-spacing:0.15pt;"> </font><font style="font-size:13pt;">later.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:41.9pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">C.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">The scope of this CIA is governed by the following</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">definitions:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.55pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><div style="margin-top:12.44pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 5.45pt 0pt 77.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.</font><font style="font-size:13pt;">For purposes of this CIA, the term &#8220;Covered Persons&#8221; includes: (a) all owners of Merit who are natural persons (other than shareholders who: (i) have an ownership interest of less than 5% and (ii) acquired the ownership interest through public trading) and all officers and directors of Merit; (b) all officers, directors and employees of Merit; and (c) all contractors, subcontractors, agents, and other persons</font><font style="font-size:13pt;letter-spacing:-0.55pt;"> </font><font style="font-size:13pt;">who perform any of the Covered Functions on behalf of</font><font style="font-size:13pt;letter-spacing:-0.2pt;"> </font><font style="font-size:13pt;">Merit.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:0pt 5.2pt 0pt 5.95pt;">Notwithstanding the above, the term &#8220;Covered Persons&#8221; does not include<font style="letter-spacing:-0.6pt;"> </font>part-time or per diem employees, contractors, subcontractors, agents, or other persons who are not reasonably expected to work more than 160 hours during a Reporting Period, except that any such individuals shall become &#8220;Covered Persons&#8221; at the point when they do work more than 160 hours during a Reporting<font style="letter-spacing:-0.25pt;"> </font>Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 8.3pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">2.</font><font style="font-size:13pt;">&#8220;Government Reimbursed Products&#8221; refers to all Merit products</font><font style="font-size:13pt;letter-spacing:-0.6pt;"> </font><font style="font-size:13pt;">that are: (a) marketed or sold by Merit in the United States (or pursuant to contracts with the United States) and (b) reimbursed by Federal health care</font><font style="font-size:13pt;letter-spacing:-0.3pt;"> </font><font style="font-size:13pt;">programs.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 5.05pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">3.</font><font style="font-size:13pt;">The term &#8220;Covered Functions&#8221; includes: (a) the selling, marketing, advertising, promoting, or branding of Government Reimbursed Products; (b) the preparation or external dissemination of promotional materials or information about, or the provision of services relating to, Government Reimbursed Products; (c) contracting with health care professionals (HCPs) for consulting services (including but not limited</font><font style="font-size:13pt;letter-spacing:-0.75pt;"> </font><font style="font-size:13pt;">to speaker programs, speaker training programs, training and education services, product development activities, presentations, consultant task force meetings, advisory boards, ad hoc advisory activities, research and any research-related activities, and authorship of articles or other publications relating to Government Reimbursed Products), or other fee- for service arrangements relating to Government Reimbursed Products; (d) contracting with HCPs or health care institutions (HCIs) for any Co-Marketing Activity; and (e) reviewing and/or approving requests for grants or charitable contributions involving HCPs or HCIs.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 5.4pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">4.</font><font style="font-size:13pt;">The term &#8220;Sponsorships&#8221; shall mean support for a program, event,</font><font style="font-size:13pt;letter-spacing:-0.7pt;"> </font><font style="font-size:13pt;">or organization in return for the advertisement, or promotion of Merit products, including healthcare-related conventions and conference sponsorships, promotional booths, exhibit space, advertisements, memberships, signage rights, naming rights, and</font><font style="font-size:13pt;letter-spacing:-0.4pt;"> </font><font style="font-size:13pt;">subscriptions.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 5.45pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">5.</font><font style="font-size:13pt;">The term &#8220;Third Party Educational Activity&#8221; shall mean any scientific, educational, or professional program, meeting, or event for HCPs conducted</font><font style="font-size:13pt;letter-spacing:-0.7pt;"> </font><font style="font-size:13pt;">by</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.25pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.55pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">2</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:12.44pt 0pt 0pt 6pt;">a third party and supported by Merit, including but not limited to, continuing medical education (CME), disease awareness, or sponsorship of symposia at medical conferences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 15.25pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">6.</font><font style="font-size:13pt;">The term &#8220;Co-Marketing Activity&#8221; shall mean any marketing or other promotional activity that Merit performs with or on behalf of (in addition to</font><font style="font-size:13pt;letter-spacing:-0.8pt;"> </font><font style="font-size:13pt;">itself) one or more HCPs or HCIs involving a Government Reimbursed</font><font style="font-size:13pt;letter-spacing:-0.1pt;"> </font><font style="font-size:13pt;">Product.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:13pt;font-weight:bold;margin-bottom:0pt;margin-left:5.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">III.</font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">CORPORATE INTEGRITY OBLIGATIONS</b></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:4.4pt 48.25pt 0pt 6pt;">Merit shall establish and maintain a Compliance Program that includes the following elements:</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 13.95pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:35.95pt;text-indent:0pt;white-space:nowrap;">A.</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Compliance Officer and Committee, Board of Directors, and</u><u style="font-size:13pt;letter-spacing:-0.55pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Management Compliance</u><u style="font-size:13pt;letter-spacing:-0.1pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Obligations</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.2pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.44pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:72pt;margin:0pt 9.35pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">1.</font><i style="font-size:13pt;font-style:italic;">Compliance Officer</i><font style="font-size:13pt;">. Within 90 days after the Effective Date,</font><font style="font-size:13pt;letter-spacing:-0.6pt;"> </font><font style="font-size:13pt;">Merit shall appoint a Compliance Officer and shall maintain a Compliance Officer for the term of the CIA. The Compliance Officer shall be an employee and a member of senior management of Merit; shall report directly to the Chief Executive Officer of Merit; and shall not be, or be subordinate to, the General Counsel or Chief Financial Officer or have any responsibilities that involve acting in any capacity as legal counsel or supervising legal counsel functions for Merit. The Compliance Officer shall be responsible for, without</font><font style="font-size:13pt;letter-spacing:-0.1pt;"> </font><font style="font-size:13pt;">limitation:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:77.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">developing and implementing policies, procedures, and practices designed to ensure compliance with the requirements set forth in this CIA and with Federal health care program and FDA</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">requirements;</font></td><td style="width:6.8pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:77.9pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">making periodic (at least quarterly) reports regarding compliance matters in person to the Audit Committee of the Board of Directors of Merit (Audit Committee) and shall be authorized to report on</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">such matters to the Audit Committee at any time. Written documentation of the Compliance Officer&#8217;s reports to the Audit Committee shall be made available to OIG upon request;</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">and</font></td><td style="width:5.05pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:77.9pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">monitoring the day-to-day compliance activities engaged in by</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Merit as well as any reporting obligations created under this</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">CIA.</font></td><td style="width:6.85pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">3</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:12.44pt 5.9pt 0pt 5.95pt;">Any noncompliance job responsibilities of the Compliance Officer shall be limited and must not interfere with the Compliance Officer&#8217;s ability to perform the duties outlined in this CIA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:0pt 36.65pt 0pt 5.95pt;">Merit shall report to OIG, in writing, any changes in the identity of the Compliance Officer, or any actions or changes that would affect the Compliance Officer&#8217;s ability to perform the duties necessary to meet the obligations in this CIA, within five business days after such a change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:72pt;margin:0pt 9.45pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">2.</font><i style="font-size:13pt;font-style:italic;">Compliance Committee</i><font style="font-size:13pt;">. Within 90 days after the Effective Date, Merit shall appoint a Compliance Committee. The Compliance Committee shall, at a minimum, include the Compliance Officer and other members of senior management necessary to meet the requirements of this CIA (</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">e.g.</u><font style="font-size:13pt;">, senior executives of relevant departments, such as sales, marketing, legal, medical affairs/medical information, regulatory affairs, research and development, human resources, audit, finance, manufacturing, and operations). The Compliance Officer shall chair the Compliance Committee and the Compliance Committee shall support the Compliance Officer in fulfilling his/her responsibilities (</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">e.g.</u><font style="font-size:13pt;">, shall assist in the analysis of Merit&#8217;s risk areas</font><font style="font-size:13pt;letter-spacing:-0.95pt;"> </font><font style="font-size:13pt;">and shall oversee monitoring of internal and external audits and investigations). The Compliance Committee shall meet at least quarterly. The minutes of the Compliance Committee meetings shall be made available to OIG upon</font><font style="font-size:13pt;letter-spacing:-0.1pt;"> </font><font style="font-size:13pt;">request.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-align:justify;text-indent:36pt;margin:0pt 13.95pt 0pt 6pt;">Merit shall report to OIG, in writing, any actions or changes that would affect<font style="letter-spacing:-0.85pt;"> </font>the Compliance Committee&#8217;s ability to perform the duties necessary to meet the obligations in this CIA, within 15 business days after such a<font style="letter-spacing:-0.3pt;"> </font>change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:72pt;margin:0pt 14.5pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">3.</font><i style="font-size:13pt;font-style:italic;">Board Compliance Obligations</i><font style="font-size:13pt;">. The Audit Committee shall be responsible for the review and oversight of matters related to compliance with Federal health care program requirements, FDA requirements, and the obligations of this CIA. The Audit Committee must include independent (</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">i.e.</u><font style="font-size:13pt;">, non-employee and</font><font style="font-size:13pt;letter-spacing:-0.65pt;"> </font><font style="font-size:13pt;">non-executive) members.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt 0pt 0pt 42pt;">The Audit Committee shall, at a minimum, be responsible for the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">meeting at least quarterly to review and oversee Merit&#8217;s Compliance Program, including but not limited to the performance of the Compliance Officer and</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Compliance Committee;</font></td><td style="width:35.25pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.55pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">4</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><div style="margin-top:12.44pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 18.8pt 0pt 113.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">b.</font><font style="font-size:13pt;">submitting to OIG a description of the documents and</font><font style="font-size:13pt;letter-spacing:-0.6pt;"> </font><font style="font-size:13pt;">other materials it reviewed, as well as any additional steps taken, such as the engagement of an independent advisor or other third party resources, in its oversight of the compliance program and in support of making the resolution below during each Reporting Period;</font><font style="font-size:13pt;letter-spacing:0.05pt;"> </font><font style="font-size:13pt;">and</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 14.5pt 0pt 113.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">c.</font><font style="font-size:13pt;">for each Reporting Period of the CIA, adopting a resolution, signed by each member of the Audit Committee, summarizing its review and oversight of Merit&#8217;s</font><font style="font-size:13pt;letter-spacing:-0.45pt;"> </font><font style="font-size:13pt;">compliance with Federal health care program requirements, FDA requirements, and the obligations of this</font><font style="font-size:13pt;letter-spacing:-0.1pt;"> </font><font style="font-size:13pt;">CIA.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 6.9pt 0pt 113.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;font-style:italic;min-width:36pt;text-indent:0pt;white-space:nowrap;">d.</font><font style="font-size:13pt;">for the first and fourth Reporting Period of the CIA, the</font><font style="font-size:13pt;letter-spacing:-0.5pt;"> </font><font style="font-size:13pt;">Audit Committee shall retain an individual or entity with expertise in compliance with Federal health care program and FDA requirements (Compliance Expert) to perform a review of the effectiveness of Merit&#8217;s Compliance Program (Compliance Program Review). The Compliance Expert shall prepare a written report about the Compliance Program Review. The written report (Compliance Program Review Report) shall include a description of the Compliance Program Review and any recommendations with respect to Merit&#8217;s compliance program. The Audit Committee shall review the Compliance Program Review Report as part of its review and oversight of Merit&#8217;s compliance program. A copy of the Compliance Program Review report shall be provided to OIG in the first and fourth Annual Report submitted by Merit. In addition, copies of any materials provided to the Audit Committee by the Compliance Expert, along with minutes of any meetings between the Compliance Expert and the Audit Committee, shall be made available to OIG upon</font><font style="font-size:13pt;letter-spacing:-0.3pt;"> </font><font style="font-size:13pt;">request</font><i style="font-size:13pt;font-style:italic;">.</i></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.25pt 0pt 0pt 0pt;"><font style="font-size:11pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt 0pt 0pt 6pt;">At minimum, the resolution shall include the following language:</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt 5pt 0pt 78pt;">&#8220;The Audit Committee has made a reasonable inquiry into the operations of Merit&#8217;s Compliance Program including the performance of the Compliance Officer and the Compliance Committee. Based on its inquiry and review, the Audit Committee has concluded that, to the best of its knowledge, Merit</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.5pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">5</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-align:justify;margin:12.44pt 15.05pt 0pt 78pt;">has implemented an effective Compliance Program to meet Federal health care program requirements, FDA requirements, and the obligations of the Corporate Integrity Agreement.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:0pt 16.75pt 0pt 5.95pt;">If the Audit Committee is unable to provide such a conclusion in the resolution, the Audit Committee shall include in the resolution a written explanation of the reasons why it is unable to provide the conclusion and the steps it is taking to implement an effective Compliance Program at Merit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-align:justify;text-indent:36pt;margin:0pt 10.45pt 0pt 5.95pt;">Merit shall report to OIG, in writing, any changes in the composition of the Audit Committee, or any actions or changes that would affect the Audit Committee&#8217;s ability to perform the duties necessary to meet the obligations in this CIA, within 15 business days after such a change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 5.4pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">4.</font><i style="font-size:13pt;font-style:italic;">Management Certifications</i><font style="font-size:13pt;">. In addition to the responsibilities set forth in this CIA for all Covered Persons, certain Merit employees (Certifying Employees) are specifically expected to monitor and oversee activities within their areas of authority and shall annually certify that the applicable Merit business unit is in compliance with applicable Federal health care program and FDA requirements and with the obligations of this CIA. These Certifying Employees shall include, at a minimum, the following: the Chief Financial Officer, the Executive Vice President &#8211; Commercial, the </font><font style="font-size:12pt;">Chief Regulatory Affairs Officer, and the Vice President &#8211; US Sales</font><font style="font-size:13pt;">. For each Reporting Period, each Certifying Employee shall sign a certification that</font><font style="font-size:13pt;letter-spacing:0.1pt;"> </font><font style="font-size:13pt;">states:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt 12.5pt 0pt 78pt;">&#8220;I have been trained on and understand the compliance requirements and responsibilities as they relate to [insert name of department], an area<font style="letter-spacing:-0.55pt;"> </font>under my supervision. My job responsibilities include ensuring compliance<font style="letter-spacing:-0.6pt;"> </font>with regard<font style="letter-spacing:-0.1pt;"> </font>to<font style="letter-spacing:-0.1pt;"> </font>the<u style="text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:32.51pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u>[insert name of the department] with all applicable Federal health care program requirements, FDA requirements, obligations of the Corporate Integrity Agreement, and Merit policies, and I have taken steps to promote such compliance. To the best of my knowledge,<font style="letter-spacing:-0.25pt;"> </font>the</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt 7.5pt 0pt 78pt;"><u style="text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:35.6pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="letter-spacing:-0.05pt;"> </font>[insert name of department] of Merit is in compliance with all applicable Federal health care program requirements, FDA requirements, and the obligations of the Corporate Integrity Agreement. I understand<font style="letter-spacing:-0.55pt;"> </font>that this certification is being provided to and relied upon by the United<font style="letter-spacing:-0.65pt;"> </font>States.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:0pt 5.3pt 0pt 6pt;">If any Certifying Employee is unable to provide such a certification, the Certifying Employee shall provide a written explanation of the reasons why he or she is unable to provide the certification outlined above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.5pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">6</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:4.4pt 5.6pt 0pt 5.95pt;">Within 90 days after the Effective Date, Merit shall develop and implement a written process for Certifying Employees to follow for the purpose of completing the certification required by this section (<u style="text-decoration:underline;text-decoration-color:#000000;">e.g.</u>, reports that must be reviewed, assessments that must be completed, sub-certifications that must be obtained, <u style="text-decoration:underline;text-decoration-color:#000000;">etc</u>. prior to the Certifying Employee making the required certification).</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:41.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">B.</font><a name="B.___Written_Standards"></a><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Written</u><u style="font-size:13pt;letter-spacing:-0.1pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Standards</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.4pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 10.2pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">1.</font><a name="1._Policies_and_Procedures.__Within_120_"></a><i style="font-size:13pt;font-style:italic;">Policies and Procedures. </i><font style="font-size:13pt;">Within 120 days after the Effective Date, Merit shall develop and implement written policies and procedures regarding the operation of its compliance program, including the compliance program requirements outlined in this CIA and Merit&#8217;s compliance with Federal health care program and FDA requirements (Policies and Procedures). Throughout the term of this CIA, Merit shall enforce its Policies and Procedures and shall make compliance with its Policies and Procedures an element of evaluating the performance of all employees. The Policies and Procedures shall be made available to all Covered Persons. At a minimum, the Policies and Procedures shall address the</font><font style="font-size:13pt;letter-spacing:-0.3pt;"> </font><font style="font-size:13pt;">following:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">appropriate ways to conduct Covered Functions in compliance with all: (i) applicable Federal healthcare program requirements, including, but not limited to the Federal Anti-Kickback Statute (codified at 42 U.S.C. &#167; 1320a-7b(b)) and the False Claims Act (codified at 31</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">U.S.C.</font></td><td style="width:9.15pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt 0pt 0pt 149.95pt;">&#167;&#167; 3729-3733); and (ii) all applicable FDA requirements;</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.9pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">the development, implementation, and compliant use</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">of promotional materials used by sales representatives (including any contract sales force) and other Merit representatives who promote and sell Government Reimbursed</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Products;</font></td><td style="width:39.45pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">the development, implementation, and review of policies for the distribution of Government Reimbursed Products for evaluation purposes (Evaluation Product). This shall include a review of the bases upon, and circumstances under, which HCPs and HCIs belonging to specified medical specialties</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">or types of clinical practice may receive Evaluation</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Product</font></td><td style="width:11.3pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.25pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.5pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">7</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:12.44pt 9.95pt 0pt 150pt;">from Merit (including, separately, from sales representatives, or through other channels);</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 13.1pt 0pt 113.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">d.</font><font style="font-size:13pt;">consultant or other fee-for-service arrangements entered into with HCPs or HCIs (including but not limited to speaker programs, speaker training programs, training and education services, product development activities, presentations, consultant task force meetings, advisory boards, ad hoc advisory activities, research and research-related activities, authorship activities, and any other financial engagement or arrangement with an HCP or HCI) and all events and expenses relating to such engagements or arrangements. The Policies and Procedures shall include requirements about</font><font style="font-size:13pt;letter-spacing:-0.65pt;"> </font><font style="font-size:13pt;">the content and circumstances of such arrangements and</font><font style="font-size:13pt;letter-spacing:-0.45pt;"> </font><font style="font-size:13pt;">events;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:109.55pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:40.45pt;padding:0pt;">e.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">agreements or arrangements with HCPs or HCIs for the purchase or licensing of intellectual property (including, </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-align:left;">but </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">not limited to, patents, patent applications, and the payment of</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">royalties);</font></td><td style="width:16.3pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">f.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">programs by HCPs to educate sales representatives,</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">including but not limited to presentations by HCPs at sales meetings, preceptorships, tutorials, and experience-based learning activities;</font></td><td style="width:8.4pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">g.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">review and approval of, and payment for, travel and related expenses for HCPs including those in connection with HCP participation in educational, research, training, or other</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Merit- sponsored programs or</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">activities;</font></td><td style="width:6.3pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">h.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">sponsorship or funding of grants (including educational grants) or charitable contributions involving HCPs and</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:left;">HCIs;</font></td><td style="width:9.45pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">i.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:justify;">funding of, or participation in, any Sponsorships, Third</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;text-align:justify;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:justify;">Party Educational Activity, or Co-Marketing Activity as defined in Sections II.C.4, II.C.5, and II.C.6</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:justify;">above;</font></td><td style="width:10.85pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.2pt 0pt 0pt 0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.55pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">8</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><div style="margin-top:12.44pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 5.6pt 0pt 113.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">j.</font><font style="font-size:13pt;">compensation (including through salaries, bonuses, or other means) for Covered Persons who are sales representatives </font><font style="font-size:13pt;letter-spacing:-0.25pt;">and </font><font style="font-size:13pt;">their</font><font style="font-size:13pt;letter-spacing:-0.1pt;"> </font><font style="font-size:13pt;">managers;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 6.95pt 0pt 113.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">k.</font><font style="font-size:13pt;">disciplinary policies and procedures for violations of Merit&#8217;s Policies and Procedures, including policies relating to</font><font style="font-size:13pt;letter-spacing:-0.7pt;"> </font><font style="font-size:13pt;">Federal health care program and FDA</font><font style="font-size:13pt;letter-spacing:-0.3pt;"> </font><font style="font-size:13pt;">requirements.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:0pt 12.5pt 0pt 6pt;">At least annually (and more frequently, if appropriate), Merit shall assess and update, as necessary, the Policies and Procedures. Any new or revised Policies and Procedures shall be made available to all Covered Persons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt 0pt 0pt 41.95pt;">All Policies and Procedures shall be made available to OIG upon request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:41.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">C.</font><a name="C.___Training_and_Education"></a><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Training and</u><u style="font-size:13pt;letter-spacing:-0.15pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Education</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.2pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.4pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 5.1pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">1.</font><i style="font-size:13pt;font-style:italic;white-space:pre-wrap;">Covered Persons Training.  </i><font style="font-size:13pt;">Within 120 days after the Effective Date, Merit shall develop a written plan (Training Plan) that outlines the steps Merit will take to ensure that: (a) all Covered Persons receive at least annual training regarding Merit&#8217;s CIA requirements and compliance program, and (b) all Covered Persons who engage in Covered Functions receive at least annual training regarding: (i) all applicable Federal health care program and FDA requirements relating to Covered Functions and</font><font style="font-size:13pt;letter-spacing:-0.85pt;"> </font><font style="font-size:13pt;">(ii) all Merit Policies and Procedures and other requirements applicable to Covered Functions. The Training Plan shall include information regarding the following: training topics, categories of Covered Persons and required to attend each training session, length of the training session(s), schedule for training, and format of the training. Merit shall furnish training to its Covered Persons pursuant to the Training Plan during each Reporting</font><font style="font-size:13pt;letter-spacing:0.05pt;"> </font><font style="font-size:13pt;">Period.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 7.6pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">2.</font><i style="font-size:13pt;font-style:italic;">Board Training</i><font style="font-size:13pt;">. In addition to the training described in Section III.C.1, within 120 days after the Effective Date, each member of the Board of Directors shall receive training regarding the corporate governance responsibilities of board members, and the responsibilities of board members with respect to review and oversight of the Compliance Program. Specifically, the training shall address the unique responsibilities of health care board members, including the risks, oversight areas, and strategic approaches to conducting oversight of a health care entity. This training may</font><font style="font-size:13pt;letter-spacing:-0.55pt;"> </font><font style="font-size:13pt;">be conducted by an outside compliance expert hired by the Board of Directors and should include a discussion of OIG&#8217;s guidance on board member</font><font style="font-size:13pt;letter-spacing:-0.3pt;"> </font><font style="font-size:13pt;">responsibilities.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.55pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">9</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:12.44pt 25.1pt 0pt 5.95pt;">New members of the Board of Directors shall receive the Board Training described above within 30 days after becoming a member or within 120 days after the Effective Date, whichever is later.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 7.9pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">3.</font><a name="3._Training_Records.__Merit_shall_make_a"></a><i style="font-size:13pt;font-style:italic;">Training Records</i><font style="font-size:13pt;">. Merit shall make available to OIG, upon request, training materials and records verifying that the training described in Sections III.C.1</font><font style="font-size:13pt;letter-spacing:-0.75pt;"> </font><font style="font-size:13pt;">and</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 6pt;">III.C.2 has been provided as required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:41.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">D.</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Risk Assessment and Internal Review</u><u style="font-size:13pt;letter-spacing:-0.15pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Process</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:4.4pt 6.2pt 0pt 5.95pt;"><font style="white-space:pre-wrap;">Within 120 days after the Effective Date, Merit shall develop and implement a centralized annual risk assessment and internal review process to identify and address risks associated with each Government Reimbursed Product, including risks associated with the Covered Functions. The Compliance Committee shall be responsible for implementation and oversight of the risk assessment and internal review process. The risk assessment and internal review process shall be conducted annually and shall require Merit to: (1) identify and prioritize risks, (2) develop internal audit work plans related to the identified risk areas, (3) implement the internal audit work plans, (4) develop corrective action plans in response to the results of any internal audits performed, and (5) track the implementation of the corrective action plans in order to assess the effectiveness of such plans.  Merit shall maintain the risk assessment and internal review process for the term of the</font><font style="letter-spacing:-0.1pt;"> </font>CIA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:41.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">E.</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Review</u><u style="font-size:13pt;letter-spacing:-0.1pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Procedures</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.44pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:77.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;font-style:italic;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.</font><i style="font-size:13pt;font-style:italic;">General</i><i style="font-size:13pt;font-style:italic;letter-spacing:-0.1pt;"> </i><i style="font-size:13pt;font-style:italic;">Description.</i></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">a.</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:italic;font-weight:normal;text-align:left;">Engagement of Independent Review Organization</i><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">. Within 90 days after the Effective Date, Merit shall engage an entity (or entities), such as an accounting, auditing, or consulting firm (hereinafter &#8220;Independent Review Organization&#8221; or &#8220;IRO&#8221;), to perform the reviews listed in this Section III.E. The applicable requirements relating to the IRO are outlined in Appendix A to this CIA, which is incorporated by</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">reference.</font></td><td style="width:7.65pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">b.</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:italic;font-weight:normal;text-align:left;">Retention of Records</i><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">. The IRO and Merit shall retain and make available to OIG, upon request, all work papers, supporting documentation, correspondence, and draft</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">reports</font></td><td style="width:12.4pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.55pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">10</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:12.44pt 16.45pt 0pt 150pt;">(those exchanged between the IRO and Merit) related to the reviews.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">c.</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:italic;font-weight:normal;text-align:left;">Access to Records and Personnel</i><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">. Merit shall ensure the</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">IRO has access to all records and personnel necessary to complete the reviews listed in this Section III.E., and that all records furnished to the IRO are accurate and</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">complete.</font></td><td style="width:7.3pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 27.8pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">2.</font><i style="font-size:13pt;font-style:italic;">Systems and Transactions Reviews. </i><font style="font-size:13pt;">As set forth more fully in Appendix B, the IRO reviews shall consist of two components: Systems Reviews</font><font style="font-size:13pt;letter-spacing:-0.75pt;"> </font><font style="font-size:13pt;">and Transactions Reviews relating to the Covered</font><font style="font-size:13pt;letter-spacing:-0.2pt;"> </font><font style="font-size:13pt;">Functions.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a.</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:italic;font-weight:normal;text-align:left;">Systems Review</i><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">. The Systems Reviews shall assess Merit&#8217;s systems, processes, policies, and procedures relating to the Covered Functions. If there are no material changes in Merit&#8217;s relevant systems, processes, policies, and procedures, the Systems Reviews shall be performed for the first and fourth Reporting Periods. If Merit materially changes its relevant systems, processes, policies, and procedures, the</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">IRO shall perform a Systems Review for the Reporting Period in which such changes were made in addition to conducting the Systems Review for the first and fourth Reporting Periods, as set forth more fully in Appendix</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">B.</font></td><td style="width:5.9pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.9pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">b.</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:italic;font-weight:normal;text-align:left;">Transactions Review. </i><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">The Transactions Reviews shall be performed annually and shall cover each of the five</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Reporting Periods. The IRO(s) shall perform all components of each annual Transaction Review. As set forth more fully in Appendix B, the Transactions Review shall include several components.</font></td><td style="width:5.95pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 27.9pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">3.</font><i style="font-size:13pt;font-style:italic;">IRO Review Reports</i><font style="font-size:13pt;">. The IRO shall prepare a report based</font><font style="font-size:13pt;letter-spacing:-0.65pt;"> </font><font style="font-size:13pt;">upon each IRO review performed (IRO Review Report). Information to be included in the IRO Review Report is described in Appendices</font><font style="font-size:13pt;letter-spacing:-0.1pt;"> </font><font style="font-size:13pt;">A-B.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 15.15pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">4.</font><i style="font-size:13pt;font-style:italic;">Independence and Objectivity Certification</i><font style="font-size:13pt;">. The IRO shall</font><font style="font-size:13pt;letter-spacing:-0.55pt;"> </font><font style="font-size:13pt;">include in its report(s) to Merit a certification that the IRO has: (a) evaluated its professional independence and objectivity with respect to the reviews required under this Section III.E; and (b) concluded that it is, in fact, independent and objective in accordance</font><font style="font-size:13pt;letter-spacing:-0.7pt;"> </font><font style="font-size:13pt;">with</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.2pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.55pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">11</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:12.44pt 12.5pt 0pt 6pt;">the requirements specified in Appendix A to this CIA. The IRO&#8217;s certification shall include a summary of current and prior engagements between Merit and IRO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:41.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">F.</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Disclosure</u><u style="font-size:13pt;letter-spacing:0.05pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Program</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:4.44pt 9.25pt 0pt 5.95pt;"><a name="Within_90_days_after_the_Effective_Date,"></a>Within 90 days after the Effective Date, Merit shall establish a Disclosure Program that includes a mechanism (<u style="text-decoration:underline;text-decoration-color:#000000;">e.g.</u>, a toll free compliance telephone line) to enable individuals to disclose, to the Compliance Officer or some other person who is not in the disclosing individual&#8217;s chain of command, any identified issues or questions associated with Merit&#8217;s policies, conduct, practices, or procedures with respect to a Federal health care program or an FDA requirement believed by the individual to be a potential violation of criminal, civil, or administrative law. Merit shall appropriately publicize the existence of the Disclosure Program and the disclosure mechanism (<u style="text-decoration:underline;text-decoration-color:#000000;">e.g.</u>, via periodic e- mails to employees, or by posting the information in prominent common areas).</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:35.95pt;margin:11.94pt 5.5pt 0pt 6pt;">The Disclosure Program shall emphasize a nonretribution, nonretaliation policy and shall include a reporting mechanism for anonymous communications for which appropriate confidentiality shall be maintained. The Disclosure Program also shall include a requirement that all of Merit&#8217;s Covered Persons shall be expected to report suspected violations of any Federal health care program or FDA requirements to the Compliance Officer or other appropriate individual designated by Merit. Upon receipt of a disclosure, the Compliance Officer (or designee) shall gather all relevant information from the disclosing individual. The Compliance Officer (or designee) shall make a preliminary, good faith inquiry into the allegations set forth in every disclosure to ensure that he or she has obtained all of the information necessary to determine whether a<font style="letter-spacing:-0.9pt;"> </font>further review should be conducted. For any disclosure that is sufficiently specific so that it reasonably: (1) permits a determination of the appropriateness of the alleged improper practice; and (2) provides an opportunity for taking corrective action, Merit shall conduct an internal review of the allegations set forth in the disclosure and ensure that proper follow-up is<font style="letter-spacing:-0.15pt;"> </font>conducted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:0pt 15.65pt 0pt 6pt;">The Compliance Officer (or designee) shall maintain a disclosure log and shall record all disclosures, whether or not related to a potential violation of criminal, civil or administrative law related to Federal health care programs or FDA requirements, in the disclosure log within two business days of receipt of the disclosure. The disclosure log shall include a summary of each disclosure received (whether anonymous or not), the individual or department responsible for reviewing the disclosure, the status of the review, and any corrective action taken in response to the review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.25pt 0pt 0pt 0pt;"><font style="font-size:14.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.55pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">12</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><div style="margin-top:12.44pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:41.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">G.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;"><a name="G.___Ineligible_Persons"></a></font><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;text-decoration:underline;text-decoration-color:#000000;">Ineligible</u><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;text-align:left;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;text-decoration:underline;text-decoration-color:#000000;">Persons</u></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.2pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.4pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:77.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">1.</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:italic;font-weight:normal;text-align:left;">Definitions</i><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">. For purposes of this CIA:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">an &#8220;Ineligible Person&#8221; shall include an individual or</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">entity who:</font></td><td style="width:25.75pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:149.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">i.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">is currently excluded from participation in the </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:left;">Federal </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">health care programs;</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">or</font></td><td style="width:11.75pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:149.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">ii.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">has been convicted of a criminal offense that falls within the scope of 42 U.S.C. &#167; 1320a-7(a), but has</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">not yet been</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">excluded.</font></td><td style="width:5.6pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 13.45pt 0pt 113.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">b.</font><font style="font-size:13pt;">&#8220;Exclusion List&#8221; means the HHS/OIG List of Excluded Individuals/Entities (LEIE) (available through the Internet </font><font style="font-size:13pt;letter-spacing:-0.3pt;">at</font><u style="color:#0000ff;font-size:13pt;letter-spacing:-0.3pt;text-decoration:underline;text-decoration-color:#0000ff;"> </u><u style="color:#0000ff;font-size:13pt;text-decoration:underline;text-decoration-color:#0000ff;">http://www.oig.hhs.gov</u><font style="font-size:13pt;">).</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.4pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 10.45pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">2.</font><i style="font-size:13pt;font-style:italic;">Screening Requirements. </i><font style="font-size:13pt;">Merit shall ensure that all prospective and current Covered Persons are not Ineligible Persons by implementing the following screening</font><font style="font-size:13pt;letter-spacing:-0.1pt;"> </font><font style="font-size:13pt;">requirements.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="display:inline-block;width:3.25pt;"></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Merit shall screen all prospective Covered Persons against the Exclusion List prior to engaging their services and, as</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">part of the hiring or contracting process, shall require such Covered Persons to disclose whether they are Ineligible Persons.</font></td><td style="width:6.55pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Merit shall screen all current Covered Persons against the Exclusion List within 90 days after the Effective Date and</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">on a monthly basis</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">thereafter.</font></td><td style="width:10.55pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Merit shall maintain a policy requiring all Covered Persons</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">to disclose immediately if they become an Ineligible</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Person.</font></td><td style="width:7.3pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:0pt 6.3pt 0pt 6pt;">Nothing in this Section III.G affects Merit&#8217;s responsibility to refrain from (and liability for) billing Federal health care programs for items or services furnished, ordered, or prescribed by an excluded person. Merit understands that items or services furnished, ordered, or prescribed by excluded persons are not payable by Federal health care</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.2pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.55pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">13</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:12.44pt 0pt 0pt 6pt;">programs and that Merit may be liable for overpayments and/or criminal, civil, and administrative sanctions for employing or contracting with an excluded person regardless of whether Merit meets the requirements of Section III.G.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 6.25pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">3.</font><i style="font-size:13pt;font-style:italic;">Removal Requirement</i><font style="font-size:13pt;">. If Merit has actual notice that a Covered Person has become an Ineligible Person, Merit shall remove such Covered Person from responsibility for, or involvement with, Merit&#8217;s business operations related to the Federal health care program(s) from which such Covered Person has been excluded and shall remove such Covered Person from any position for which the Covered Person&#8217;s compensation is paid in whole or part, directly or indirectly, by any Federal health care program(s) from which the Covered Person has been excluded at least until such time as the Covered Person is reinstated into participation in such Federal health care</font><font style="font-size:13pt;letter-spacing:-0.8pt;"> </font><font style="font-size:13pt;">program(s).</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 6.1pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">4.</font><i style="font-size:13pt;font-style:italic;">Pending Charges and Proposed Exclusions</i><font style="font-size:13pt;">. If Merit has actual notice that a Covered Person is charged with a criminal offense that falls within the scope of 42 U.S.C. &#167;&#167; 1320a-7(a), 1320a-7(b)(1)-(3), or is proposed for exclusion during the Covered Person&#8217;s employment or contract term, Merit shall take all appropriate actions to ensure that the responsibilities of that Covered Person have not and shall not adversely affect the quality of care rendered to any beneficiary, or the accuracy of any claims submitted to any Federal health care</font><font style="font-size:13pt;letter-spacing:0.1pt;"> </font><font style="font-size:13pt;">program.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:41.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">H.</font><a name="H.___Notification_of_Government_Investig"></a><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Notification of Government Investigation or Legal</u><u style="font-size:13pt;letter-spacing:-0.25pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Proceeding</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:4.4pt 7.5pt 0pt 6pt;">Within 30 days after discovery, Merit shall notify OIG, in writing, of any ongoing investigation or legal proceeding known to Merit conducted or brought by a governmental entity or its agents involving an allegation that Merit has committed a crime or has engaged in fraudulent activities. This notification shall include a<font style="letter-spacing:-0.65pt;"> </font>description of the allegation, the identity of the investigating or prosecuting agency, and the status of such investigation or legal proceeding. Merit also shall provide written notice to OIG within 30 days after the resolution of the matter and describe the findings and/or results of the investigation or proceeding, if<font style="letter-spacing:0.1pt;"> </font>any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:41.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">I.</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Reportable</u><u style="font-size:13pt;letter-spacing:0.05pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Events</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.4pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 53.75pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.</font><i style="font-size:13pt;font-style:italic;">Definition of Reportable Event</i><font style="font-size:13pt;">. For purposes of this CIA, a &#8220;Reportable Event&#8221; means anything that involves:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 13.8pt 0pt 113.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">a.</font><font style="font-size:13pt;">a matter that a reasonable person would consider a probable violation of criminal, civil, or administrative laws</font><font style="font-size:13pt;letter-spacing:-0.55pt;"> </font><font style="font-size:13pt;">applicable</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.55pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">14</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:12.44pt 12.5pt 0pt 150pt;">to any Federal health care program for which penalties or exclusion may be authorized;</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 9.85pt 0pt 113.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">b.</font><font style="font-size:13pt;">a matter that a reasonable person would consider a probable violation of FDA requirements relating to the promotion of Government Reimbursed Products, unless otherwise</font><font style="font-size:13pt;letter-spacing:-1pt;"> </font><font style="font-size:13pt;">reported to the FDA in accordance with Section III.J</font><font style="font-size:13pt;letter-spacing:-0.45pt;"> </font><font style="font-size:13pt;">below;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 8.05pt 0pt 113.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">c.</font><font style="font-size:13pt;">the employment of or contracting with a Covered Person</font><font style="font-size:13pt;letter-spacing:-0.55pt;"> </font><font style="font-size:13pt;">who is an Ineligible Person as defined by Section III.G.1.a;</font><font style="font-size:13pt;letter-spacing:-0.5pt;"> </font><font style="font-size:13pt;">or</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">d.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">the filing of a bankruptcy petition by</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Merit.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt 0pt 0pt 6pt;">A Reportable Event may be the result of an isolated event or a series of occurrences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 16.3pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">2.</font><i style="font-size:13pt;font-style:italic;">Reporting of Reportable Events</i><font style="font-size:13pt;">. If Merit determines (after a reasonable opportunity to conduct an appropriate review or investigation of the allegations) through any means that there is a Reportable Event, Merit shall notify</font><font style="font-size:13pt;letter-spacing:-0.75pt;"> </font><font style="font-size:13pt;">OIG, in writing, within 30 days after making the determination that the Reportable Event exists.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 51.95pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">3.</font><i style="font-size:13pt;font-style:italic;">Reportable Events under Sections III.I.1.a and III.I.1.b</i><font style="font-size:13pt;">. </font><font style="font-size:13pt;letter-spacing:-0.25pt;">For </font><font style="font-size:13pt;">Reportable Events under Sections III.I.1.a and b, the report to OIG shall</font><font style="font-size:13pt;letter-spacing:-0.7pt;"> </font><font style="font-size:13pt;">include:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36pt;text-indent:-36pt;margin:0pt 5.95pt 0pt 114pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:35.95pt;text-indent:0pt;white-space:nowrap;">a.</font><font style="font-size:13pt;">a complete description of all details relevant to the</font><font style="font-size:13pt;letter-spacing:-0.95pt;"> </font><font style="font-size:13pt;">Reportable Event, including, at a minimum, the types of claims, transactions or other conduct giving rise to the Reportable Event, the period during which the conduct occurred, and the names of individuals and entities believed to be implicated, including an explanation of their roles in the Reportable Event;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:justify;">a statement of the Federal criminal, civil or administrative laws that are probably violated by the Reportable Event,</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;text-align:justify;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:justify;">if any;</font></td><td style="width:24.95pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:justify;">the Federal health care programs affected by the</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;text-align:justify;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:justify;">Reportable Event, if</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:justify;">any;</font></td><td style="width:17.85pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.55pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">15</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><div style="margin-top:12.44pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 6.65pt 0pt 113.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">d.</font><font style="font-size:13pt;">a statement of the FDA requirements probably violated by</font><font style="font-size:13pt;letter-spacing:-0.55pt;"> </font><font style="font-size:13pt;">the Reportable Event, if any;</font><font style="font-size:13pt;letter-spacing:0.05pt;"> </font><font style="font-size:13pt;">and</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 63.25pt 0pt 113.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">e.</font><font style="font-size:13pt;">a description of Merit&#8217;s actions taken to correct</font><font style="font-size:13pt;letter-spacing:-0.5pt;"> </font><font style="font-size:13pt;">the Reportable Event and prevent it from</font><font style="font-size:13pt;letter-spacing:-0.3pt;"> </font><font style="font-size:13pt;">recurring.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 24.9pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">4.</font><i style="font-size:13pt;font-style:italic;">Reportable Events under Section III.I.1.c. </i><font style="font-size:13pt;">For Reportable Events under Section III.I.1.c, the report to OIG shall</font><font style="font-size:13pt;letter-spacing:-0.05pt;"> </font><font style="font-size:13pt;">include:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36pt;text-indent:-36pt;margin:0pt 49.9pt 0pt 114pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:35.95pt;text-indent:0pt;white-space:nowrap;">a.</font><font style="font-size:13pt;">the identity of the Ineligible Person and the job</font><font style="font-size:13pt;letter-spacing:-0.6pt;"> </font><font style="font-size:13pt;">duties performed by that</font><font style="font-size:13pt;letter-spacing:-0.2pt;"> </font><font style="font-size:13pt;">individual;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 5.55pt 0pt 113.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">b.</font><font style="font-size:13pt;">the dates of the Ineligible Person&#8217;s employment or</font><font style="font-size:13pt;letter-spacing:-0.55pt;"> </font><font style="font-size:13pt;">contractual relationship;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36pt;text-indent:-36pt;margin:0pt 6.95pt 0pt 114pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:35.95pt;text-indent:0pt;white-space:nowrap;">c.</font><font style="font-size:13pt;">a description of the Exclusion List screening that Merit completed before and/or during the Ineligible Person&#8217;s employment or contract and any flaw or breakdown in the screening process that led to the hiring or contracting with</font><font style="font-size:13pt;letter-spacing:-0.65pt;"> </font><font style="font-size:13pt;">the Ineligible</font><font style="font-size:13pt;letter-spacing:0.05pt;"> </font><font style="font-size:13pt;">Person;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:113.9pt;margin-top:0pt;padding-left:36.1pt;text-indent:-36.1pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">d.</font><font style="font-size:13pt;">a description of how the Ineligible Person was identified;</font><font style="font-size:13pt;letter-spacing:-0.35pt;"> </font><font style="font-size:13pt;">and</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">e.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">a description of any corrective action implemented to</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">prevent future employment or contracting with an Ineligible</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Person.</font></td><td style="width:9.15pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 16.75pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">5.</font><i style="font-size:13pt;font-style:italic;">Reportable Events under Section III.I.1.d</i><font style="font-size:13pt;">. For Reportable Events under Section III.I.1.d, the report to OIG shall include documentation of the</font><font style="font-size:13pt;letter-spacing:-0.75pt;"> </font><font style="font-size:13pt;">bankruptcy filing and a description of any Federal health care program and/or FDA requirements implicated.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:41.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">J.</td><td style="padding:0pt;"><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;text-decoration:underline;text-decoration-color:#000000;">Notification of Communications with</u><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;text-align:left;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;text-decoration:underline;text-decoration-color:#000000;">FDA</u></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.2pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:4.4pt 8.35pt 0pt 6pt;">Within 30 days after the date of any written report, correspondence, or communication between Merit and the FDA that materially discusses Merit&#8217;s or a Covered Person&#8217;s actual or potential unlawful or improper promotion of Merit&#8217;s<font style="letter-spacing:-0.65pt;"> </font>products (including any improper dissemination of information about off-label indications), Merit shall provide a copy of the report, correspondence, or communication to OIG. Merit shall also provide written notice to OIG within 30 days after the resolution of any<font style="letter-spacing:-0.85pt;"> </font>such</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.55pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">16</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:12.44pt 12.5pt 0pt 6pt;">disclosed improper promotional matter, and shall provide OIG with a description of the findings and/or results of the matter, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:41.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">K.</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Requirements Relating to Certain Promotional</u><u style="font-size:13pt;letter-spacing:0.1pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Activities</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:35.95pt;margin:4.44pt 5.55pt 0pt 6pt;">Within 120 days following the Effective Date, Merit shall establish and implement the following requirements relating to: (1) arrangements with HCPs to serve as presenters on behalf of Merit or participate in training programs related to the safe and effective use of Government Reimbursed Products (Speaker Programs); and (2) arrangements for marketing or other promotional activity that Merit performs with or on behalf of one or more HCPs or HCIs involving a Government Reimbursed Product (Co-Marketing).</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:77.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.</font><i style="font-size:13pt;font-style:italic;">Speaker Programs. </i><font style="font-size:13pt;">Merit shall establish and</font><font style="font-size:13pt;letter-spacing:-0.4pt;"> </font><font style="font-size:13pt;">implement:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">A process to require all speakers to complete training and enter written agreements that describe the scope of work to</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">be performed, the speaker fees to be paid, and compliance obligations for the speakers (including requirements regarding the use of Merit approved</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">materials).</font></td><td style="width:6.3pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.9pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">A centralized, electronic system to initiate and track all speaker programs that includes controls designed to ensure that speaker programs are used for legitimate and lawful purposes in accordance with all applicable Federal health care program and FDA</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">requirements.</font></td><td style="width:6.2pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">A process to ensure speakers are paid according to a</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">centrally managed, pre-set rate structure determined based on an independent fair-market value</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">analysis.</font></td><td style="width:8.45pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.9pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">d.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">A comprehensive list of speaker program attendees through its centralized system. In addition, Merit shall use its centralized system to handle all logistics and spending associated with speaker programs, including the tracking and review of the aggregate amount (including speaker fees, travel, and other expenses) paid to each speaker in</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">connection with speaker</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">programs.</font></td><td style="width:7pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.9pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">e.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">A requirement for certifications by sales representatives</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">or</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.2pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.55pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">17</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:12.44pt 8.5pt 0pt 150pt;">other Merit personnel that a speaker program complied with Merit requirements, or in the event of non-compliance, Merit shall require the identification of the policy violation and ensure appropriate follow up activity to address the violation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:77.9pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">2.</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:italic;font-weight:normal;text-align:left;">Co-Marketing Activities</i><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">. Merit shall establish and</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">implement:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">A process to ensure that a needs assessment has been complete for any Co-Marketing Activity. The needs assessment shall identify the business need for performing the Co-Marketing Activity and provide details about the Co- Marketing Activity (i.e., information about the type of Co- Marketing Activity and the role and contribution of each </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-align:left;">HCP </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">or HCI involved in the Co-Marketing</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Activity);</font></td><td style="width:5.9pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.9pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">A centralized, electronic system to track all</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Co-Marketing Activities;</font></td><td style="width:26.5pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">A process to evaluate the fair market value of any</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Co- Marketing</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Activity;</font></td><td style="width:47.55pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.9pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">d.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">A process to ensure that all arrangements to engage in Co- Marketing Activities are set forth in a written agreement</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">that describes the scope of work to be performed by all parties to the arrangement, the fees to be paid, and any work product that will be</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">produced.</font></td><td style="width:13.15pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:41.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">L.</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Field Force Monitoring and Review Efforts</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:4.44pt 6.7pt 0pt 5.95pt;">Within 120 days after the Effective Date, Merit shall establish a comprehensive Field Force Monitoring Program (FFMP) to evaluate and monitor its sales personnel&#8217;s interactions with HCPs and HCIs. The FFMP shall be a formalized process designed to directly and indirectly observe the appropriateness of sales personnel&#8217;s interactions with HCPs and HCIs and to identify potential improper conduct. As described in more detail below, the FFMP shall include: (1) direct field observations (Observations) of sales personnel and (2) the monitoring and review of other records relating to sales personnel&#8217;s interactions with HCPs and HCIs (Records Reviews).</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">18</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><div style="margin-top:12.44pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 10.1pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">1.</font><i style="font-size:13pt;font-style:italic;">Observations</i><font style="font-size:13pt;">. As a component of the FFMP, Monitoring Personnel shall conduct observations of sales representatives (including any contract sales personnel) to assess whether the messages delivered and materials distributed to HCPs and HCIs are consistent with applicable legal requirements and with Merit&#8217;s Policies</font><font style="font-size:13pt;letter-spacing:-0.75pt;"> </font><font style="font-size:13pt;">and Procedures. These observations shall be full day ride-alongs with sales representatives (Observations), and each Observation shall consist of directly observing all meetings between a sales representative and HCPs and HCIs during the workday. The Observations shall be scheduled throughout the year, judgmentally selected by Monitoring Personnel, and be conducted across the United</font><font style="font-size:13pt;letter-spacing:-0.35pt;"> </font><font style="font-size:13pt;">States.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:0pt 34.95pt 0pt 5.95pt;">At the completion of each Observation, Monitoring Personnel shall prepare a report which includes:</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:14.9pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:77.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;">1)</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;line-height:14.9pt;text-align:left;">the identity of the sales representative;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:77.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;">2)</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">the identity of the Monitoring Personnel who conducted </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-align:left;">the </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Observation;</font></td><td style="width:72.45pt;"></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:14.9pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:77.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;">3)</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;line-height:14.9pt;text-align:left;">the date and duration of the</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;line-height:14.9pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;line-height:14.9pt;text-align:left;">Observation;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:14.9pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:77.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;">4)</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;line-height:14.9pt;text-align:left;">the product(s) promoted during the</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;line-height:14.9pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;line-height:14.9pt;text-align:left;">Observation;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:77.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;">5)</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">an overall assessment of compliance with Merit Policies</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">and Procedures;</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">and</font></td><td style="width:68.15pt;"></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0.05pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:77.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;">6)</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">the identification of any potential improper conduct by the field</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">sales representative.</font></td><td style="width:23.4pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:0.05pt 9.25pt 0pt 6pt;">Monitoring Personnel shall conduct at least 5 Observations during each Reporting Period. Monitoring Personnel shall have access to all relevant records and information necessary to assess sales representatives&#8217; interactions with HCPs and HCIs and to identify potential or actual compliance violations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 23.55pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">2.</font><i style="font-size:13pt;font-style:italic;">Records Reviews</i><font style="font-size:13pt;">. As a component of the FFMP, Merit shall also review various types of records to assess sales representatives&#8217; interactions with</font><font style="font-size:13pt;letter-spacing:-0.75pt;"> </font><font style="font-size:13pt;">HCPs and HCIs and to identify potential or actual compliance</font><font style="font-size:13pt;letter-spacing:-0.25pt;"> </font><font style="font-size:13pt;">violations.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:114pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">For each Reporting Period, Merit shall develop and implement a plan for conducting Records Reviews associated with at least five Government Reimbursed Products. The Records Reviews shall include a review of records relating to the activities of sales representatives in every separate</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">district and/or region (as applicable) who promoted the products under</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">review.</font></td><td style="width:8.4pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.25pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.55pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">19</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.4pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">The Records Reviews shall include the monitoring</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">and review</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">of:</font></td><td style="width:43.4pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:149.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">(i)</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">records and systems associated with sales representatives&#8217; interactions with HCPs and HCIs (including records relating to Co-Marketing</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">activities, consulting and other fee-for-service arrangements, speaker program activities, travel and entertainment, expense reports, any payments to HCPs or HCIs, and sales communications from</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">managers);</font></td><td style="width:11.35pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:149.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">records relating to requests for medical</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">information about or inquiries relating to, the Government Reimbursed Products under</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">review;</font></td><td style="width:25.1pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:149.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">sales representative call</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">notes;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:149.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">(iv)</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">sales representatives&#8217; e-mails and other electronic records;</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">and</font></td><td style="width:34.05pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:149.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">(v)</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">recorded results of the Observations of sales force representatives, coaching guides, and manager</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">notes.</font></td><td style="width:17.2pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:72pt;margin:0pt 5.7pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">3.</font><i style="font-size:13pt;font-style:italic;">Reporting and Follow-up</i><font style="font-size:13pt;">. Results from the FFMP shall be compiled and reported to the Compliance Officer for review and remediation as</font><font style="font-size:13pt;letter-spacing:-0.45pt;"> </font><font style="font-size:13pt;">appropriate.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:41.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">M.</td><td style="padding:0pt;"><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;text-decoration:underline;text-decoration-color:#000000;">Requirements Relating to Certain Non-Promotional</u><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:left;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;text-decoration:underline;text-decoration-color:#000000;">Activities</u></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:4.44pt 5.5pt 0pt 6pt;">Within 120 days after the Effective Date, Merit shall develop policies, procedures, and systems to implement the requirements outlined below relating to the following types of activities: (1) consultant arrangement activities; and (2) grant and charitable contribution activities involving HCPs and HCIs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 5.25pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.</font><i style="font-size:13pt;font-style:italic;">Consulting Arrangement Activities</i><font style="font-size:13pt;">. To the extent that Merit engages HCPs for services other than for speaker programs (</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">e.g.,</u><font style="font-size:13pt;"> training and education services, product development activities, presentations, consultant task force meetings, advisory boards, ad hoc advisory activities, research and research-related activities, authorship activities, and any other financial engagement or arrangement with an HCP), such</font><font style="font-size:13pt;letter-spacing:-0.65pt;"> </font><font style="font-size:13pt;">HCPs</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.55pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">20</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:12.44pt 12.5pt 0pt 6pt;">shall be referred to herein as Consultants. Within 90 days of the Effective date, Merit shall:</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Require all Consultants to enter written agreements describing the scope of work to be performed, the</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">consultant fees to be paid, and compliance obligations for the Consultants. Consultants shall be paid according to a centrally managed, pre-set rate structure that is determined based on an independent fair-market value</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">analysis.</font></td><td style="width:13.45pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.9pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Establish a process to develop an annual budgeting plan that specifies (i) the business needs for, and the estimated numbers of, the various Consultant engagements and activities to occur during the following year and (ii)the budgeted amounts to be spent on Consultant-related</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">activities. Merit compliance personnel shall be involved in the review and approval of such plans, including any subsequent modification of an approved plan for the purpose of ensuring that Consultant arrangements and related events are used for legitimate and lawful purposes in accordance with applicable Federal health care program and FDA requirements and Merit Policies and</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Procedures.</font></td><td style="width:5.5pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Establish a process to ensure that a needs assessment has been completed to justify the retention of a Consultant prior to the retention of the Consultant. The needs assessment shall identify the business need for the retention of the Consultant and provide specific details about the consulting arrangement (</font><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;text-decoration:underline;text-decoration-color:#000000;">e.g</u><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">., information about the numbers and qualifications of the HCPs and HCIs to be engaged, the agenda for the proposed meeting, and a description of the proposed work to be done and the type of work product to be generated).  Any deviations from the Consultant budgeting plans shall be documented in the needs assessment form and shall be</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">subject to review and approval by Merit compliance</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">personnel.</font></td><td style="width:5.2pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.9pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">d.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Amend its policies and procedures in a manner designed to ensure that each Consultant performs the work for which</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">the</font></td><td style="width:13.8pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.5pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">21</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:12.44pt 0pt 0pt 150pt;">Consultant is engaged and that, as applicable, Merit receives the work product generated by the Consultant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 20.8pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">4.</font><i style="font-size:13pt;font-style:italic;">Grant and Charitable Contribution Activities involving HCPs </i><i style="font-size:13pt;font-style:italic;letter-spacing:-0.2pt;">and </i><i style="font-size:13pt;font-style:italic;">HCIs. </i><font style="font-size:13pt;">Within 120 days of the Effective date, Merit shall:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:114pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Establish a centralized system which shall be the exclusive mechanism through which requestors may request or be awarded amounts for Third Party Educational Activities, other grant activities involving HCPs and HCIs (referred</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">to below as &#8220;Grants&#8221;), and charitable contributions involving HCPs or HCIs (referred to below as</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">&#8220;Contributions&#8221;).</font></td><td style="width:20.75pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 6.55pt 0pt 113.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">b.</font><font style="font-size:13pt;">Establish a process to review requests for Grants and Contributions according to standardized, objective criteria developed by Merit (such as based upon the qualifications of the requestor, or the quality of the program funded by the Grant or Contribution) and to ensure that Grants and Contributions are provided only pursuant to a written agreement with the funding recipient and that payments to</font><font style="font-size:13pt;letter-spacing:-0.6pt;"> </font><font style="font-size:13pt;">the funding recipient are consistent with the written agreement. Merit&#8217;s sales and marketing personnel shall have no involvement in, or influence over, the review and approval of requests for Grants and</font><font style="font-size:13pt;letter-spacing:0.2pt;"> </font><font style="font-size:13pt;">Contributions.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:41.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">N.</td><td style="padding:0pt;"><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;text-decoration:underline;text-decoration-color:#000000;">Reporting of Physician</u><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;text-align:left;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;text-decoration:underline;text-decoration-color:#000000;">Payments</u></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.25pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.44pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:72pt;margin:0pt 15.65pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.</font><i style="font-size:13pt;font-style:italic;">Reporting of Payment Information. </i><font style="font-size:13pt;">Within 90 days after the Effective Date, Merit shall post on its website a description of the types of Payments it makes to Covered Recipients and include a link to CMS&#8217;s Open Payments Data</font><font style="font-size:13pt;letter-spacing:-0.8pt;"> </font><font style="font-size:13pt;">website (</font><u style="color:#0000ff;font-size:13pt;text-decoration:underline;text-decoration-color:#0000ff;">www.openpaymentsdata.cms.gov</u><font style="font-size:13pt;">). Merit also shall include on its website instructions regarding how to utilize the CMS Open Payments Data search tool to search for information regarding Payments provided to Covered Recipients from</font><font style="font-size:13pt;letter-spacing:-0.05pt;"> </font><font style="font-size:13pt;">Merit.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 21.2pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">2.</font><i style="font-size:13pt;font-style:italic;">Definitions. </i><font style="font-size:13pt;">For purposes of this Section III.M, the terms &#8220;Payments&#8221; and &#8220;Covered Recipient&#8221; are defined as specified in 42 U.S.C. &#167; 1320a-7h and the related regulations and guidance (including FAQs) published by</font><font style="font-size:13pt;letter-spacing:-0.55pt;"> </font><font style="font-size:13pt;">CMS.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">22</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:13pt;font-weight:bold;margin-left:5.95pt;margin-top:12.44pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">IV.</font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SUCCESSOR</b><b style="font-weight:bold;letter-spacing:-0.1pt;text-decoration:underline;text-decoration-color:#000000;"> </b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">LIABILITY</b></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.2pt 0pt 0pt 0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:4.4pt 4.6pt 0pt 6pt;">In the event that, after the Effective Date, Merit proposes to (a) sell any or all of its business, business units or locations (whether through a sale of assets, sale of stock or other type of transaction) that are subject to this CIA; or (b) purchases or establishes a new business, business unit or location related to or engaged in any of the Covered Functions, the CIA shall be binding on the purchaser of any business, business unit or location. Any such new business, business unit or location (and all Covered Persons at each new business, business unit or location) shall be subject to the applicable requirements of this CIA, unless otherwise determined and agreed to in writing by OIG. Merit shall give notice of such sale or purchase to OIG within 30 days following the closing of the transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:0pt 7.4pt 0pt 5.95pt;">If, in advance of a proposed sale or a proposed purchase, Merit wishes to obtain a determination by OIG that the proposed purchaser or the proposed acquisition will not be subject to the requirements of the CIA, Merit must notify OIG in writing of the proposed sale or purchase at least 30 days in advance. This notification shall include a description of the business, business unit, or location to be sold or purchased, a brief description of the terms of the transaction and, in the case of a proposed sale, the name and contact information of the prospective purchaser.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:13pt;font-weight:bold;margin-bottom:0pt;margin-left:5.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">V.</font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">IMPLEMENTATION AND ANNUAL</b><b style="font-weight:bold;letter-spacing:-0.05pt;text-decoration:underline;text-decoration-color:#000000;"> </b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">REPORTS</b></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.4pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:41.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">A.</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Implementation</u><u style="font-size:13pt;letter-spacing:-0.1pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Report</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:4.44pt 26.65pt 0pt 5.95pt;">Within 150 days after the Effective Date, Merit shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 26pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">1.</font><font style="font-size:13pt;">the name, business address, business phone number, and</font><font style="font-size:13pt;letter-spacing:-0.65pt;"> </font><font style="font-size:13pt;">position description of the Compliance Officer required by Section III.A.1, and a summary of other noncompliance job responsibilities the Compliance Officer may</font><font style="font-size:13pt;letter-spacing:-0.25pt;"> </font><font style="font-size:13pt;">have;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:75.2pt;margin:0pt 56.95pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:32.8pt;text-indent:0pt;white-space:nowrap;">2.</font><font style="font-size:13pt;">the names and positions of the members of the</font><font style="font-size:13pt;letter-spacing:-0.55pt;"> </font><font style="font-size:13pt;">Compliance Committee required by Section</font><font style="font-size:13pt;letter-spacing:0.2pt;"> </font><font style="font-size:13pt;">III.A.2;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 9pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">3.</font><font style="font-size:13pt;">the names of the Audit Committee members who are responsible</font><font style="font-size:13pt;letter-spacing:-0.65pt;"> </font><font style="font-size:13pt;">for satisfying the Board compliance obligations described in Section</font><font style="font-size:13pt;letter-spacing:-0.2pt;"> </font><font style="font-size:13pt;">III.A.3;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:13.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.55pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">23</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><div style="margin-top:12.44pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:72pt;margin:0pt 20.5pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.</font><font style="font-size:13pt;">the names and positions of the Certifying Employees required by Section III.A.4 and a copy of the written process for Certifying Employees to follow</font><font style="font-size:13pt;letter-spacing:-1.05pt;"> </font><font style="font-size:13pt;">in order to complete the certification required by Section</font><font style="font-size:13pt;letter-spacing:-0.2pt;"> </font><font style="font-size:13pt;">III.A.4;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:77.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">a list of the Policies and Procedures required by Section</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">III.B.1;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 6.5pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">6.</font><font style="font-size:13pt;">the Training Plan required by Section III.C.1 and a description of</font><font style="font-size:13pt;letter-spacing:-0.75pt;"> </font><font style="font-size:13pt;">the Board of Directors training required by Section III.C.2 (including a summary of the topics covered, the length of the training and when the training was</font><font style="font-size:13pt;letter-spacing:-0.4pt;"> </font><font style="font-size:13pt;">provided);</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 35.4pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">7.</font><font style="font-size:13pt;">a description of the risk assessment and internal review</font><font style="font-size:13pt;letter-spacing:-0.6pt;"> </font><font style="font-size:13pt;">process required by Section</font><font style="font-size:13pt;letter-spacing:0.1pt;"> </font><font style="font-size:13pt;">III.D;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 6.15pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">8.</font><font style="font-size:13pt;">the following information regarding the IRO(s): (a) identity,</font><font style="font-size:13pt;letter-spacing:-0.65pt;"> </font><font style="font-size:13pt;">address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; and (d) a certification from the IRO regarding its professional independence and objectivity with respect to Merit that includes a summary of all current and prior engagements between Merit and the</font><font style="font-size:13pt;letter-spacing:-0.2pt;"> </font><font style="font-size:13pt;">IRO;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:77.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">9.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">a description of the Disclosure Program required by Section</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">III.F;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 4.9pt 0pt 6.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">10.</font><font style="font-size:13pt;">a description of the Ineligible Persons screening and removal process required by Section</font><font style="font-size:13pt;letter-spacing:0.1pt;"> </font><font style="font-size:13pt;">III.G;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 36.05pt 0pt 6.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">11.</font><font style="font-size:13pt;">a description of policies, procedures, and systems</font><font style="font-size:13pt;letter-spacing:-0.6pt;"> </font><font style="font-size:13pt;">implemented pursuant to the Requirements Relating to Certain Promotional Activities outlined in Section</font><font style="font-size:13pt;letter-spacing:-0.1pt;"> </font><font style="font-size:13pt;">III.K;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:78pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">12.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">a description of the FFMP required by Section</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">III.L;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 10.65pt 0pt 6.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">13.</font><font style="font-size:13pt;">a description of the policies, procedures, and systems implemented pursuant to the Requirements Relating to Certain Non-Promotional Activities outlined in Section</font><font style="font-size:13pt;letter-spacing:-0.1pt;"> </font><font style="font-size:13pt;">III.M;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 31.45pt 0pt 6.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">14.</font><font style="font-size:13pt;">a certification from the Compliance Officer that information regarding Payments has been posted on Merit&#8217;s website as required by Section</font><font style="font-size:13pt;letter-spacing:-0.9pt;"> </font><font style="font-size:13pt;">III.N;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">24</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><div style="margin-top:12.44pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 10.1pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">15.</font><font style="font-size:13pt;">a list of all of Merit&#8217;s locations (including locations and mailing addresses); the corresponding name under which each location is doing business; and</font><font style="font-size:13pt;letter-spacing:-0.7pt;"> </font><font style="font-size:13pt;">the locations&#8217; Medicare and state Medicaid provider number and/or supplier number(s) if any;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.2;text-indent:72pt;margin:0pt 14.4pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">16.</font><font style="font-size:13pt;">a description of Merit&#8217;s corporate structure, includin</font><font style="font-family:'Goudy Old Style';font-size:13pt;">g</font><font style="font-family:'Goudy Old Style';font-size:13pt;letter-spacing:-0.55pt;"> </font><font style="font-size:13pt;">identification of any parent and sister companies, subsidiaries, and their respective lines of business; and</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.25pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:77.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">17.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">the certifications required by Section</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">V.C.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:41.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">B.</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Annual</u><u style="font-size:13pt;letter-spacing:-0.1pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Reports</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:4.4pt 12.5pt 0pt 5.95pt;">Merit shall submit a written report to OIG on its compliance with the CIA requirements for each of the five Reporting Periods (Annual Report). Each Annual Report shall include, at a minimum, the following information:</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 17pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">1.</font><font style="font-size:13pt;">any change in the identity, position description, or other noncompliance job responsibilities of the Compliance Officer; a current list of the Compliance Committee members; a current list of the Audit Committee members who are responsible for satisfying the Board compliance obligations; and a current list of</font><font style="font-size:13pt;letter-spacing:-0.75pt;"> </font><font style="font-size:13pt;">the Certifying Employees, along with the identification of any changes made during the Reporting Period to the Compliance Committee, Audit Committee, and Certifying Employees;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 23.9pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">2.</font><font style="font-size:13pt;">a description of any changes to the written process for Certifying Employees to follow in order to complete the certification required by Section</font><font style="font-size:13pt;letter-spacing:-0.7pt;"> </font><font style="font-size:13pt;">III.A.4;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 12.35pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">3.</font><font style="font-size:13pt;">the dates of each report made by the Compliance Officer to the Audit Committee (written documentation of such reports shall be made available to</font><font style="font-size:13pt;letter-spacing:-0.9pt;"> </font><font style="font-size:13pt;">OIG upon</font><font style="font-size:13pt;letter-spacing:-0.1pt;"> </font><font style="font-size:13pt;">request);</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 22.1pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">4.</font><font style="font-size:13pt;">the Audit Committee resolution required by Section III.A.3, a description of the documents and other materials reviewed by the Audit Committee,</font><font style="font-size:13pt;letter-spacing:-0.7pt;"> </font><font style="font-size:13pt;">as well as any additional steps taken, in its oversight of the compliance program and in support of making the resolution, and the Compliance Expert report as required in Section</font><font style="font-size:13pt;letter-spacing:-0.1pt;"> </font><font style="font-size:13pt;">III.A.3.d.;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 34pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">5.</font><font style="font-size:13pt;">a list of any new or revised Policies and Procedures required</font><font style="font-size:13pt;letter-spacing:-0.65pt;"> </font><font style="font-size:13pt;">by Section III.B.1 developed during the Reporting</font><font style="font-size:13pt;letter-spacing:-0.35pt;"> </font><font style="font-size:13pt;">Period;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.55pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">25</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.4pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 31.1pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">6.</font><font style="font-size:13pt;">a description of any changes to Merit&#8217;s Training Plan</font><font style="font-size:13pt;letter-spacing:-0.65pt;"> </font><font style="font-size:13pt;">developed pursuant to Section III.C and a summary of any Board of Directors training provided during the Reporting</font><font style="font-size:13pt;letter-spacing:-0.05pt;"> </font><font style="font-size:13pt;">Period;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 35.75pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">7.</font><font style="font-size:13pt;">a description of any changes to the risk assessment and</font><font style="font-size:13pt;letter-spacing:-0.65pt;"> </font><font style="font-size:13pt;">internal review process required by Section III.D, including the reasons for such</font><font style="font-size:13pt;letter-spacing:-0.65pt;"> </font><font style="font-size:13pt;">changes;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:72pt;margin:0pt 15.5pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:35.95pt;text-indent:0pt;white-space:nowrap;">8.</font><font style="font-size:13pt;">a summary of the following components of the risk assessment</font><font style="font-size:13pt;letter-spacing:-0.6pt;"> </font><font style="font-size:13pt;">and internal review process during the Reporting Period: (a) work plans developed; (b) internal audits performed; (c) corrective action plans developed in response to internal audits; and (d) steps taken to track the implementation of the corrective action plans. Copies of any work plans, internal audit reports, and corrective action plans shall be made available to OIG upon</font><font style="font-size:13pt;letter-spacing:-0.15pt;"> </font><font style="font-size:13pt;">request;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.2pt 0pt 0pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 8.3pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">9.</font><font style="font-size:13pt;">a complete copy of all reports prepared pursuant to Section III.E</font><font style="font-size:13pt;letter-spacing:-0.7pt;"> </font><font style="font-size:13pt;">and Merit&#8217;s response to the reports, along with corrective action plan(s) related to any issues raised by the</font><font style="font-size:13pt;letter-spacing:-0.2pt;"> </font><font style="font-size:13pt;">reports;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 9.75pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">10.</font><font style="font-size:13pt;">a certification from the IRO regarding its professional</font><font style="font-size:13pt;letter-spacing:-0.6pt;"> </font><font style="font-size:13pt;">independence and objectivity with respect to Merit, including a summary of all current and prior engagements between Merit and the</font><font style="font-size:13pt;letter-spacing:-0.15pt;"> </font><font style="font-size:13pt;">IRO;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 5.1pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">11.</font><font style="font-size:13pt;">a summary of the disclosures in the disclosure log required by Section III.F that relate to Federal health care programs, FDA requirements, or Government Reimbursed Products, including at least the following information: (a) a description of the disclosure, (b) the date the disclosure was received, (c) the resolution</font><font style="font-size:13pt;letter-spacing:-0.85pt;"> </font><font style="font-size:13pt;">of the disclosure, and (d) the date the disclosure was resolved (if applicable). The complete disclosure log shall be made available to OIG upon</font><font style="font-size:13pt;letter-spacing:-0.25pt;"> </font><font style="font-size:13pt;">request;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 12.6pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">12.</font><font style="font-size:13pt;">a description of any changes to the Ineligible Persons screening</font><font style="font-size:13pt;letter-spacing:-0.6pt;"> </font><font style="font-size:13pt;">and removal process required by Section III.G, including the reasons for such</font><font style="font-size:13pt;letter-spacing:-0.65pt;"> </font><font style="font-size:13pt;">changes;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 8.25pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">13.</font><font style="font-size:13pt;">a summary describing any ongoing investigation or legal</font><font style="font-size:13pt;letter-spacing:-0.5pt;"> </font><font style="font-size:13pt;">proceeding required to have been reported pursuant to Section III.H. The summary shall include a description of the allegation, the identity of the investigating or prosecuting agency, and the status of such investigation or legal</font><font style="font-size:13pt;letter-spacing:-0.25pt;"> </font><font style="font-size:13pt;">proceeding;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:77.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">14.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">a summary of Reportable Events (as defined in Section</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">III.I)</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.5pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">26</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:12.44pt 0pt 0pt 6pt;">identified during the Reporting Period;</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 23.15pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">15.</font><font style="font-size:13pt;">a summary describing any written communication with the FDA required to have been reported pursuant to Section III.J. This summary shall include</font><font style="font-size:13pt;letter-spacing:-0.75pt;"> </font><font style="font-size:13pt;">a description of each matter and the status of each</font><font style="font-size:13pt;letter-spacing:-0.05pt;"> </font><font style="font-size:13pt;">matter;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 16.9pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">16.</font><font style="font-size:13pt;">a summary of any changes to the policies, procedures, and</font><font style="font-size:13pt;letter-spacing:-0.55pt;"> </font><font style="font-size:13pt;">systems relating to the Requirements for Certain Promotional Activities described in Section III.K, including the reasons for such</font><font style="font-size:13pt;letter-spacing:-0.2pt;"> </font><font style="font-size:13pt;">changes;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 17.6pt 0pt 6.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">17.</font><font style="font-size:13pt;">the results of the FFMP required by Section III.L, including</font><font style="font-size:13pt;letter-spacing:-0.6pt;"> </font><font style="font-size:13pt;">copies of the Observations for any instances in which it was determined that improper conduct occurred and a description of the action(s) that Merit took as a result of such determinations;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 8.6pt 0pt 6.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">17.</font><font style="font-size:13pt;">a summary of any changes to the policies, procedures, and systems relating to the Requirements for Certain Non-Promotional Activities described in</font><font style="font-size:13pt;letter-spacing:-0.6pt;"> </font><font style="font-size:13pt;">Section III.M, including the reasons for such</font><font style="font-size:13pt;letter-spacing:-0.35pt;"> </font><font style="font-size:13pt;">changes;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 31.4pt 0pt 6.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">18.</font><font style="font-size:13pt;">a certification from the Compliance Officer that information regarding Payments has been posted on Merit&#8217;s website as required by Section</font><font style="font-size:13pt;letter-spacing:-0.9pt;"> </font><font style="font-size:13pt;">III.N;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 33.9pt 0pt 6.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">19.</font><font style="font-size:13pt;">a description of all changes to the most recently provided list</font><font style="font-size:13pt;letter-spacing:-0.7pt;"> </font><font style="font-size:13pt;">of Merit&#8217;s locations (including addresses) as required by Section</font><font style="font-size:13pt;letter-spacing:-0.5pt;"> </font><font style="font-size:13pt;">V.A.13;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 5.35pt 0pt 6.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">20.</font><font style="font-size:13pt;">a description of any changes to Merit&#8217;s corporate structure,</font><font style="font-size:13pt;letter-spacing:-0.6pt;"> </font><font style="font-size:13pt;">including any parent and sister companies, subsidiaries, and their respective lines of business;</font><font style="font-size:13pt;letter-spacing:-0.8pt;"> </font><font style="font-size:13pt;">and</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:78pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">21.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">the certifications required by Section</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">V.C.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:0pt 12.5pt 0pt 6pt;">The first Annual Report shall be received by OIG no later than 60 days after the end of the first Reporting Period. Subsequent Annual Reports shall be received by OIG no later than the anniversary date of the due date of the first Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:41.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">C.</td><td style="padding:0pt;"><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;text-decoration:underline;text-decoration-color:#000000;">Certifications</u></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 20.3pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">1.</font><i style="font-size:13pt;font-style:italic;">Certifying Employees</i><font style="font-size:13pt;">. In each Annual Report, Merit shall include the certifications of Certifying Employees as required by Section</font><font style="font-size:13pt;letter-spacing:-0.05pt;"> </font><font style="font-size:13pt;">III.A.4;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">27</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><div style="margin-top:12.44pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 43pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">2.</font><i style="font-size:13pt;font-style:italic;">Compliance Officer and Chief Executive Officer</i><font style="font-size:13pt;">. The Implementation Report and each Annual Report shall include a certification by</font><font style="font-size:13pt;letter-spacing:-0.75pt;"> </font><font style="font-size:13pt;">the Compliance Officer and Chief Executive Officer</font><font style="font-size:13pt;letter-spacing:-0.05pt;"> </font><font style="font-size:13pt;">that:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:justify;">to the best of his or her knowledge, except as otherwise described in the report, Merit has implemented and is</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;text-align:justify;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:justify;">in compliance with all requirements of this</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;text-align:justify;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:justify;">CIA;</font></td><td style="width:38.05pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 6.95pt 0pt 113.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">b.</font><font style="font-size:13pt;">he or she has reviewed the report and has made reasonable inquiry regarding its content and believes that the</font><font style="font-size:13pt;letter-spacing:-0.6pt;"> </font><font style="font-size:13pt;">information in the report is accurate and truthful;</font><font style="font-size:13pt;letter-spacing:-0.15pt;"> </font><font style="font-size:13pt;">and</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">he or she understands that the certification is being</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">provided to and relied upon by the United States.</font></td><td style="width:15.25pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:41.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">D.</td><td style="padding:0pt;"><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;text-decoration:underline;text-decoration-color:#000000;">Designation of</u><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:left;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;text-decoration:underline;text-decoration-color:#000000;">Information</u></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:4.44pt 1.8pt 0pt 6pt;">Merit shall clearly identify any portions of its submissions that it believes are trade secrets, or information that is commercial or financial and privileged or confidential, and therefore potentially exempt from disclosure under the Freedom of Information Act (FOIA), 5 U.S.C. &#167; 552. Merit shall refrain from identifying any information as exempt from disclosure if that information does not meet the criteria for exemption from disclosure under FOIA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:13pt;font-weight:bold;margin-bottom:0pt;margin-left:5.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">VI.</font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">NOTIFICATIONS AND SUBMISSION OF</b><b style="font-weight:bold;letter-spacing:-0.25pt;text-decoration:underline;text-decoration-color:#000000;"> </b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">REPORTS</b></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:4.4pt 24.5pt 0pt 5.95pt;">Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities:</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt 0pt 0pt 150pt;"><a name="OIG:"></a><u style="text-decoration:underline;text-decoration-color:#000000;">OIG</u>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-align:justify;margin:4.44pt 104.5pt 0pt 150pt;"><a name="Administrative_and_Civil_Remedies_Branch"></a>Administrative and Civil Remedies <font style="letter-spacing:-0.15pt;">Branch</font><a name="Office_of_Counsel_to_the_Inspector_Gener"></a><font style="letter-spacing:-0.15pt;"> </font><a name="Office_of_Inspector_General"></a>Office of Counsel to the Inspector General Office of Inspector General</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt 77.45pt 0pt 150pt;"><a name="U.S._Department_of_Health_and_Human_Serv"></a><a name="Cohen_Building,_Room_5527"></a>U.S. Department of Health and Human Services Cohen Building, Room 5527</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt 157.7pt 0pt 149.95pt;"><a name="330_Independence_Avenue,_S.W."></a>330 Independence Avenue, <font style="letter-spacing:-0.2pt;">S.W.</font><a name="Washington,_DC__20201"></a><font style="letter-spacing:-0.2pt;"> </font>Washington, DC<font style="letter-spacing:3.2pt;"> </font>20201</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;line-height:14.9pt;margin:0pt 0pt 0pt 149.95pt;"><a name="Telephone:__202.619.2078"></a>Telephone: 202.619.2078</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.55pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">28</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;line-height:2.38;margin:12.44pt 168.55pt 0pt 150pt;"><a name="Facsimile:__202.205.0604"></a>Facsimile: 202.205.0604 Merit:</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;line-height:14.9pt;margin:0pt 0pt 0pt 150pt;">David Lewis</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 168.55pt 0pt 150pt;">1600 West Merit Parkway South Jordan, UT 84095 Telephone: (801) 316-3835</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 149.95pt;">Email Address:<font style="letter-spacing:3.1pt;"> </font>David.Lewis@merit.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:0pt 1.8pt 0pt 6pt;">Unless otherwise specified, all notifications and reports required by this CIA may be made by electronic mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. Upon request by OIG, Merit may be required to provide OIG with an additional copy of each notification or report required by this CIA in OIG&#8217;s requested format (electronic or paper).</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:13pt;font-weight:bold;margin-bottom:0pt;margin-left:5.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">VII.</font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">OIG INSPECTION, AUDIT, AND REVIEW</b><b style="font-weight:bold;letter-spacing:-0.15pt;text-decoration:underline;text-decoration-color:#000000;"> </b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">RIGHTS</b></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:4.44pt 8.8pt 0pt 5.95pt;">In addition to any other rights OIG may have by statute, regulation, or contract, OIG or its duly authorized representative(s) may conduct interviews, examine and/or request copies of or copy Merit&#8217;s books, records, and other documents and supporting materials and/or conduct on-site reviews of any of Merit&#8217;s locations for the purpose of verifying and evaluating: (a) Merit&#8217;s compliance with the terms of this CIA and (b) Merit&#8217;s compliance with Federal health care program requirements and with all applicable FDA requirements. The documentation described above shall be made available by Merit to OIG or its duly authorized representative(s) at all reasonable times for inspection, audit, and/or reproduction. Furthermore, for purposes of this provision, OIG or its duly authorized representative(s) may interview any of Merit&#8217;s owners, employees, contractors and directors who consent to be interviewed at the individual&#8217;s place of business during normal business hours or at such other place and time as may be mutually agreed upon between the individual and OIG. Merit shall assist OIG or its duly authorized representative(s) in contacting and arranging interviews with such individuals upon OIG&#8217;s request. Merit&#8217;s owners, employees, contractors and directors may elect to be interviewed with or without a representative of Merit present.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-size:14pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.55pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">29</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:13pt;margin-top:12.44pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:5.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">VIII.</td><td style="padding:0pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:bold;text-align:left;text-decoration:underline;text-decoration-color:#000000;">DOCUMENT AND RECORD</b><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:bold;letter-spacing:-0.05pt;text-align:left;text-decoration:underline;text-decoration-color:#000000;"> </b><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:bold;text-align:left;text-decoration:underline;text-decoration-color:#000000;">RETENTION</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.2pt 0pt 0pt 0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:4.4pt 19.35pt 0pt 5.95pt;">Merit shall maintain for inspection all documents and records relating to reimbursement from the Federal health care programs and to compliance with this CIA for six years (or longer if otherwise required by law) from the Effective Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:13pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:5.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">IX.</td><td style="padding:0pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:bold;text-align:left;text-decoration:underline;text-decoration-color:#000000;">DISCLOSURES</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.25pt 0pt 0pt 0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:4.44pt 12.5pt 0pt 5.95pt;">Consistent with HHS&#8217;s FOIA procedures, set forth in 45 C.F.R. Part 5, OIG shall make a reasonable effort to notify Merit prior to any release by OIG of information submitted by Merit pursuant to its obligations under this CIA and identified upon submission by Merit as trade secrets, or information that is commercial or financial and privileged or confidential, under the FOIA rules. With respect to such releases, Merit shall have the rights set forth at 45 C.F.R. &#167; 5.42 (a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:13pt;font-weight:bold;margin-bottom:0pt;margin-left:5.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">X.</font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">BREACH AND DEFAULT</b><b style="font-weight:bold;letter-spacing:0.1pt;text-decoration:underline;text-decoration-color:#000000;"> </b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">PROVISIONS</b></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.25pt 0pt 0pt 0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:4.44pt 0pt 0pt 42pt;">Merit is expected to fully and timely comply with all of its CIA<font style="letter-spacing:-0.65pt;"> </font>obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:41.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">A.</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Stipulated Penalties for Failure to Comply with Certain</u><u style="font-size:13pt;letter-spacing:-0.55pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Obligations</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:4.44pt 13.7pt 0pt 5.95pt;">As a contractual remedy, Merit and OIG hereby agree that failure to comply with certain obligations as set forth in this CIA may lead to the imposition of the following monetary penalties (hereinafter referred to as &#8220;Stipulated Penalties&#8221;) in accordance with the following provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 19.2pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">1.</font><font style="font-size:13pt;">A Stipulated Penalty of $2,500 (which shall begin to accrue on</font><font style="font-size:13pt;letter-spacing:-0.75pt;"> </font><font style="font-size:13pt;">the day after the date the obligation became due) per obligation for each day Merit fails to establish, implement or comply with any of the following obligations as described in Section</font><font style="font-size:13pt;letter-spacing:-0.1pt;"> </font><font style="font-size:13pt;">III:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">a Compliance</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Officer;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">a Compliance</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Committee;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">the Board compliance obligations and the engagement of</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">a Compliance Expert, the performance of a Compliance Program Review, and the preparation of a Compliance Program Review Report, as required by Section</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">III.A.3;</font></td><td style="width:23.6pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.55pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">30</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.4pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 31.2pt 0pt 113.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">d.</font><font style="font-size:13pt;">the management certification obligations and the development and implementation of a written process </font><font style="font-size:13pt;letter-spacing:-0.2pt;">for </font><font style="font-size:13pt;">Certifying Employees, as required by Section</font><font style="font-size:13pt;letter-spacing:-0.05pt;"> </font><font style="font-size:13pt;">III.A.4;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:113.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">e.</font><font style="font-size:13pt;">written Policies and</font><font style="font-size:13pt;letter-spacing:-0.2pt;"> </font><font style="font-size:13pt;">Procedures;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">f.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">the development of a written training plan and the</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">training and education of Covered Persons and Board</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">members</font><font style="color:#000000;font-family:'Goudy Old Style';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">;</font></td><td style="width:25.45pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-family:'Goudy Old Style';visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">g.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">a risk assessment and internal review</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">process;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:13.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">h.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">a Disclosure</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Program;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">i.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Ineligible Persons screening and removal</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">requirements;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">j.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">notification of Government investigations or </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:left;">legal </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">proceedings;</font></td><td style="width:68.6pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">k.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">reporting of Reportable</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:0.1pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Events;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">l.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">notification of written communications with FDA;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:114pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">m.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">the Requirements Relating to Certain Promotional</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Activities;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:114pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">n.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">the</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">FFMP;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:114pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">n.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">the Requirements Relating to Certain</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Non-Promotional Activities;</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">and,</font></td><td style="width:41.2pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:114pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">o.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">posting of any Payment-related</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">information.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 17.4pt 0pt 6.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">2.</font><font style="font-size:13pt;">A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day Merit fails to engage and</font><font style="font-size:13pt;letter-spacing:-0.8pt;"> </font><font style="font-size:13pt;">use an IRO as required by Section III.E and Appendix</font><font style="font-size:13pt;letter-spacing:-0.25pt;"> </font><font style="font-size:13pt;">B.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-size:13.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 7.2pt 0pt 6.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">3.</font><font style="font-size:13pt;">A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day Merit fails to timely submit</font><font style="font-size:13pt;letter-spacing:-0.65pt;"> </font><font style="font-size:13pt;">(a) a complete Implementation Report or Annual Report, (b) a certification to OIG</font><font style="font-size:13pt;letter-spacing:-0.4pt;"> </font><font style="font-size:13pt;">in</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.55pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">31</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:12.44pt 8.15pt 0pt 6pt;">accordance with the requirements of Section V, or (c) a complete response to any request for information from OIG.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-size:13.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 13.75pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">4.</font><font style="font-size:13pt;">A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day Merit fails to submit any IRO Review report in accordance with the requirements of Section III.E and Appendix</font><font style="font-size:13pt;letter-spacing:-0.7pt;"> </font><font style="font-size:13pt;">B.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 21.05pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">5.</font><font style="font-size:13pt;">A Stipulated Penalty of $1,500 for each day Merit fails to grant access as required in Section VII. (This Stipulated Penalty shall begin to accrue on</font><font style="font-size:13pt;letter-spacing:-0.9pt;"> </font><font style="font-size:13pt;">the date Merit fails to grant</font><font style="font-size:13pt;letter-spacing:-0.15pt;"> </font><font style="font-size:13pt;">access.)</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 5.9pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">6.</font><font style="font-size:13pt;">A Stipulated Penalty of $50,000 for each false certification submitted by or on behalf of Merit as part of its Implementation Report, any Annual Report, additional documentation to a report (as requested by OIG), or otherwise</font><font style="font-size:13pt;letter-spacing:-0.8pt;"> </font><font style="font-size:13pt;">required by this</font><font style="font-size:13pt;letter-spacing:-0.15pt;"> </font><font style="font-size:13pt;">CIA.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 12.45pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">7.</font><font style="font-size:13pt;">A Stipulated Penalty of $2,500 for each day Merit fails to grant the IRO access to all records and personnel necessary to complete the reviews required by Section III.E and for each day Merit fails to furnish accurate and complete records to</font><font style="font-size:13pt;letter-spacing:-0.95pt;"> </font><font style="font-size:13pt;">the IRO, as required by Section III.E and Appendix B;</font><font style="font-size:13pt;letter-spacing:-0.35pt;"> </font><font style="font-size:13pt;">and</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 7.2pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">8.</font><font style="font-size:13pt;">A Stipulated Penalty of $1,000 for each day Merit fails to comply fully and adequately with any obligation of this CIA. OIG shall provide notice to Merit stating the specific grounds for its determination that Merit has failed to comply fully</font><font style="font-size:13pt;letter-spacing:-0.7pt;"> </font><font style="font-size:13pt;">and adequately with the CIA obligation(s) at issue and steps Merit shall take to comply with the CIA. (This Stipulated Penalty shall begin to accrue 10 business days after the date Merit receives this notice from OIG of the failure to comply.) A Stipulated Penalty as described in this Subsection shall not be demanded for any violation for which OIG has sought a Stipulated Penalty under Subsections 1- 7 of this</font><font style="font-size:13pt;letter-spacing:-0.2pt;"> </font><font style="font-size:13pt;">Section.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:41.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">B.</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Timely Written Requests for</u><u style="font-size:13pt;letter-spacing:-0.25pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Extensions</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:4.44pt 19.35pt 0pt 5.95pt;">Merit may, in advance of the due date, submit a timely written request for an extension of time to perform any act or file any notification or report required by this CIA. Notwithstanding any other provision in this Section, if OIG grants the timely written request with respect to an act, notification, or report, Stipulated Penalties for failure to perform the act or file the notification or report shall not begin to accrue until one day after Merit fails to meet the revised deadline set by OIG. Notwithstanding any other provision in this Section, if OIG denies such a timely written request, Stipulated</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:8.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.55pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">32</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:12.44pt 5.2pt 0pt 6pt;">Penalties for failure to perform the act or file the notification or report shall not begin to accrue until three business days after Merit receives OIG&#8217;s written denial of such request or the original due date, whichever is later. A &#8220;timely written request&#8221; is defined as a request in writing received by OIG at least five business days prior to the date by which any act is due to be performed or any notification or report is due to be filed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:41.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">C.</font><a name="C.___Payment_of_Stipulated_Penalties"></a><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Payment of Stipulated</u><u style="font-size:13pt;letter-spacing:0.1pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Penalties</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.4pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 8pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.</font><i style="font-size:13pt;font-style:italic;">Demand Letter</i><font style="font-size:13pt;">. Upon a finding that Merit has failed to comply with any of the obligations described in Section X.A and after determining that Stipulated Penalties are appropriate, OIG shall notify Merit of: (a) Merit&#8217;s failure to comply;</font><font style="font-size:13pt;letter-spacing:-0.75pt;"> </font><font style="font-size:13pt;">and</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt 0pt 0pt 6pt;">(b) OIG&#8217;s exercise of its contractual right to demand payment of the Stipulated Penalties (this notification is referred to as the &#8220;Demand Letter&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 5.1pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">2.</font><i style="font-size:13pt;font-style:italic;">Response to Demand Letter. </i><font style="font-size:13pt;">Within 10 business days after the receipt of the Demand Letter, Merit shall either: (a) cure the breach to OIG&#8217;s satisfaction and pay the applicable Stipulated Penalties or (b) request a hearing before an HHS administrative law judge (ALJ) to dispute OIG&#8217;s determination of noncompliance, pursuant to the agreed upon provisions set forth below in Section X.E. In the event Merit elects to request an ALJ hearing, the Stipulated Penalties shall continue to accrue until Merit cures, to OIG&#8217;s satisfaction, the alleged breach in dispute. Failure to respond to the Demand Letter in one of these two manners within the allowed time period shall be considered a material breach of this CIA and shall be grounds for exclusion under</font><font style="font-size:13pt;letter-spacing:-0.75pt;"> </font><font style="font-size:13pt;">Section X.D.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.2pt 0pt 0pt 0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.4pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 16.4pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">3.</font><i style="font-size:13pt;font-style:italic;">Form of Payment</i><font style="font-size:13pt;">. Payment of the Stipulated Penalties shall be made by electronic funds transfer to an account specified by OIG in the Demand</font><font style="font-size:13pt;letter-spacing:-0.8pt;"> </font><font style="font-size:13pt;">Letter.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 13.85pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.</font><i style="font-size:13pt;font-style:italic;">Independence from Material Breach Determination</i><font style="font-size:13pt;">. Except as set forth in Section X.D.1.d, these provisions for payment of Stipulated Penalties shall not affect or otherwise set a standard for OIG&#8217;s decision that Merit has materially breached this CIA, which decision shall be made at OIG&#8217;s discretion and shall be governed by</font><font style="font-size:13pt;letter-spacing:-0.8pt;"> </font><font style="font-size:13pt;">the provisions in Section X.D,</font><font style="font-size:13pt;letter-spacing:-0.1pt;"> </font><font style="font-size:13pt;">below.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:41.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">D.</font><a name="D.___Exclusion_for_Material_Breach_of_th"></a><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Exclusion for Material Breach of this</u><u style="font-size:13pt;letter-spacing:-0.2pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">CIA</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.2pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.4pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:77.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.</font><i style="font-size:13pt;font-style:italic;">Definition of Material Breach</i><font style="font-size:13pt;">. A material breach of this CIA</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 6pt;">means:</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.55pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">33</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><div style="margin-top:12.44pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 16.3pt 0pt 113.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">a.</font><font style="font-size:13pt;">repeated violations or a flagrant violation of any of the obligations under this CIA, including, but not limited to, </font><font style="font-size:13pt;letter-spacing:-0.2pt;">the </font><font style="font-size:13pt;">obligations addressed in Section</font><font style="font-size:13pt;letter-spacing:-0.1pt;"> </font><font style="font-size:13pt;">X.A;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 40.25pt 0pt 113.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">b.</font><font style="font-size:13pt;">a failure by Merit to report a Reportable Event and</font><font style="font-size:13pt;letter-spacing:-0.6pt;"> </font><font style="font-size:13pt;">take corrective action as required in Section</font><font style="font-size:13pt;letter-spacing:-0.4pt;"> </font><font style="font-size:13pt;">III.I;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">a failure to engage and use an IRO in accordance with</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Section</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 150pt;">III.E and Appendix B; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 20.3pt 0pt 113.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">d.</font><font style="font-size:13pt;">a failure to respond to a Demand Letter concerning the payment of Stipulated Penalties in accordance with</font><font style="font-size:13pt;letter-spacing:-0.95pt;"> </font><font style="font-size:13pt;">Section X.C.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 14.2pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">2.</font><i style="font-size:13pt;font-style:italic;">Notice of Material Breach and Intent to Exclude</i><font style="font-size:13pt;">. The parties agree that a material breach of this CIA by Merit constitutes an independent basis for Merit&#8217;s exclusion from participation in the Federal health care programs. The length of the exclusion shall be in OIG&#8217;s discretion, but not more than five years per material breach. Upon a determination by OIG that Merit has materially breached this CIA and that exclusion is the appropriate remedy, OIG shall notify Merit of: (a) Merit&#8217;s material breach; and (b) OIG&#8217;s intent to exercise its contractual right to impose exclusion (this notification is hereinafter referred to as the &#8220;Notice of Material Breach and Intent to Exclude&#8221;).</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:72pt;margin:0pt 21.05pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">3.</font><i style="font-size:13pt;font-style:italic;">Opportunity to Cure</i><font style="font-size:13pt;">. Merit shall have 30 days from the date of receipt of the Notice of Material Breach and Intent to Exclude to demonstrate to</font><font style="font-size:13pt;letter-spacing:-0.75pt;"> </font><font style="font-size:13pt;">OIG&#8217;s satisfaction</font><font style="font-size:13pt;letter-spacing:0.05pt;"> </font><font style="font-size:13pt;">that:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">the alleged material breach has been cured; or</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">the alleged material breach cannot be cured within the 30</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">day period, but that: (i) Merit has begun to take action to cure the material breach; (ii) Merit is pursuing such action with due diligence; and (iii) Merit has provided to OIG a reasonable timetable for curing the material</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">breach.</font></td><td style="width:9.1pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 9.45pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">4.</font><i style="font-size:13pt;font-style:italic;">Exclusion Letter</i><font style="font-size:13pt;">. If, at the conclusion of the 30 day period, Merit fails to satisfy the requirements of Section X.D.3, OIG may exclude Merit from participation in the Federal health care programs. OIG shall notify Merit in writing of</font><font style="font-size:13pt;letter-spacing:-0.9pt;"> </font><font style="font-size:13pt;">its</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.2pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.55pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">34</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:12.44pt 6.45pt 0pt 6pt;"><font style="white-space:pre-wrap;">determination to exclude Merit (this letter shall be referred to hereinafter as the &#8220;Exclusion Letter&#8221;). Subject to the Dispute Resolution provisions in Section X.E, below, the exclusion shall go into effect 30 days after the date of Merit&#8217;s receipt of the Exclusion Letter. The exclusion shall have national effect. Reinstatement to program participation is not automatic.  At the end of the period of exclusion, Merit may apply for reinstatement by submitting a written request for reinstatement in accordance with the provisions at 42 C.F.R. &#167;&#167;</font><font style="letter-spacing:0.15pt;"> </font>1001.3001-.3004.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:41.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">E.</font><a name="E.___Dispute_Resolution"></a><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Dispute</u><u style="font-size:13pt;letter-spacing:-0.1pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Resolution</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.44pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 6.85pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.</font><i style="font-size:13pt;font-style:italic;">Review Rights</i><font style="font-size:13pt;">. Upon OIG&#8217;s delivery to Merit of its Demand Letter or of its Exclusion Letter, and as an agreed-upon contractual remedy for the resolution of disputes arising under this CIA, Merit shall be afforded certain review rights comparable to the ones that are provided in 42 U.S.C. &#167; 1320a-7(f) and 42 C.F.R. Part 1005 as if they applied to the Stipulated Penalties or exclusion sought pursuant to this CIA. Specifically, OIG&#8217;s determination to demand payment of Stipulated Penalties or to seek exclusion shall be subject to review by an HHS ALJ and, in the event of an appeal, the HHS Departmental Appeals Board (DAB), in a manner consistent with the provisions in</font><font style="font-size:13pt;letter-spacing:-0.4pt;"> </font><font style="font-size:13pt;">42</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt 0pt 0pt 6pt;">C.F.R. &#167; 1005.2-1005.21. Notwithstanding the language in 42 C.F.R. &#167; 1005.2(c), the request for a hearing involving Stipulated Penalties shall be made within 10 days after receipt of the Demand Letter and the request for a hearing involving exclusion shall be made within 25 days after receipt of the Exclusion Letter. The procedures relating to the filing of a request for a hearing can be found at<u style="color:#0000ff;text-decoration:underline;text-decoration-color:#0000ff;"> http://www.hhs.gov/dab/divisions/civil/procedures/divisionprocedures.html</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.44pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 7.2pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">2.</font><i style="font-size:13pt;font-style:italic;">Stipulated Penalties Review</i><font style="font-size:13pt;">. Notwithstanding any provision of Title 42 of the United States Code or Title 42 of the Code of Federal Regulations, the only issues in a proceeding for Stipulated Penalties under this CIA shall be: (a) whether Merit was in full and timely compliance with the obligations of this CIA for which OIG demands payment; and (b) the period of noncompliance. Merit shall have the burden of proving its full and timely compliance and the steps taken to cure the noncompliance, if any. OIG shall not have the right to appeal to the DAB an adverse ALJ decision related to Stipulated Penalties. If the ALJ agrees with OIG with regard to a finding of a breach of this CIA and orders Merit to pay Stipulated Penalties, such Stipulated Penalties shall become due and payable 20 days after the ALJ issues such a decision unless Merit requests review of the ALJ decision by the DAB. If the ALJ decision is properly appealed to the DAB and the DAB upholds the determination of OIG, the Stipulated Penalties shall become due and payable 20 days after the DAB issues its</font><font style="font-size:13pt;letter-spacing:-0.5pt;"> </font><font style="font-size:13pt;">decision.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.55pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">35</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><div style="margin-top:12.44pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 10.8pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">3.</font><i style="font-size:13pt;font-style:italic;">Exclusion Review</i><font style="font-size:13pt;">. Notwithstanding any provision of Title 42 of</font><font style="font-size:13pt;letter-spacing:-0.55pt;"> </font><font style="font-size:13pt;">the United States Code or Title 42 of the Code of Federal Regulations, the only issues in a proceeding for exclusion based on a material breach of this CIA shall be whether Merit was in material breach of this CIA and, if so,</font><font style="font-size:13pt;letter-spacing:-0.15pt;"> </font><font style="font-size:13pt;">whether:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Merit cured such breach within 30 days of its receipt of</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">the Notice of Material Breach;</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">or</font></td><td style="width:21.85pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">the alleged material breach could not have been cured within the 30 day period, but that, during the 30 day period following Merit&#8217;s receipt of the Notice of Material Breach:</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">(i) Merit had begun to take action to cure the material breach within that period; (ii) Merit pursued such action with due diligence; and (iii) Merit provided to OIG within that period a reasonable timetable for curing the material breach.</font></td><td style="width:6.65pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:0pt 7.55pt 0pt 6pt;"><font style="white-space:pre-wrap;">For purposes of the exclusion herein, exclusion shall take effect only after an ALJ decision favorable to OIG, or, if the ALJ rules for Merit, only after a DAB decision in favor of OIG. Merit&#8217;s election of its contractual right to appeal to the DAB shall not abrogate OIG&#8217;s authority to exclude Merit upon the issuance of an ALJ&#8217;s decision in favor of OIG.  If the ALJ sustains the determination of OIG and determines that exclusion is authorized, such exclusion shall take effect 20 days after the ALJ issues such a decision, notwithstanding that Merit may request review of the ALJ decision by the DAB. If the DAB finds in favor of OIG after an ALJ decision adverse to OIG, the exclusion shall take effect 20 days after the DAB decision. Merit shall waive its right to any notice of such an exclusion if a decision upholding the exclusion is rendered by the ALJ or DAB. If the DAB finds in favor of Merit, Merit shall be reinstated effective on the date of the original</font><font style="letter-spacing:-0.15pt;"> </font>exclusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:71.95pt;margin:0pt 11.9pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">4.</font><i style="font-size:13pt;font-style:italic;">Finality of Decision. </i><font style="font-size:13pt;">The review by an ALJ or DAB provided for above shall not be considered to be an appeal right arising under any statutes or regulations. Consequently, the parties to this CIA agree that the DAB&#8217;s decision (or the ALJ&#8217;s decision if not appealed) shall be considered final for all purposes under this</font><font style="font-size:13pt;letter-spacing:-0.85pt;"> </font><font style="font-size:13pt;">CIA.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:13.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:13pt;font-weight:bold;margin-bottom:0pt;margin-left:5.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">XI.</font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">EFFECTIVE AND BINDING</b><b style="font-weight:bold;letter-spacing:-0.2pt;text-decoration:underline;text-decoration-color:#000000;"> </b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">AGREEMENT</b></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:4.4pt 0pt 0pt 41.95pt;">Merit and OIG agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-size:14.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.55pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">36</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><div style="margin-top:12.44pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 19.3pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">A.</font><font style="font-size:13pt;">This CIA shall become final and binding on the date the final signature</font><font style="font-size:13pt;letter-spacing:-0.65pt;"> </font><font style="font-size:13pt;">is obtained on the</font><font style="font-size:13pt;letter-spacing:-0.05pt;"> </font><font style="font-size:13pt;">CIA.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 14.65pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">B.</font><font style="font-size:13pt;">This CIA constitutes the complete agreement between the parties and</font><font style="font-size:13pt;letter-spacing:-0.55pt;"> </font><font style="font-size:13pt;">may not be amended except by written consent of the parties to this</font><font style="font-size:13pt;letter-spacing:-0.3pt;"> </font><font style="font-size:13pt;">CIA.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 20.05pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">C.</font><font style="font-size:13pt;">All requirements and remedies set forth in this CIA are in addition to and do not affect (1) Merit&#8217;s responsibility to follow all applicable Federal health care program and FDA requirements or (2) the government&#8217;s right to impose appropriate remedies for failure to follow applicable Federal health care program or FDA requirements.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 13.15pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">D.</font><font style="font-size:13pt;">The undersigned Merit signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they</font><font style="font-size:13pt;letter-spacing:-0.75pt;"> </font><font style="font-size:13pt;">are signing this CIA in their official capacity and that they are authorized to execute this CIA.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 26.95pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">E.</font><font style="font-size:13pt;">This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Electronically-transmitted signatures shall constitute acceptable, binding signatures for purposes of this</font><font style="font-size:13pt;letter-spacing:-0.4pt;"> </font><font style="font-size:13pt;">CIA.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">37</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:0.1pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;font-weight:bold;text-align:center;text-indent:0pt;margin:12.44pt 83.85pt 0pt 84.7pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"><a name="On_Behalf_of_Merit_Medical_systems,_Inc."></a></b><b style="font-weight:bold;text-decoration:none;text-decoration-color:#000000;">ON BEHALF OF MERIT MEDICAL SYSTEMS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.2pt 0pt 0pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:4.44pt 0pt 0pt 6pt;">/s/ Fred Lampropoulos<font style="display:inline-block;width:89.37pt;"></font><font style="display:inline-block;width:78.7pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;">October 13, 2020</u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:89.78pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><div style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1pt;margin:0pt 0pt 0pt 5.65pt;"><div style="display:inline-block;height:1.5pt;width:203.25pt;"><div style="height:0.55pt;left:0.85pt;padding-bottom:0.45pt;position:relative;top:0.5pt;width:201.4pt;"><div style="height:0.1pt;left:0pt;position:absolute;top:0.24pt;width:201.4pt;"><img src="mmsi-20201013ex102809a99001.jpg" alt="Graphic" style="height:0.1pt;width:201.4pt;"></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;line-height:13.9pt;margin:0pt 0pt 0pt 5.95pt;">FRED<font style="letter-spacing:-0.1pt;"> </font>LAMPROPOULOS<font style="display:inline-block;width:146.88pt;"></font>DATE</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 324.35pt 0pt 5.95pt;">Chief Executive Officer Merit Medical Systems, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:4.44pt 0pt 0pt 6pt;">/s/ Seth Lundy</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:4.44pt 0pt 0pt 6pt;">/s/ Michael Pauze<font style="display:inline-block;width:115.38pt;"></font><font style="display:inline-block;width:78.7pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;">October 13, 2020</u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:89.78pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><div style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1pt;margin:0pt 0pt 0pt 5.65pt;"><div style="display:inline-block;height:1.5pt;width:209.25pt;"><div style="height:0.55pt;left:0.85pt;padding-bottom:0.65pt;position:relative;top:0.3pt;width:207.85pt;"><div style="height:0.1pt;left:0pt;position:absolute;top:0.24pt;width:207.85pt;"><img src="mmsi-20201013ex102809a99002.jpg" alt="Graphic" style="height:0.1pt;width:207.85pt;"></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;line-height:13.9pt;margin:0pt 0pt 0pt 5.95pt;">SETH<font style="letter-spacing:-0.1pt;"> </font>LUNDY<font style="display:inline-block;width:206.86pt;"></font>DATE</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;line-height:14.9pt;margin:0pt 0pt 0pt 5.95pt;"><a name="Counsel_for_Merit_Medical_Systems,_Inc."></a>MICHAEL PAUZE</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 237pt 0pt 6pt;"><a name="King_&amp;_Spalding_LLP"></a>Counsel for Merit Medical Systems, Inc. King &amp; Spalding LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.55pt 0pt 0pt 6pt;"><i style="font-style:italic;">Merit Medical Systems, Inc. CIA</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">38</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;font-weight:bold;text-indent:14.85pt;margin:12.44pt 49pt 0pt 50.85pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"><a name="On_behalf_of_the_Office_of_Inspector_Gen"></a></b><b style="font-weight:bold;text-decoration:none;text-decoration-color:#000000;">ON BEHALF OF THE OFFICE OF INSPECTOR GENERAL</b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"><a name="of_the_Department_of_Health_and_Human_Se"></a></b><b style="font-weight:bold;text-decoration:none;text-decoration-color:#000000;"> OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:4.44pt 0pt 0pt 6pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">/s/ Lisa M. Re </u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:130.88pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="display:inline-block;width:116.2pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;">October 13, 2020</u><u style="text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:49.03pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;line-height:14.9pt;margin:0.05pt 0pt 0pt 6pt;">LISA<font style="letter-spacing:-0.1pt;"> </font>M.<font style="letter-spacing:0.05pt;"> </font>RE<font style="display:inline-block;width:257.24pt;"></font>DATE</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt 237pt 0pt 6pt;">Assistant Inspector General for Legal Affairs Office of Inspector General</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 6pt;">U.S. Department of Health and Human Services</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 6pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">/s/ Madeline J. Bainer</u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:93.76pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="display:inline-block;width:116.15pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;">October 13, 2020</u><u style="text-decoration:underline;text-decoration-color:#000000;"> </u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:49.08pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;line-height:14.9pt;margin:0.05pt 0pt 0pt 6.05pt;">MADELINE<font style="letter-spacing:-0.1pt;"> </font>J.<font style="letter-spacing:-0.05pt;"> </font>BAINER<font style="display:inline-block;width:193.08pt;"></font>DATE</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;line-height:14.9pt;margin:0pt 0pt 0pt 6.05pt;">Senior Counsel</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 237pt 0pt 6.05pt;">Administrative and Civil Remedies Branch Office of Counsel to the Inspector General</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;line-height:14.9pt;margin:0pt 0pt 0pt 6.05pt;">U.S. Department of Health and Human Services</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:13pt;line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:7.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">39</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;font-weight:bold;text-align:center;text-indent:0pt;margin:0pt;">APPENDIX A</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;font-weight:bold;text-align:center;text-indent:0pt;margin:0pt;">INDEPENDENT REVIEW ORGANIZATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt 71.6pt 0pt 6pt;">This Appendix contains the requirements relating to the Independent Review Organization (IRO) required by Section III.E of the CIA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:5.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">A.</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">IRO</u><u style="font-size:13pt;letter-spacing:-0.1pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Engagement</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.44pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 5pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.</font><font style="font-size:13pt;white-space:pre-wrap;">Merit shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below.  The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph E. Within 30 days after OIG receives the information identified in Section V.A.8 of the CIA or any additional information submitted by Merit in response to a request by OIG, whichever is later, OIG will notify Merit if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Merit may continue to engage the</font><font style="font-size:13pt;letter-spacing:-0.1pt;"> </font><font style="font-size:13pt;">IRO.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 8.9pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">2.</font><font style="font-size:13pt;">If Merit engages a new IRO during the term of the CIA, that IRO must</font><font style="font-size:13pt;letter-spacing:-0.85pt;"> </font><font style="font-size:13pt;">also meet the requirements of this Appendix. If a new IRO is engaged, Merit shall submit the information identified in Section V.A.8 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by Merit at the request of OIG, whichever is later, OIG will notify Merit if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Merit may continue to engage the</font><font style="font-size:13pt;letter-spacing:0.05pt;"> </font><font style="font-size:13pt;">IRO.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:5.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">B.</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">IRO</u><u style="font-size:13pt;letter-spacing:-0.1pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Qualifications</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:4.44pt 0pt 0pt 42pt;">The IRO shall:</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 11.35pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.</font><font style="font-size:13pt;">assign individuals to conduct the IRO Reviews who have expertise in the pharmaceutical industry and in all applicable Federal health care program and FDA requirements relating to the Covered Functions, including but not limited to expertise relating to marketing and promotional activities associated with pharmaceutical</font><font style="font-size:13pt;letter-spacing:-0.7pt;"> </font><font style="font-size:13pt;">products and the Federal Anti-Kickback Statute and False Claims</font><font style="font-size:13pt;letter-spacing:-0.2pt;"> </font><font style="font-size:13pt;">Act.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 14.8pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">2.</font><font style="font-size:13pt;">assign individuals to design and select the samples for the IRO Transactions Reviews who are knowledgeable about the appropriate statistical sampling techniques;</font><font style="font-size:13pt;letter-spacing:0.05pt;"> </font><font style="font-size:13pt;">and</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 20.85pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">3.</font><font style="font-size:13pt;">have sufficient staff and resources to conduct the reviews required by</font><font style="font-size:13pt;letter-spacing:-0.45pt;"> </font><font style="font-size:13pt;">the CIA on a timely</font><font style="font-size:13pt;letter-spacing:-0.25pt;"> </font><font style="font-size:13pt;">basis.</font></div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:45pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">1</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.5pt 0.05pt 0pt 1pt;"><i style="font-style:italic;">Merit Medical Systems, Inc.<br>Appendix A</i></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="margin-top:3.09pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:5.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">C.</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">IRO</u><u style="font-size:13pt;letter-spacing:-0.1pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Responsibilities</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:4.4pt 0pt 0pt 42pt;">The IRO shall:</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:35.95pt;margin:0pt 43.55pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">1.</font><font style="font-size:13pt;">perform each component of the IRO Reviews in accordance with</font><font style="font-size:13pt;letter-spacing:-0.5pt;"> </font><font style="font-size:13pt;">the specific requirements of the</font><font style="font-size:13pt;letter-spacing:-0.25pt;"> </font><font style="font-size:13pt;">CIA;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 8.95pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">2.</font><font style="font-size:13pt;">follow all applicable Federal health care program and FDA requirements</font><font style="font-size:13pt;letter-spacing:-0.65pt;"> </font><font style="font-size:13pt;">in making assessments in the IRO</font><font style="font-size:13pt;letter-spacing:-0.15pt;"> </font><font style="font-size:13pt;">Reviews;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:41.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">respond to all OIG inquires in a prompt, objective, and factual manner;</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 20.15pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.</font><font style="font-size:13pt;">prepare timely, clear, well-written reports that include all the</font><font style="font-size:13pt;letter-spacing:-0.55pt;"> </font><font style="font-size:13pt;">information required by Appendix B to the</font><font style="font-size:13pt;letter-spacing:-0.05pt;"> </font><font style="font-size:13pt;">CIA.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:5.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">D.</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Merit</u><u style="font-size:13pt;letter-spacing:-0.1pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Responsibilities</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.2pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:4.4pt 8.75pt 0pt 6pt;">Merit shall ensure that the IRO has access to all records and personnel necessary to complete the reviews listed in III.E of this CIA and that all records furnished to the IRO are accurate and complete.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:5.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">E.</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">IRO Independence and</u><u style="font-size:13pt;letter-spacing:-0.05pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Objectivity</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-align:justify;text-indent:36pt;margin:4.4pt 21.7pt 0pt 5.95pt;">The IRO must perform each component of the IRO Reviews in a professionally independent and objective fashion, as defined in the most recent Government Auditing Standards issued by the U.S. Government Accountability Office.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:5.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">F.</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">IRO</u><u style="font-size:13pt;letter-spacing:-0.1pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Removal/Termination</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.44pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 9.75pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.</font><i style="font-size:13pt;font-style:italic;">Merit and IRO</i><font style="font-size:13pt;">. If Merit terminates its IRO or if the IRO withdraws from the engagement during the term of the CIA, Merit must submit a notice explaining (a) its reasons for termination of the IRO or (b) the IRO&#8217;s reasons for its withdrawal to OIG,</font><font style="font-size:13pt;letter-spacing:-0.75pt;"> </font><font style="font-size:13pt;">no later than 30 days after termination or withdrawal. Merit must engage a new IRO in accordance with Paragraph A of this Appendix and within 60 days of termination or withdrawal of the</font><font style="font-size:13pt;letter-spacing:-0.05pt;"> </font><font style="font-size:13pt;">IRO.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 5.15pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">2.</font><i style="font-size:13pt;font-style:italic;">OIG Removal of IRO</i><font style="font-size:13pt;">. In the event OIG has reason to believe the IRO does not possess the qualifications described in Paragraph B, is not independent and objective as set forth in Paragraph E or has failed to carry out its responsibilities as described in Paragraph C, OIG shall notify Merit in writing regarding OIG&#8217;s basis for determining</font><font style="font-size:13pt;letter-spacing:-0.7pt;"> </font><font style="font-size:13pt;white-space:pre-wrap;">that the IRO has not met the requirements of this Appendix.  Merit shall have 30 days from the date of OIG&#8217;s written notice to provide information regarding the IRO&#8217;s</font></div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:45pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.5pt 0.05pt 0pt 1pt;"><i style="font-style:italic;">Merit Medical Systems, Inc.<br>Appendix A</i></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.95%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:3.09pt 8.75pt 0pt 5.95pt;">qualifications, independence or performance of its responsibilities in order to resolve the concerns identified by OIG. If, following OIG&#8217;s review of any information provided by Merit regarding the IRO, OIG determines that the IRO has not met the requirements of this Appendix, OIG shall notify Merit in writing that Merit shall be required to engage a new IRO in accordance with Paragraph A of this Appendix. Merit must engage a new IRO within 60 days of its receipt of OIG&#8217;s written notice. The final determination as to whether or not to require Merit to engage a new IRO shall be made at the sole discretion of OIG.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:13pt;line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.55pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">3</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.5pt 0.05pt 0pt 1pt;"><i style="font-style:italic;">Merit Medical Systems, Inc.<br>Appendix A</i></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.95%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.76%;padding-right:10.92%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;font-weight:bold;line-height:1.28;text-align:center;text-indent:0pt;margin:3.09pt 0pt 0pt 0pt;">APPENDIX B</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;font-weight:bold;line-height:1.28;text-align:center;text-indent:0pt;margin:3.09pt 0pt 0pt 0pt;">IRO<b style="font-weight:bold;letter-spacing:0.15pt;"> </b><b style="font-weight:bold;letter-spacing:-0.15pt;">REVIEWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-size:14pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:5.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">A.</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">IRO Engagement, General</u><u style="font-size:13pt;letter-spacing:-0.35pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Description</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.25pt 0pt 0pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:4.44pt 9.55pt 0pt 6pt;">As specified more fully below, Merit shall retain an IRO to perform engagements to assist Merit in assessing and evaluating certain of its systems, processes, policies, and procedures related to Merit&#8217;s Covered Functions (IRO Review). The IRO Review shall consist of two components&#8212;a systems review (Systems Review) and a transactions review (Transactions Review) as described more fully below. Merit may engage, at its discretion, a single entity to perform both components of the IRO Reviews, provided that the entity has the necessary expertise and capabilities to perform both.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:0pt 5.55pt 0pt 5.95pt;">If there are no material changes in Merit&#39;s systems, processes, policies, and procedures relating to Covered Functions, the IRO shall perform the Systems Review of certain systems, processes, policies and procedures relating to Covered Functions (as set forth below) for the first and fourth Reporting Periods. If Merit materially changes its systems, processes, policies, and procedures relating to Covered Functions, the IRO shall perform a Systems Review for the Reporting Period(s) in which such changes were made in addition to conducting the Review as set forth above. The additional Systems Review(s) shall consist of: (1) an identification of the material changes, and (2) a review of the systems, processes, policies, and procedures that materially changed. The IRO shall conduct the Transactions Review for each Reporting Period of the CIA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:13.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:5.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">B.</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">IRO Systems</u><u style="font-size:13pt;letter-spacing:-0.15pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Review</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:4.4pt 11.05pt 0pt 5.95pt;">The Systems Review shall be a review of Merit&#39;s systems, processes, policies, and procedures (including the controls on those systems, processes, policies, and procedures) relating to Covered Functions. More specifically, the IRO shall review Merit&#39;s systems, processes, policies, and procedures associated with the following (hereafter &#8220;Reviewed Policies and Procedures&#8221;):</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:14pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 14.55pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">1.</font><font style="font-size:13pt;">Merit&#8217;s systems, policies, processes, and procedures relating to the development, implementation, and compliant use of promotional materials used by</font><font style="font-size:13pt;letter-spacing:-0.7pt;"> </font><font style="font-size:13pt;">sales representatives (including any contract sales force) and other Merit representatives who promote and sell Government Reimbursed</font><font style="font-size:13pt;letter-spacing:-0.15pt;"> </font><font style="font-size:13pt;">Products;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 7.25pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">2.</font><font style="font-size:13pt;">Merit&#8217;s systems, policies, processes, and procedures relating to the development, implementation, and review of all policies for the distribution of Government Reimbursed Products for evaluation purposes (Evaluation Product). This shall include a review of the bases upon, and circumstances under, which HCPs and</font><font style="font-size:13pt;letter-spacing:-0.8pt;"> </font><font style="font-size:13pt;">HCIs</font></div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">1</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><i style="font-style:italic;">Merit Medical Systems, Inc.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><i style="font-style:italic;">Appendix B</i><font style="display:inline-block;width:236.44pt;"></font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.76%;margin-right:10.92%;margin-top:30pt;page-break-after:always;width:78.32%;border-width:0;"><div style="max-width:100%;padding-left:10.76%;padding-right:10.92%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:3pt 38.1pt 0pt 6pt;">belonging to specified medical specialties or types of clinical practice may receive Evaluation Product from Merit (including, separately, from sales representatives, or through other channels);</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 14.5pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">3.</font><font style="font-size:13pt;">Merit&#8217;s systems, policies, processes, and procedures relating to consultant or other fee-for-service arrangements entered into with HCPs or HCIs (including but</font><font style="font-size:13pt;letter-spacing:-0.7pt;"> </font><font style="font-size:13pt;">not limited to speaker programs, speaker training programs, training and education services, product development activities, presentations, consultant task force meetings, advisory boards, ad hoc advisory activities, research and research-related activities, authorship activities, and any other financial engagement or arrangement with an HCP or HCI) and all events and expenses relating to such engagements or</font><font style="font-size:13pt;letter-spacing:-0.25pt;"> </font><font style="font-size:13pt;">arrangements;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 12.05pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">4.</font><font style="font-size:13pt;">Merit&#8217;s systems, policies, processes, and procedures relating to agreements or arrangements with HCPs or HCIs for the purchase or licensing of intellectual</font><font style="font-size:13pt;letter-spacing:-0.75pt;"> </font><font style="font-size:13pt;">property (including, but not limited to, patents, patent applications, and payment of</font><font style="font-size:13pt;letter-spacing:-0.55pt;"> </font><font style="font-size:13pt;">royalties);</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 6pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">5.</font><font style="font-size:13pt;">Merit&#8217;s systems, policies, processes, and procedures relating to programs</font><font style="font-size:13pt;letter-spacing:-0.7pt;"> </font><font style="font-size:13pt;">by HCPs to educate sales representatives, including but not limited to presentations by HCPs at sales meetings, preceptorships, tutorials, and experience-based learning</font><font style="font-size:13pt;letter-spacing:-0.35pt;"> </font><font style="font-size:13pt;">activities;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 5.8pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">6.</font><font style="font-size:13pt;">Merit&#8217;s systems, policies, processes, and procedures relating to the review and approval of, and payment for, travel and related expenses for HCPs including those in connection with an HCP&#8217;s participation in educational, research, training, or other Merit- sponsored programs or</font><font style="font-size:13pt;letter-spacing:0.1pt;"> </font><font style="font-size:13pt;">activities;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 5.8pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">7.</font><font style="font-size:13pt;">Merit&#8217;s systems, policies, processes, and procedures relating to the sponsorship or funding of grants (including educational grants) or charitable</font><font style="font-size:13pt;letter-spacing:-0.65pt;"> </font><font style="font-size:13pt;">contributions involving HCPs or</font><font style="font-size:13pt;letter-spacing:0.1pt;"> </font><font style="font-size:13pt;">HCIs;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 11.95pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">8.</font><font style="font-size:13pt;">Merit&#8217;s systems, policies, processes, and procedures relating to funding of, or participation in, any Sponsorships, Third Party Educational Activity, or</font><font style="font-size:13pt;letter-spacing:-0.85pt;"> </font><font style="font-size:13pt;">Co-Marketing Activity as defined in Sections II.C.4, II.C.5, and II.C.6 of the</font><font style="font-size:13pt;letter-spacing:-0.35pt;"> </font><font style="font-size:13pt;">CIA;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 13.7pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">9.</font><font style="font-size:13pt;">Merit&#8217;s systems, policies, processes, and procedures relating to compensation (including through salaries, bonuses, or other means) for Covered Persons who are sales representatives and their managers;</font><font style="font-size:13pt;letter-spacing:-0.4pt;"> </font><font style="font-size:13pt;">and</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 10pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">10.</font><font style="font-size:13pt;">Merit&#8217;s systems, policies, processes, and procedures relating to</font><font style="font-size:13pt;letter-spacing:-0.65pt;"> </font><font style="font-size:13pt;">disciplinary policies and procedures for violations of Merit&#8217;s Policies and Procedures, including policies relating to Federal health care program and FDA</font><font style="font-size:13pt;letter-spacing:-0.45pt;"> </font><font style="font-size:13pt;">requirements.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">2</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><i style="font-style:italic;">Merit Medical Systems, Inc.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><i style="font-style:italic;">Appendix B</i><font style="display:inline-block;width:236.44pt;"></font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.76%;margin-right:10.92%;margin-top:30pt;page-break-after:always;width:78.32%;border-width:0;"><div style="max-width:100%;padding-left:10.76%;padding-right:10.92%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:5.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">C.</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">IRO Systems Review</u><u style="font-size:13pt;letter-spacing:-0.25pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Report</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:3pt 17.7pt 0pt 5.95pt;"><font style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:3pt 17.7pt 0pt 5.95pt;">The IRO shall prepare a report based upon each Systems Review performed. For each of the Reviewed Policies and Procedures identified in Section B above, the report shall include the following items:</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 22.25pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.</font><font style="font-size:13pt;">a description of the documentation (including policies) reviewed and any personnel</font><font style="font-size:13pt;letter-spacing:-0.1pt;"> </font><font style="font-size:13pt;">interviewed;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 17.4pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">2.</font><font style="font-size:13pt;">a detailed description of Merit&#39;s systems, policies, processes, and procedures relating to the items identified in Sections B.1-10 above, including a general description of Merit&#39;s control and accountability systems (</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">e.g.</u><font style="font-size:13pt;">, documentation and approval requirements, and tracking mechanisms) and written policies regarding the Reviewed Policies and</font><font style="font-size:13pt;letter-spacing:0.25pt;"> </font><font style="font-size:13pt;">Procedures;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 8.4pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">3.</font><font style="font-size:13pt;">a description of the manner in which the control and accountability systems and the written policies relating to the items identified in Sections B.1-10 above are</font><font style="font-size:13pt;letter-spacing:-0.9pt;"> </font><font style="font-size:13pt;">made known or disseminated within</font><font style="font-size:13pt;letter-spacing:0.05pt;"> </font><font style="font-size:13pt;">Merit;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 35.05pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.</font><font style="font-size:13pt;">findings and supporting rationale regarding any weaknesses. in Merit&#39;s systems, processes, policies, and procedures relating to the Reviewed Policies and Procedures, if any;</font><font style="font-size:13pt;letter-spacing:-0.05pt;"> </font><font style="font-size:13pt;">and</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 29.75pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">5.</font><font style="font-size:13pt;">recommendations to improve any of the systems, policies, processes, or procedures relating to the Reviewed Policies and Procedures, if</font><font style="font-size:13pt;letter-spacing:-0.55pt;"> </font><font style="font-size:13pt;">any.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:5.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">D.</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">IRO Transactions Review</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.25pt 0pt 0pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-indent:36pt;margin:4.44pt 17.65pt 0pt 6pt;">The Transactions Review shall include a review of: (1) a sample of consultant or other fee-for-service arrangements entered into with HCPs (including all events and expenses related to such engagements or arrangements), (2) a sample of Co-Marketing Activity agreements, (3) a sample of medical education grants and charitable contributions, and (4) a sample of Payments. The IRO shall report on all aspects of its reviews in the Transactions Review Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:35.95pt;margin:0pt 6.25pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">1.</font><i style="font-size:13pt;font-style:italic;">Review of Consulting Activities. </i><font style="font-size:13pt;">For purposes of this Appendix B, the term &#8220;Consulting Activities&#8221; shall include all consulting and other fee for service</font><font style="font-size:13pt;letter-spacing:-0.85pt;"> </font><font style="font-size:13pt;">arrangements entered with HCPs (including but not limited to speaker programs, speaker training programs, training and education services, product development activities, presentations, consultant task force meetings, advisory boards, ad hoc advisory activities, research and research-related activities, authorship and authorship-related activities, and any other financial engagement or arrangement with an HCP or HCI) and all events and expenses relating to such engagements or</font><font style="font-size:13pt;letter-spacing:-0.15pt;"> </font><font style="font-size:13pt;">arrangements.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;text-indent:0pt;">3</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;"><i style="font-style:italic;">Merit Medical Systems, Inc.</i></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;"><i style="font-style:italic;">Appendix B</i><font style="display:inline-block;width:236.44pt;"></font></div></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.76%;margin-right:10.92%;margin-top:30pt;page-break-after:always;width:78.32%;border-width:0;"><div style="max-width:100%;padding-left:10.76%;padding-right:10.92%;position:relative;"><div style="width:100%;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></div></div><div style="clear:both;max-width:100%;position:relative;"><div style="margin-top:3pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:77.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">For the first Reporting Period, the IRO shall select and review a sample of 10 Consulting Activities entered into with HCPs and all related expenses. For the second and subsequent Reporting Periods, the IRO shall review a total of at least 10 Consulting Activities which shall include a review of specified numbers of each type of Consulting Activities as determined by OIG. Prior to the determination of the number of each type of Consulting Activity to be reviewed during the second and subsequent Reporting Periods, Merit shall provide to OIG the information specified below in the next paragraph within 60 days prior to the end of the applicable preceding Reporting</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Period.</font></td><td style="width:10.85pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 5.75pt 0pt 77.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">b.</font><font style="font-size:13pt;">The IRO shall select its sample of Consulting Activities for review</font><font style="font-size:13pt;letter-spacing:-0.65pt;"> </font><font style="font-size:13pt;">in consultation with OIG after the provision of information about the Consulting Activities to the OIG. Merit shall provide the following information to the OIG: (1) a description of each type of Consulting Activity undertaken during the Reporting Period and a description of the services to be provided under each Consulting Activity; (2) the number of each type of Consulting Activity undertaken during the Reporting Period; and (3) the overall budgeted amount to be spent in connection with each type of Consulting Activity during the Reporting</font><font style="font-size:13pt;letter-spacing:0.05pt;"> </font><font style="font-size:13pt;">Period.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:78pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">For each Consulting Activity reviewed, the IRO shall</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">determine whether:</font></td><td style="width:33.25pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">i.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">a written agreement was in place for each Consulting</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Activity that describes the scope of work to be performed, the fees and related expenses to be paid for the Consulting Activity, and the compliance obligations for the</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Consultant;</font></td><td style="width:8.05pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">ii.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:justify;">the compensation to be paid for the Consulting Activity was determined in accordance with a centrally managed, pre-set rate structure established by</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:justify;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:justify;">Merit;</font></td><td style="width:17.35pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">iii.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">the rate structure was established based on an</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">independent FMV</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">analysis;</font></td><td style="width:27.25pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">iv.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">the Consulting Activity was identified in the annual Consultant budgeting plan developed by</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Merit;</font></td><td style="width:61.4pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">v.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">a needs assessment that identifies the business need for the Consulting Activity and provides details about the</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Consulting</font></td><td style="width:8.7pt;"></td></tr></table><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">4</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><i style="font-style:italic;">Merit Medical Systems, Inc.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><i style="font-style:italic;">Appendix B</i><font style="display:inline-block;width:236.44pt;"></font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.76%;margin-right:10.92%;margin-top:30pt;page-break-after:always;width:78.32%;border-width:0;"><div style="max-width:100%;padding-left:10.76%;padding-right:10.92%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:3pt 61.6pt 0pt 150pt;">Activity was completed prior to the initiation of the Consulting Activity;</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 47pt 0pt 113.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">vi.</font><font style="font-size:13pt;">the Consulting Activity was reviewed and approved</font><font style="font-size:13pt;letter-spacing:-0.55pt;"> </font><font style="font-size:13pt;">in accordance with Merit Policies and</font><font style="font-size:13pt;letter-spacing:-0.25pt;"> </font><font style="font-size:13pt;">Procedures;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 15.25pt 0pt 113.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">vii.</font><font style="font-size:13pt;">Merit collected and retained a record of the specific activity performed by the HCP and, if applicable, a copy of the</font><font style="font-size:13pt;letter-spacing:-0.7pt;"> </font><font style="font-size:13pt;">work product generated by the HCP in connection with the Consulting Activity;</font><font style="font-size:13pt;letter-spacing:-0.15pt;"> </font><font style="font-size:13pt;">and</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 6.95pt 0pt 113.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">viii.</font><font style="font-size:13pt;">the activity undertaken by the Consultant and/or the work product generated by the HCP was used by Merit in a manner consistent with the needs assessment that was completed </font><font style="font-size:13pt;letter-spacing:-0.15pt;">prior </font><font style="font-size:13pt;">to the initiation of the Consulting</font><font style="font-size:13pt;letter-spacing:-0.1pt;"> </font><font style="font-size:13pt;">Activity.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 16.3pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">2.</font><i style="font-size:13pt;font-style:italic;">Review of Co-Marketing Activities</i><font style="font-size:13pt;">. If Merit engages in any Co-Marketing Activity during the term of the CIA, the IRO shall review such Co-Marketing Activity agreements entered into during the applicable Reporting Period. For each Co-Marketing Activity agreement, the IRO shall</font><font style="font-size:13pt;letter-spacing:0.15pt;"> </font><font style="font-size:13pt;">review:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:59.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">How Merit determined the business need for performing Co-Marketing Activities with the HCP(s) and HCI(s);</font></td><td style="width:32pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:59.9pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">How the targets or audience of each Co-Marketing Activity were selected and by</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">whom;</font></td><td style="width:19.05pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:59.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">The contributions of each party to each Co-Marketing Activity, and the financial value of those</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">contributions;</font></td><td style="width:31.6pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:59.9pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;">d.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">How Merit determined that each party was contributing to and receiving fair market value from the Co-Marketing</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Activities;</font></td><td style="width:26.25pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:59.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">e.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Whether Merit reviewed and approved the Co-Marketing Activity agreement in accordance with Merit&#8217;s Policies and Procedures;</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">and</font></td><td style="width:52.25pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:59.9pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;">f.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Whether Merit collected and retained records of the activities of each party to the Co-Marketing Activity</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">agreement.</font></td><td style="width:12.2pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 9pt 0pt 5.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">3.</font><i style="font-size:13pt;font-style:italic;">Review of Grants and Charitable Contributions involving HCPs or HCIs</i><font style="font-size:13pt;">. For purposes of this Appendix B, the term &#8220;Grants&#8221; shall include any awarded amounts for Third Party Educational Activities (as defined in Section II.C.5 of the CIA) or other grant activities involving HCPs and HCIs, and the term &#8220;Contributions&#8221; shall include</font><font style="font-size:13pt;letter-spacing:-0.8pt;"> </font><font style="font-size:13pt;">any</font></div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:37pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">5</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><i style="font-style:italic;">Merit Medical Systems, Inc.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><i style="font-style:italic;">Appendix B</i><font style="display:inline-block;width:236.44pt;"></font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.76%;margin-right:10.92%;margin-top:30pt;page-break-after:always;width:78.32%;border-width:0;"><div style="max-width:100%;padding-left:10.76%;padding-right:10.92%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:3pt 9.55pt 0pt 6pt;">charitable contributions involving HCPs or HCIs provided by Merit. For each Reporting Period, the IRO shall review a sample of the greater of 10% or 5 Grants and Contributions to HCPs or HCIs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:77.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">The IRO shall select its sample of Grants and Contributions for review in consultation with OIG after the provision of information about each to OIG. Merit shall provide the following information to OIG: (1) a description of each type of Grant and Contribution provided during the Reporting Period and a description of the purpose of, and activity to be undertaken in connection with, each type of Grant and Contribution; (2) the number of each type of</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Grant and Contribution provided during the Reporting Period; and (3) the budgeted amount to be spent on each type of Grant and Contribution during the Reporting</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Period.</font></td><td style="width:7.65pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:77.9pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">The IRO&#8217;s review shall include, but not be limited to: proposal documents (including Grant and Contribution requests), approval documents, contracts, payments and materials relating to the centralized system&#8217;s review of the requests, and documents and materials relating to the Grants and Contributions and any events or activities funded through the Grants and</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Contributions.</font></td><td style="width:14.05pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:77.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">For each Grant and Contribution reviewed, the IRO shall</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">determine whether:</font></td><td style="width:14.85pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.9pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">i.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">The request for the Grant or Contribution was</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">submitted through Merit&#8217;s centralized system and processed in accordance with standardized objective</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">criteria;</font></td><td style="width:37.35pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:113.9pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">ii.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:justify;">The terms of the Grant or Contribution are reflected in a written agreement between Merit and the recipient of</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;text-align:justify;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:justify;">the grant or</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:justify;">contribution;</font></td><td style="width:34.5pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:113.9pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">iii.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:justify;">The Grant or Contribution was reviewed and approved</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;text-align:justify;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:justify;">in accordance with Merit policies and</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:justify;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:justify;">procedures;</font></td><td style="width:32.35pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.9pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">iv.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Merit records identify the purpose or use for which the</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Grant or Contribution was requested;</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">and</font></td><td style="width:12.8pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.9pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">v.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Applicable documents or other records verify that the purpose of use for which the Grant or Contribution was requested occurred or was satisfied (e.g., if the Grant or</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Contribution</font></td><td style="width:7.7pt;"></td></tr></table><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:37pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">6</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><i style="font-style:italic;">Merit Medical Systems, Inc.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><i style="font-style:italic;">Appendix B</i><font style="display:inline-block;width:236.44pt;"></font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.76%;margin-right:10.92%;margin-top:30pt;page-break-after:always;width:78.32%;border-width:0;"><div style="max-width:100%;padding-left:10.76%;padding-right:10.92%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:3pt 44.95pt 0pt 150pt;">was provided to sponsor an event, the IRO shall assess whether the event, in fact, occurred.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:0pt 16.75pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.</font><i style="font-size:13pt;font-style:italic;">Review of Payments. </i><font style="font-size:13pt;">For purposes of this Appendix B, the term &#8220;Control Documents&#8221; shall include all material documents or electronic records associated with each Merit Payment reflected in the Open Payments database for that calendar year.</font><font style="font-size:13pt;letter-spacing:-0.7pt;"> </font><font style="font-size:13pt;">For example, the term &#8220;Control Documents&#8221; includes, but is not limited to, documents relating to the nature, purpose, and amount of the Payment; contracts relating to the Payment; documents relating to the occurrence of Payment; documents reflecting any work product generated in connection with the Payment; documents submitted by sales representatives or headquarters personnel to request approval for the Payment; and business rationale or justification forms relating to the</font><font style="font-size:13pt;letter-spacing:-0.35pt;"> </font><font style="font-size:13pt;">Payment.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:77.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">For each Reporting Period, the OIG shall have the discretion to identify up to 15 Covered Recipients who received Payments from Merit during the prior calendar year and will be subject to the IRO review described below. If the OIG elects to exercise this discretion, it shall notify the IRO of the Covered Recipients subject to the IRO Review. If the OIG elects not to exercise its discretion, the IRO shall randomly select 15 Covered Recipients to be included in the</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">review.</font></td><td style="width:5.1pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:77.9pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">For each selected Covered Recipient, the IRO shall review the Control Documents associated with the Payments to the Covered Recipient for all categories reflected in the Open Payments Data website except for the Food/Beverage and Travel/Lodging categories of Payments. Specifically, for each Covered Recipient selected as part of the sample, the IRO shall review the Control Documents identified by the IRO as necessary and sufficient to validate each Payment reported to CMS to evaluate the</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">following:</font></td><td style="width:6.55pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 30.4pt 0pt 113.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">i.</font><font style="font-size:13pt;">whether Control Documents are available relating to each Payment;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 8.1pt 0pt 113.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">ii.</font><font style="font-size:13pt;">whether the Control Documents were completed and</font><font style="font-size:13pt;letter-spacing:-0.5pt;"> </font><font style="font-size:13pt;">archived in accordance with the requirements set forth in Merit&#39;s policies;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 6.95pt 0pt 113.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">iii.</font><font style="font-size:13pt;">whether the aggregate value of the Payment as reflected in the Open Payments Database is consistent with the value of the Payment reflected in the Control Documents; and</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:14pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 21.55pt 0pt 113.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">iv.</font><font style="font-size:13pt;">whether the Control Documents reflect that Merit&#39;s policies were followed in connection with the Payment (</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">e.g.</u><font style="font-size:13pt;">,</font><font style="font-size:13pt;letter-spacing:-0.35pt;"> </font><font style="font-size:13pt;">all</font></div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:37pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">7</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><i style="font-style:italic;">Merit Medical Systems, Inc.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><i style="font-style:italic;">Appendix B</i><font style="display:inline-block;width:236.44pt;"></font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.76%;margin-right:10.92%;margin-top:30pt;page-break-after:always;width:78.32%;border-width:0;"><div style="max-width:100%;padding-left:10.76%;padding-right:10.92%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:3pt 22.65pt 0pt 150pt;">required written approvals for the activity were obtained in accordance with Merit&#39;s policies.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:13.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:5.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">E.</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Transactions Review</u><u style="font-size:13pt;letter-spacing:-0.15pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Report</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.4pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 8.75pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">A.</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">General Elements to be Included in the</u><font style="font-size:13pt;"> Report. For each Reporting Period, the IRO shall prepare a report based on its Transactions Review. The report shall</font><font style="font-size:13pt;letter-spacing:-0.65pt;"> </font><font style="font-size:13pt;">include the</font><font style="font-size:13pt;letter-spacing:-0.1pt;"> </font><font style="font-size:13pt;">following:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-size:14pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:72pt;margin:0pt 19.4pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">1.</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Review Objectives</u><font style="font-size:13pt;">: A clear statement of the objectives intended to be achieved by each part of the</font><font style="font-size:13pt;letter-spacing:-0.1pt;"> </font><font style="font-size:13pt;">review;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:13.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:72pt;margin:0pt 14.9pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">2.</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Review Protocol</u><font style="font-size:13pt;">: A detailed narrative description of the</font><font style="font-size:13pt;letter-spacing:-0.75pt;"> </font><font style="font-size:13pt;">procedures performed and a description of the sampling unit and universe utilized in performing</font><font style="font-size:13pt;letter-spacing:-0.9pt;"> </font><font style="font-size:13pt;">the procedures for each sample reviewed;</font><font style="font-size:13pt;letter-spacing:-0.3pt;"> </font><font style="font-size:13pt;">and</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:14pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-indent:72pt;margin:0pt 5.45pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:35.95pt;text-indent:0pt;white-space:nowrap;">3.</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Sources of Data</u><font style="font-size:13pt;">: A full description of documentation and other information, if applicable, relied upon by the IRO in performing the Transactions</font><font style="font-size:13pt;letter-spacing:-0.65pt;"> </font><font style="font-size:13pt;">Review.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-size:14pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 12.15pt 0pt 6pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">B.</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Results to be Included in Report</u><i style="font-size:13pt;font-style:italic;">. </i><font style="font-size:13pt;">The following results shall be included</font><font style="font-size:13pt;letter-spacing:-0.75pt;"> </font><font style="font-size:13pt;">in each Transactions Review</font><font style="font-size:13pt;letter-spacing:-0.2pt;"> </font><font style="font-size:13pt;">Report:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:13.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:77.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">1.</td><td style="padding:0pt;"><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;text-decoration:underline;text-decoration-color:#000000;">Relating to the Review of Consulting</u><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:left;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;text-decoration:underline;text-decoration-color:#000000;">Activities</u></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.25pt 0pt 0pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.44pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">a description of each type of Consulting Activity reviewed, including the number of each type of Consulting Activity reviewed and an identification of the types of documents and information reviewed for each Consulting</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Activity;</font></td><td style="width:13.1pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.9pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">for each Consulting Activity reviewed, the IRO&#39;s findings and supporting rationale as to</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">whether:</font></td><td style="width:7.8pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:149.9pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">i.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">a written agreement was in place for each Consulting Activity that describes the scope of work to be performed, the fees and expenses to be paid for each Consulting Activity, and the compliance obligations for the</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Consultant;</font></td><td style="width:17.9pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:149.9pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">ii.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">the compensation to be paid for the Consulting Activity was determined in accordance with a centrally managed, pre-set rate structure set by</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Merit;</font></td><td style="width:7.45pt;"></td></tr></table><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:37pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">8</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><i style="font-style:italic;">Merit Medical Systems, Inc.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><i style="font-style:italic;">Appendix B</i><font style="display:inline-block;width:236.44pt;"></font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.76%;margin-right:10.92%;margin-top:30pt;page-break-after:always;width:78.32%;border-width:0;"><div style="max-width:100%;padding-left:10.76%;padding-right:10.92%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.4pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 58pt 0pt 149.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">iii.</font><font style="font-size:13pt;">the rate structure was established based on </font><font style="font-size:13pt;letter-spacing:-0.3pt;">an </font><font style="font-size:13pt;">independent FMV</font><font style="font-size:13pt;letter-spacing:0.15pt;"> </font><font style="font-size:13pt;">analysis;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 25.4pt 0pt 149.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">iv.</font><font style="font-size:13pt;">the Consulting Activity was identified in the annual Consulting budgeting plan developed by</font><font style="font-size:13pt;letter-spacing:-0.2pt;"> </font><font style="font-size:13pt;">Merit;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 7.8pt 0pt 149.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">v.</font><font style="font-size:13pt;">a needs assessment that identifies the business need</font><font style="font-size:13pt;letter-spacing:-0.5pt;"> </font><font style="font-size:13pt;">for the Consulting Activity and provides detail about the activity was prepared prior to the initiation of the Consulting</font><font style="font-size:13pt;letter-spacing:-0.1pt;"> </font><font style="font-size:13pt;">Activity;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 11pt 0pt 149.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">vi.</font><font style="font-size:13pt;">the Consulting Activity was reviewed and approved</font><font style="font-size:13pt;letter-spacing:-0.55pt;"> </font><font style="font-size:13pt;">in accordance with Merit Policies and</font><font style="font-size:13pt;letter-spacing:-0.2pt;"> </font><font style="font-size:13pt;">Procedures,</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 9.25pt 0pt 149.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">vii.</font><font style="font-size:13pt;">Merit collected and retained a record of the specific activity performed by the HCP and, if applicable, a copy of the work product generated in connection</font><font style="font-size:13pt;letter-spacing:-0.5pt;"> </font><font style="font-size:13pt;">with the Consulting Activity;</font><font style="font-size:13pt;letter-spacing:-0.2pt;"> </font><font style="font-size:13pt;">and</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 7.45pt 0pt 149.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">viii.</font><font style="font-size:13pt;">the activity undertaken by the Consultant and/or the work product generated was used by Merit in a</font><font style="font-size:13pt;letter-spacing:-0.55pt;"> </font><font style="font-size:13pt;">manner consistent with the needs assessment that was completed prior to the initiation of the Consulting Activity;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="display:inline-block;width:3.25pt;"></font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">any weaknesses in Merit&#39;s systems, processes, policies, procedures and/or practices relating to Consulting</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Activities identified by the IRO;</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">and</font></td><td style="width:17.1pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.9pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">d.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">any recommendations for improvements to Merit&#39;s</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">systems, processes, policies, procedures and/or practices relating to Consulting</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Activities.</font></td><td style="width:19.45pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:77.95pt;margin-top:0pt;padding-left:36.05pt;text-indent:-36.05pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">2.</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Relating to the Review of Co-Marketing</u><u style="font-size:13pt;letter-spacing:-0.1pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Activities</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.44pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">a description of each type of Consulting Activity reviewed, including the number of each type of Consulting Activity reviewed and an identification of the types of documents and information reviewed for each Consulting</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Activity</font></td><td style="width:13.1pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.9pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">For each Co-Marketing Activity reviewed, the IRO&#8217;s</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">findings and supporting rationale as</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">to:</font></td><td style="width:8.45pt;"></td></tr></table><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:37pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">9</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><i style="font-style:italic;">Merit Medical Systems, Inc.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><i style="font-style:italic;">Appendix B</i><font style="display:inline-block;width:236.44pt;"></font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.76%;margin-right:10.92%;margin-top:30pt;page-break-after:always;width:78.32%;border-width:0;"><div style="max-width:100%;padding-left:10.76%;padding-right:10.92%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.4pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 8.55pt 0pt 149.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">i.</font><font style="font-size:13pt;">whether and how Merit determined a business need </font><font style="font-size:13pt;letter-spacing:-0.25pt;">for </font><font style="font-size:13pt;">performing the Co-Marketing Activities with the HCP(s) and the</font><font style="font-size:13pt;letter-spacing:-0.2pt;"> </font><font style="font-size:13pt;">HCI(s);</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 20.4pt 0pt 149.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">ii.</font><font style="font-size:13pt;">whether and how the targets or audience of each Co- Marketing Activity were selected, and by</font><font style="font-size:13pt;letter-spacing:-0.2pt;"> </font><font style="font-size:13pt;">whom;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 7.1pt 0pt 149.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">iii.</font><font style="font-size:13pt;">the contributions of each party to each Co-Marketing Activity, and the financial value of those</font><font style="font-size:13pt;letter-spacing:-1.05pt;"> </font><font style="font-size:13pt;">contributions;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 7.85pt 0pt 149.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">iv.</font><font style="font-size:13pt;">whether and how Merit determined that each party </font><font style="font-size:13pt;letter-spacing:-0.25pt;">was </font><font style="font-size:13pt;">contributing to and receiving fair market value from the Co-Marketing Activities;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:149.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">v.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">whether the Co-Marketing Activity was reviewed and approved in accordance with Merit&#8217;s Policies and Procedures;</font></td><td style="width:14.25pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:149.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">vi.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">whether Merit collected and retained records of the activities of each party to the Co-Marketing</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Activities;</font></td><td style="width:9.55pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:149.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">vii.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">any weaknesses in Merit&#8217;s systems, processes,</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">policies, procedures and/or practices relating to Co-Marketing Activities;</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">and</font></td><td style="width:5.95pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:149.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">viii.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">any recommendations for improvements to Merit&#8217;s systems, processes, policies, procedures and/or practices relating to Co-Marketing</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">Activities.</font></td><td style="width:29pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.15pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 40.8pt 0pt 78pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:35.95pt;white-space:nowrap;">3.</font><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Relating to the Review of Grants and Charitable</u><u style="font-size:13pt;letter-spacing:-0.55pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">Contributions involving HCPs and</u><u style="font-size:13pt;letter-spacing:0.1pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:13pt;text-decoration:underline;text-decoration-color:#000000;">HCIs</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.4pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">a description of each type of Grant or Contribution reviewed, including the number of each type of Grant or Contribution reviewed and an identification of the types of documents and information reviewed for each Grant or Contribution reviewed;</font></td><td style="width:12pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">for each Grant or Contribution reviewed, the IRO&#8217;s</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">findings and supporting rationale as to</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">whether:</font></td><td style="width:17.4pt;"></td></tr></table><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:37pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">10</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><i style="font-style:italic;">Merit Medical Systems, Inc.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><i style="font-style:italic;">Appendix B</i><font style="display:inline-block;width:236.44pt;"></font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.76%;margin-right:10.92%;margin-top:30pt;page-break-after:always;width:78.32%;border-width:0;"><div style="max-width:100%;padding-left:10.76%;padding-right:10.92%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="margin-top:3pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 5.6pt 0pt 149.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">i.</font><font style="font-size:13pt;">the request for the Grant or Contribution was</font><font style="font-size:13pt;letter-spacing:-0.55pt;"> </font><font style="font-size:13pt;">submitted through the Merit centralized system and processed in accordance with standardized objective</font><font style="font-size:13pt;letter-spacing:-0.25pt;"> </font><font style="font-size:13pt;">criteria;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 6.35pt 0pt 149.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">ii.</font><font style="font-size:13pt;">the terms of the Grant or Contribution are reflected in</font><font style="font-size:13pt;letter-spacing:-0.55pt;"> </font><font style="font-size:13pt;">a written agreement between Merit and the recipient of the Grant or</font><font style="font-size:13pt;letter-spacing:-0.05pt;"> </font><font style="font-size:13pt;">Contribution;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 13.95pt 0pt 149.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">iii.</font><font style="font-size:13pt;">the Grant or Contribution was reviewed and</font><font style="font-size:13pt;letter-spacing:-0.5pt;"> </font><font style="font-size:13pt;">approved in accordance with Merit policies and</font><font style="font-size:13pt;letter-spacing:-0.1pt;"> </font><font style="font-size:13pt;">procedures;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 10.25pt 0pt 149.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">iv.</font><font style="font-size:13pt;">the purpose or use for which the Grant or Contribution was requested is identified in Merit</font><font style="font-size:13pt;letter-spacing:-0.35pt;"> </font><font style="font-size:13pt;">records;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 18.25pt 0pt 149.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">v.</font><font style="font-size:13pt;">records verify that the purpose of use for which the Grant or Contribution was requested occurred or </font><font style="font-size:13pt;letter-spacing:-0.2pt;">was </font><font style="font-size:13pt;">satisfied;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 11.4pt 0pt 149.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">vi.</font><font style="font-size:13pt;">the IRO identified any weaknesses in Merit&#8217;s</font><font style="font-size:13pt;letter-spacing:-0.95pt;"> </font><font style="font-size:13pt;">systems, processes, policies, procedures, and/or practices relating to Grants or Contributions;</font><font style="font-size:13pt;letter-spacing:-0.15pt;"> </font><font style="font-size:13pt;">and</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 8.55pt 0pt 149.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">vii.</font><font style="font-size:13pt;">the IRO has recommendations for improvements to Merit&#8217;s systems, processes, policies, procedures</font><font style="font-size:13pt;letter-spacing:-1pt;"> </font><font style="font-size:13pt;">and/or practices relating to Grants or</font><font style="font-size:13pt;letter-spacing:-0.2pt;"> </font><font style="font-size:13pt;">Contributions.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:77.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">4.</td><td style="padding:0pt;"><u style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;text-decoration:underline;text-decoration-color:#000000;">Relating to the Review of Payments</u></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.25pt 0pt 0pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.44pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">a description of the entry in the Open Payments Database</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">for each Payment sampled and a description of Control Documents reviewed in connection with each sampled Payment;</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">and</font></td><td style="width:13.5pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-size:14pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:113.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">for each sampled Payment, findings and supporting</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">rationale as to</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">whether:</font></td><td style="width:14.15pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:149.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">i.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">all required Control Documents</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">exist;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:149.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">ii.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:justify;">each Control Document was completed in</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;text-align:justify;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:justify;">accordance with all of the requirements set forth in the applicable Merit</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-align:justify;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:justify;">policy;</font></td><td style="width:14.3pt;"></td></tr></table><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:37pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">11</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><i style="font-style:italic;">Merit Medical Systems, Inc.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><i style="font-style:italic;">Appendix B</i><font style="display:inline-block;width:236.44pt;"></font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.76%;margin-right:10.92%;margin-top:30pt;page-break-after:always;width:78.32%;border-width:0;"><div style="max-width:100%;padding-left:10.76%;padding-right:10.92%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="margin-top:3pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:149.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">iii.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:justify;">the aggregate value of the Payment as reflected in the Open Payments Database is consistent with the value of the Payment reflected in the Control</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;text-align:justify;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:justify;">Documents;</font></td><td style="width:16.1pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 20.7pt 0pt 149.95pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:13pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">iv.</font><font style="font-size:13pt;">each Control Document reflects that Merit&#8217;s policies were followed in connection with the underlying activity reflected in the document (all required approvals were obtained);</font><font style="font-size:13pt;letter-spacing:-0.05pt;"> </font><font style="font-size:13pt;">and</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:149.95pt;"></td><td style="font-family:'Times New Roman';font-size:13pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">v.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">any corrective action or disciplinary action was undertaken in those instances in which Merit</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">policies were not</font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:left;"> </font><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:13pt;font-style:normal;font-weight:normal;text-align:left;">followed.</font></td><td style="width:17.5pt;"></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:37pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">12</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><i style="font-style:italic;">Merit Medical Systems, Inc.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><i style="font-style:italic;">Appendix B</i><font style="display:inline-block;width:236.44pt;"></font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.76%;margin-right:10.92%;margin-top:30pt;page-break-after:avoid;width:78.32%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>mmsi-20201013ex991f93af4.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.7.0.58--><!--Created on: 10/16/2020 09:26:19 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><img src="mmsi-20201013ex991f93af4001.jpg" alt="Graphic" style="display:inline-block;height:105.12pt;width:507.05pt;"></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">FOR IMMEDIATE RELEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">MERIT MEDICAL SYSTEMS FINALIZES RESOLUTION WITH THE GOVERNMENT</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">SOUTH JORDAN, Utah, October 13, 2020 -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced today that it has finalized its settlement with the U.S. Department of Justice and the U.S. Department of Health and Human Services. &#160;In order to avoid distraction from its core mission, and the cost of litigating the matter to success, Merit agreed to pay $18 million to the federal government and certain states. &#160;The settlement agreement does not constitute a finding of wrongdoing by Merit or its management, and it expressly recognizes that Merit denies the allegations.</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Merit looks forward to continuing to focus each day on its mission: &#160;To be the most customer-focused company in healthcare.</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">ABOUT MERIT</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></font><font style="font-size:11pt;">Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture and distribution of proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy.&#160;Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling in excess of 500 individuals.&#160;Merit employs approximately 6,000 people worldwide with facilities in South Jordan, Utah; Pearland, Texas; Richmond, Virginia; Malvern, Pennsylvania; Rockland, Massachusetts; Aliso Viejo, California; Maastricht and Venlo, The Netherlands; Paris, France; Galway, Ireland; Beijing, China; Tijuana, Mexico; Joinville, Brazil; Markham, Ontario, Canada; Melbourne, Australia; Tokyo, Japan; Reading, United Kingdom; Johannesburg, South Africa; and Singapore.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.79;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">CONTACTS:</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Teresa Johnson</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Corporate Communications<br>(801) 208-4295 (office)</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">tjohnson@merit.com</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Patrick McCarty<br>Investor Relations<br>(801) 208-4581 (office)</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">patrick.mccarty@merit.com</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">FORWARD-LOOKING STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;">Statements contained in this release which are not purely historical, including, without limitation, statements regarding the anticipated resolution of an ongoing investigation being conducted by the DOJ, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties such as those described in Merit&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019 (as amended by an Amendment No. 1 to Annual Report on Form 10-K/A, the &#8220;Annual Report on Form 10-K&#8221;) and subsequent filings with the Securities and Exchange Commission. Such risks and uncertainties include inherent risks and uncertainties relating to risks and uncertainties associated with the COVID-19 pandemic; risks relating to Merit&#8217;s potential inability to successfully manage growth through acquisitions generally, including the inability to effectively integrate acquired operations or products or commercialize technology developed internally or acquired through completed, proposed or future transactions; negative changes in economic and industry conditions in the United States or other countries; expenditures relating to research, development, testing and regulatory approval or clearance of Merit&#8217;s products and risks that such products may not be developed successfully or approved for commercial use; governmental scrutiny and regulation of the medical device industry, including governmental inquiries, investigations and proceedings involving Merit; litigation and other judicial proceedings affecting Merit; restrictions on Merit&#8217;s liquidity or business operations resulting from its debt agreements; infringement of Merit&#8217;s technology or the assertion that Merit&#8217;s technology infringes the rights of other parties; actions of activist shareholders; product recalls and product liability claims; changes in customer purchasing patterns or the mix of products Merit sells; risks and uncertainties associated with Merit&#8217;s information technology systems, including the potential for breaches of security and evolving regulations regarding privacy and data protection; increases in the prices of commodity components; the potential of fines, penalties or other adverse consequences if Merit&#8217;s employees or agents violate the U.S. Foreign Corrupt Practices Act or other laws or regulations; laws and regulations targeting fraud and abuse in the healthcare industry; potential for significant adverse changes in governing regulations, including reforms to the procedures for approval or clearance of Merit&#8217;s products by the U.S. Food &amp; Drug Administration or comparable regulatory authorities in other jurisdictions; changes in tax laws and regulations in the United States or other countries; termination or interruption of relationships with Merit&#8217;s suppliers, or failure of such suppliers to perform; fluctuations in exchange rates; uncertainties relating to the LIBOR calculation method and the expected discontinuation of LIBOR; concentration of a substantial portion of Merit&#8217;s revenues among a few products and procedures; development of new products and technology that could render Merit&#8217;s existing or future products obsolete; market acceptance of new products; volatility in the market price of Merit&#8217;s common stock; modification or limitation of governmental or private insurance reimbursement policies; changes in healthcare policies or markets related to healthcare reform initiatives; failure to comply with applicable environmental laws; changes in key personnel; work stoppage or transportation risks; introduction of products in a timely fashion; price and product competition; availability of labor and materials; fluctuations in and obsolescence of inventory; and other factors referenced in the Annual Report on Form 10-K and other materials filed with the Securities and Exchange Commission. All subsequent forward-looking statements attributable to Merit or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Actual results will likely differ, and may differ materially, from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and Merit assumes no obligation to update or disclose revisions to those estimates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:avoid;width:82.35%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>mmsi-20201013ex102809a99001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mmsi-20201013ex102809a99001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  " 9,# 2(  A$! Q$!_\0
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MY_X,9O\ XJBB@ _X3OQA_P!#7KG_ (,9O_BJ/^$[\8?]#7KG_@QF_P#BJ**
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M/^AKUS_P8S?_ !5%% !_PG?C#_H:]<_\&,W_ ,51_P )WXP_Z&O7/_!C-_\
M%444 '_"=^,/^AKUS_P8S?\ Q5'_  G?C#_H:]<_\&,W_P 5110 ?\)WXP_Z
M&O7/_!C-_P#%5--XY\7". CQ5K@S'D_\3"7GYC_M444 0_\ "=^,/^AKUS_P
M8S?_ !5'_"=^,/\ H:]<_P#!C-_\5110 ?\ "=^,/^AKUS_P8S?_ !5'_"=^
M,/\ H:]<_P#!C-_\5110 ?\ "=^,/^AKUS_P8S?_ !5'_"=^,/\ H:]<_P#!
MC-_\5110 ?\ "=^,/^AKUS_P8S?_ !5'_"=^,/\ H:]<_P#!C-_\5110 ?\
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&HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>mmsi-20201013ex102809a99002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mmsi-20201013ex102809a99002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  " : # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#Q_P#X3OQA
M_P!#7KG_ (,9O_BJ/^$[\8?]#7KG_@QF_P#BJ** #_A._&'_ $->N?\ @QF_
M^*H_X3OQA_T->N?^#&;_ .*HHH /^$[\8?\ 0UZY_P"#&;_XJC_A._&'_0UZ
MY_X,9O\ XJBB@ _X3OQA_P!#7KG_ (,9O_BJ/^$[\8?]#7KG_@QF_P#BJ**
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0 *&O7/\ P8S?_%444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>mmsi-20201013ex991f93af4001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mmsi-20201013ex991f93af4001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #4 _X# 2(  A$! Q$!_\0
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M4E% "T4E% "T49HS0 449HS0 449HS0 449HS0 449HS0 449HS0 449HS0
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M[C_O^O\ A3A\8;<?\P:X_P"_Z_X4>VAW#^S,5_(>GYI:\P_X7%;?] 6?_O\
MK_A2_P#"XK7_ * MQ_W_ %_PH]M#N']F8O\ D_(].HKS+_A<-K_T!I_^_P"O
M^%'_  N&U_Z T_\ W_7_  H]M#N']F8O^3\CTVBO,O\ A<5K_P! :?\ \"%_
MPH_X7':_] :?_P "%_PH]M#N']F8O^3\CTW-+FO,?^%R6G_0&G_\"%_PI/\
MA<EI_P! :?\ [_K_ (4>VAW%_9F*_D_(]/HKS#_A<MI_T!I_^_Z_X4G_  N:
MT_Z MQ_W_7_"CVL.X?V;BOY/R/4**\O_ .%S6O\ T!+C_O\ K_A2?\+GM?\
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M '_7_"E_X6[:_P#0&G_[_K_A3]M#N']F8O\ D/0_+]J<(_:O.O\ A;UK_P!
M:?\ [_K_ (4?\+>M?^@-/_W_ %_PH]M#N']F8O\ D/1ME+LKSC_A;UK_ - :
M?_O^O^%+_P +>M?^@-<?]_U_PI>VAW#^S,7_ "'HX44;17G'_"W[7_H#3_\
M?]?\*/\ A;]K_P! :X_[_K_A3]M#N']F8O\ D/2,4N*\V_X6_:_] :X_[_K_
M (4?\+?M?^@+/_W_ %_PH]M#N']F8O\ D/2:,5YM_P +?M?^@+/_ -_U_P *
M/^%OVO\ T!KC_O\ K_A1[:'</[,Q?\AZ5BBO-?\ A;]K_P! 6X_[_K_A1_PM
M^U_Z L__ '_7_"CVT.X?V9B_Y#TJC%>:_P#"W[;_ * MQ_W_ %_PH_X7!;?]
M 6?_ +_K_A1[:'</[,Q?\AZ51BO-?^%OVW_0&N/^_P"O^%'_  M^V_Z T_\
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M^O\ A1[:'</[,Q7\AZ+N%&\5YU_PMBT_Z UQ_P!_U_PI?^%LV?\ T!KC_O\
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M ._Z_P"%'MH=P_LS%_R'H7ER>E'E2>E>?#XQVO\ T!I_^_Z_X4[_ (7%:_\
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M 44E% 7%HI** N+FBDHH 7-)FBB@ S11FC- !129HS0(6BDS1F@+BT4G-'-
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M*9TK_H*W_P"2?X4?\*9TK_H*W_Y)_A6OL)GG?VQA>[^X\:Q17LG_  IG2O\
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M7> ?<'K5SQYJWB*PDTFT\-K&UW>3,A62,,,!<YYZ >M7O"B>+4^T?\)/-82
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M,&&2*Y9U/LP;V]*.72[9+K_O.11;MOY7.?YHKKM+MM$M/!_]JZCI+WTS79@
M6X:+ VY[5DZO?Z-=PQKIFBO8.&RSM=-+N'I@CBAPLKW%#$<\W%1=D[7TM^9C
MT4M%2=(F*,4M% "8I<444 %%%% !1110 449%)D4 +129%&: %HI,T<T +12
M<T8/K0 M%&#1B@ HS1BEQ0,;FEI<48H"Q;TJ_.F:G#>"/S/+.2N<9'L>Q]ZV
M8])BU4P2VVHW,M@7<NDW^LB8#<0.2#D=Q6%:74UC<I<6[[)4Z' /Z'BK=SKN
MHW3PLTZQ^2VZ-8(UB56]<*!S5QDDK,Y:U&<I\T-//_@%_3]'T[55BGMQ<0P^
M;Y4D;RAR?E)!#8'IR,4:!I]H5M;ZXBDE_P!.6#8' 4C!/H<UFRZSJ$LL4K7+
M!H6W1[%5 I]<  9]Z6;6M1G55DNFVI()55550K>H  Q34HD.A7:M?1^9NWG]
MFC1[C?;W A&ILJPI* >AR=VW@>V*Y_5[&/3M4FMHW9HTP5+=<$ \_G3)]0NK
MA&267*M)YI 4 %_7@4C7UP]Z+R1P\X(.YU!!QP,C&#2E),NC0G3=[F_/8Q7.
MG6$UR7\FVT\RLD9 9_G( !/3ZTRQT+3;UK>Y+W,5G-%*Y3<&=2@[' !'X5E2
M:SJ$M]]L-R1,%V#:H"A?[H7&,>V*:VKW[S^<;EM_EF,84 !3U  & /I3YHD*
MA62LG;^OZU->SM=+M+K3+HQ7;B[E!A4S*/+ (&2=OS'/;BB^L;"*[:YODGF-
MW>21HL4HC" -@DD@Y//2LFTUC4+")8[:Y*(K;E!56VGU&0<?A2PZUJ,!D,=R
M?G?S#N16&_\ O#(.#[BCFC8'AZW-=/\ %_TC6O-'TFP1Y)1=R_Z:UNJ+(%^4
M <DX//-8NJV:Z?JEQ:(Y=8VPI;J1C-)<:E>7?^OG9\R&7D#[YZFI9]3>XLY(
MI$#3RRB26<XRP P!TXJ6XLTITZL&G)W+-B,^&-5P.CQ$^PS5[2!#_96FBXB,
MD3ZE]T-MW<?0UAV.HW6FS&6UDV,PVL"H96'H0>"*?>:O>WTT4LTP!A_U2QH$
M5/HH  IJ21,Z$Y2:6S=_PL:^HV>EQ3W-[+;W'E/=M D$<X7!'4EMOY#%7+^T
MT[3M'NX'6YD@2]38@D 8Y3/+8]_2N>36M0CDFD6XYF;=("BD,WK@C&?>F76J
M7UZKK<7#2"1Q(V0.6 QG@>E/FB1]6JMI-Z+S9-J6GK8ZU]EMR74E&C\SK\V"
M :Z?4I+:5=9BMKFXDU$PJ+B"0'R4"XSL/?VSBN,N+J:ZF\Z>0O)@#=TX' JW
M<:]JEW9_99[V1X< %2 "P'0$@9/XFB,DKCJX>I/D=]5_P#IK+1)[30;V.);:
M1YK0R2RBXC)'H@&[(QW-0>9.GBC3K>)W%J;55"*?E,94[N.F/6N3AGEMUE6)
MMHE38X 'S+Z5;CUK4HK V*7DBVQ!&P8Z'J >H'MFCG1#PM2[;:=_Z\SJ-.EL
MKZX@ODU.>TBTR(^9 (V*X!.-K X^;T-9-MJMI.(+&YTEY(Y)W9'2=XV <_P@
M<''XUBF\N/L0L_,(MPV_8  "WJ?7\:M6NO:I96OV:WO9(XN<+@';G^Z2,K^%
M/G#ZFTGU[:VM]Q7U&V6RU&YME?>L4A4,>]5J4DL2222>23WI*R9WQ344F)BB
MEHH&)12TE !1110 ^BBBD4%%%% !BDQ2T4 (>E>L_!C_ )!^K_\ 7:/_ -!-
M>3'I7K7P9_Y!^K_]=H__ $$UMA_C/*SG_='\OS.[\0:PNB:1+=[#+-D1P0CK
M+*QPB#ZG^M<GK%^?A]X&DDDE676KUV9I/^>EP_+-_NJ.GL!5_P 17<%AXOTJ
M\U<R)I<$$C0R!"R+<D@ M@'!V9QGU->7?$:XU?6M<@O9+&Z3370K8 Q-\RYY
M8C'!8\X/.,5USE971\Y@Z"J3C&6V[_R,+POH-QXG\0P6*ECYC%YY3R53JS'W
M_J:](^*6OPZ1H]OX6TW$>^-?-"_P1#[J_CC\A[U'X$EM?!FG7@U6SN8M9N-K
M10>2S-,A&45,#&<DY'8]:X#6;#Q!J/BJZ2]L+EM3FD+-$B$_0*>F .AZ5AK&
M&F[/5O&OB;R?N0V\WW*ZZ-.GAX:S)\L#W(MXQC[YVDD_08 KTCX+?ZS6?I%_
M[-5/QC=6.H>"M-TS0+:ZE6P*R7"BW8>0 I!WY'WBQ_F:T_@S8W4-MJEW-!)'
M#*T:QLZD;B,YQGZBB$+5%8,5B/:X*3EH[[?,?\;/^0'I?_7V?_0#7D-O&\TB
M11*7D=@JJ.I)X KU[XV?\@/2_P#KZ/\ Z :Y#X6064WC*$W;*'CC9[=6Z-)V
M_$#)HJQYIV*RZK['!.I;:Y[#X1\/IX:\/066 9R/,G8?Q.>OY=/PK7LKR"_M
MA<6T@DB+,H8="58J?U!KDOB3XI'ASPW)%;R!;^[!BA ZJ/XG_ ?J13_A?<12
M_#[3(XY S0AXY #RK;R<'\"*Z$TGRH\*I3G.#Q$^K.IO+VWL5B:XD">;*L*?
M[3L< "H]5U*#2-+NM1N0Y@MHS(^P9.!UQ7D_BWQ?%?\ Q,T6R2=1IVFWB&5\
M_*TF<$GV7I^=>PO''/$R2(LD;#!5AD,/ZTU*][$U*+I*+EUU/.6^-GA@H2D.
MH,V.!Y2C/_CU4?A=K!U_QAXDU1D6,W"QL$4YVC) 'Y"O2?[$TG_H&67_ (#I
M_A4UO8V=F6-M:P0EN&,407/Y"ERRO=LT=:BH2C"+N_,Y#QUKL?AS6?#FH3#,
M'VF2.7V5DP3^'7\*[/<7@WPE6)7*'/!]/PKRCXWSPM;:3:B13.)'D*9Y"XQG
M\ZV/A1XF_M70?[*N9,W=B JY/+Q=C^'3\J2G[[B5+#-X:-9+U./\,ZCJNH_&
MN-]:VK>Q&6(Q+PL:A&P%]N^>^<UZ#\5!GX>:E]8__1BUUOV6W%Q]H\B+SO\
MGIL&[\^M<;\5[B*+P#>1R2!7F>-8U/5CO!X_ &AJT6$:JJUZ=E:UD<W\#QBW
MUG_?B_DU0_' 9ET/_MM_[+3_ ()W$2'5K9G F?RW5.Y4;@2/S%:?Q :SO/&O
MANSE*221":7R6/WFP#&#]67%0M:9UR;ACW*VW^1YMJBC1M&M]$7 N9=MS?'N
M&(^2,_[H.3[FJVIZ)+I6FZ9<3Y$E]&\H0]D! 7\^OY5/I=C/J>LW%[K"RK!
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M"BBB@ HHHH ,4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"%9>*?^?*'_P "%KWC%&*/JT _MW%=E]W_  3P?_A67BG_ )\H?_ A:/\
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MJT _MW%=E]W_  3P?_A67BG_ )\H?_ A:/\ A67BK_GRA_\  A:]XQ1BCZM
M/[=Q79?=_P $\'_X5EXI_P"?*'_P(6C_ (5EXI_Y\H?_  (6O>,48H^K0#^W
M<5V7W?\ !/!_^%9>*?\ GRA_\"%H_P"%9>*?^?*'_P "%KWC%&*/JT _MW%=
ME]W_  3P?_A67BG_ )\H?_ A:/\ A67BG_GRA_\  A:]XQ1BCZM /[=Q79?=
M_P $\'_X5EXI_P"?*'_P(6C_ (5EXJ_Y\H?_  (6O>,48H^K0#^W<5V7W?\
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MQ3_SY0_^!"U[K2T?5X!_;F)[+[CPG_A6GBG_ )\H?_ A:/\ A6?BG_GRA_\
M A:]VI*/J\ _MS$]E]QX5_PK/Q3_ ,^4/_@0M'_"M/%'_/G#_P"!"U[K11]7
M@']N8GLON_X)X5_PK3Q3_P ^4/\ X$+1_P *T\4?\^</_@0M>ZT4?5X!_;F)
M[+[CPK_A6GBC_GSA_P# A:/^%:>*?^?.'_P(6O=:*/J\ _MS$]E]W_!/"O\
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MER*;Y?O2>6?6@!^?>C-,V'L:-C4 /S14>UZ,/0!)14?ST9?T- $E%1Y>C+4
M245'EZ3+^E $M%19?WH^?WH EHS46&HPU $M)FH]K4;&H DR*3<*9Y9I?+-
M#MXI/,%)Y=+Y= !Y@I/,]J=Y8H\L4 ,WFDW-4NP4NV@"'YC1M)J?;1MH @V&
ME$=3[:-M $/ET[8*EVT8H C"4NWVJ3%+B@"/;1MJ3%&* &;:7;3\48H 9MI<
M4_%% #=M&*=BC% "8HQ2XI<4 )BBEHH 3%+BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "C%%% "8HQ2T4
M)BC%+10 W%&*=10 W%)MI]&* (\4;:?BC% #-M&VGXHQ0!'MHVU)BC% $>VD
MVU)BC% $>*-M28HQ0!'MHVU)BC% $>VC;4F!1@4 1[:-M28HQ0!'MHVU)BC%
M $>VC%28HQ0 S%&VGXHQ0 W%&VGXHQ0 S%&VGXHQ0 W;1BG8I<4 -Q1BG44
M-Q1BG44 )BC%+10 F*7%%% !BBBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>mmsi-20201013x8k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mmsi-20201013x8k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !E C # 2(  A$! Q$!_\0
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MKQ#?M\)(IC(XFDD\@R=]O(_I7F'7DG)]35SQ#5N4XL'DRJ\SJRV;6GD?0?\
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M?\A2S_Z[I_,4R[_X_9_^NAI^G?\ (4L_^NZ?S%>4?HK^#Y'TW;_\>L7^XO\
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MCU5[A1=W420Y^8J,DC\ZQ/\ A8?B7_G]7_OV*UM!^)^K0:A%'J;)/;.P5B%
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M>)S.+)XU\G&[?[UA5ZG\'/OZG]%_F:QIQ4I),];'UYT,/*I#=&0/A+KI/,\
M'KQ_C7H'A/PG;>#[">>6427#+F63H !V'Y5UE<;XXU">=[3P[8D_:;YL2$?P
M1]S^E=?LX4_>1\P\=B<:U1F[+KZ%?PO$_B+Q'=^)IP3;*3#9J>RC//X@UW55
M--T^#2M.@LK=<10J%'%6ZTA'E6IP8FJJM2\=EHO1'GOCK48](\6:/?2YVQ1L
M0!W/S 5J>"-*F$$VN7Z_Z?J!WMG^%>P_G3?$_AIO$'BG2GD7-K;+OD/KR>/U
M%=>JA5"J  .@%1&+<VV=5;$16&A3ANUKZ7>@M<SXA\7?V%J5O8QZ=+=S3IO
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M9[G\+/\ D3$_Z[-_(4WXJ_\ (G-_UV7^1IWPL_Y$Q/\ KLW\A3?BK_R)S?\
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M[XI7.IZ<]G9VOV?S!AI">0/:G&M",;&>(RO%5L0YVLI.^^QP5T0;R<CIO/\
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L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>mmsi-20201013.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7556.35618 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/16/2020 9:26:28 PM-->
<!--Modified on: 10/16/2020 9:26:28 PM-->
<xsd:schema targetNamespace="http://www.merit.com/20201013" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:mmsi="http://www.merit.com/20201013">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.merit.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="mmsi-20201013_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="mmsi-20201013_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>mmsi-20201013_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7556.35618 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/16/2020 9:26:28 PM-->
<!--Modified on: 10/16/2020 9:26:28 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cover [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>mmsi-20201013_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7556.35618 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/16/2020 9:26:28 PM-->
<!--Modified on: 10/16/2020 9:26:28 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="mmsi-20201013.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.merit.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.merit.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637384803886380248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637384803886380248" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637384803886380248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637384803886380248" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637384803886380248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637384803886380248" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637384803886380248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637384803886380248" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637384803886380248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637384803886380248" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637384803886380248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637384803886380248" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637384803886380248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637384803886380248" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637384803886380248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637384803886380248" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637384803886380248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637384803886380248" order="9" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637384803886380248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637384803886380248" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637384803886380248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637384803886380248" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637384803886380248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637384803886380248" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_637384803886380248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications_637384803886380248" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_637384803886380248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial_637384803886380248" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_637384803886390250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_637384803886390250" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_637384803886390250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_637384803886390250" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637384803886390250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637384803886390250" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637384803886390250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637384803886390250" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637384803886390250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637384803886390250" order="19" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637384803886390250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637384803886390250" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637384803886390250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637384803886390250" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637384803886390250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637384803886390250" order="22" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>mmsi-20201013x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mmsi-20201013.xsd" xlink:type="simple"/>
    <context id="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000856982</identifier>
        </entity>
        <period>
            <startDate>2020-10-13</startDate>
            <endDate>2020-10-13</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig"
      id="Tc_D7TGQShzE0KPqd7DFPj_hA_2_1">0000856982</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig"
      id="Tc_NwLtxPWj8EeTZuqig3pmrw_3_1">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName
      contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig"
      id="Hidden__CX5Zu6a-US0rFDjN6L4cQ">MERIT MEDICAL SYSTEMS INC</dei:EntityRegistrantName>
    <dei:DocumentType
      contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig"
      id="Narr_pK-JLRrmJEWcRHTAyM7XcA">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig"
      id="Narr_3rrz0JuCXUe9IAbH9R7eJg">2020-10-13</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig"
      id="Tc_jmdvAA8hKEWPCPjakEbWng_1_0">UT</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig"
      id="Tc_gMjSD8NizEWWYBQbPtD_dQ_1_2">0-18592</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig"
      id="Tc_uLz39PH8jUeEVBGTMwkcPw_1_4">87-0447695</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig"
      id="Tc_lSccnRLs10SmsfLQYbfFzQ_1_0">1600 West Merit Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig"
      id="Narr_qPB3st1P10us2Igu94NBBQ">South Jordan</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig"
      id="Narr_phkVjhK5Vk6tGlkhNNaaYw">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig"
      id="Tc_3v8P_MD2nkeNEPtMsdHgGg_2_2">84095</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig"
      id="Narr_o316idkVX0uNXZaBMDwATA">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig"
      id="Narr_D98cUfVJ-EGW-Cirm9APGQ">253-1600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig"
      id="Narr_fRB_wH2WZ0OmXVlIDHUMYA">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig"
      id="Narr__2fVXgeczkCus8551t9ILA">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig"
      id="Narr_LjtltwS_50OGoYVKSXVqrw">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig"
      id="Narr_nHH52VZTWEaGB45QTjhSag">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig"
      id="Tc_pzwSR8gahk2DW_PxaK2dXQ_1_0">Common Stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig"
      id="Tc_7au7S0PGrUW23r--sC0AjA_1_2">MMSI</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig"
      id="Narr_W3M6L5J4dUKalXdStigoJw">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig"
      id="Narr_K6YZ9WfSYkOJuas5En_EYQ">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139937312067480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 13, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 13,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-18592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MERIT MEDICAL SYSTEMS INC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0447695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1600 West Merit Parkway<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South Jordan<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">253-1600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, no par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MMSI<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000856982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M*N.$Z\PF+],%F4WNI^/1(PG^"!:364"F3V.$L5,P=BYAG(I0JE2J?.Y<D<#
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MU6-8EZ5JCS^%]RBYGQON_Q+%#U!+ P04    " "0BU!1EXJ[',     3 @
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MBBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @
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MX3]>?P%02P$"% ,4    " "0BU!1!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( )"+4%&H&>?G[P
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( )"+4%&97)PC$ 8  )PG   3              "  <T!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ D(M04<_$$?HZ!   1Q   !@
M             ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( )"+4%&#J:4#U $  #(&   -              "  7X,  !X;"]S
M='EL97,N>&UL4$L! A0#%     @ D(M049>*NQS     $P(   L
M     ( !?0X  %]R96QS+RYR96QS4$L! A0#%     @ D(M041PX9>H_ 0
M/ (   \              ( !9@\  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( )"+4%$D'INBK0   /@!   :              "  =(0  !X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( )"+4%%ED'F2&0$  ,\#
M   3              "  ;<1  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0   )  D /@(   $3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="mmsi-20201013x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merit.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="mmsi-20201013x8k.htm">mmsi-20201013x8k.htm</File>
    <File>mmsi-20201013.xsd</File>
    <File>mmsi-20201013_lab.xml</File>
    <File>mmsi-20201013_pre.xml</File>
    <File>mmsi-20201013ex1017cba2a.htm</File>
    <File>mmsi-20201013ex102809a99.htm</File>
    <File>mmsi-20201013ex991f93af4.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mmsi-20201013x8k001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>20
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mmsi-20201013x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "mmsi-20201013x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mmsi-20201013_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mmsi-20201013_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "mmsi-20201013.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "mmsi",
   "nsuri": "http://www.merit.com/20201013",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mmsi-20201013x8k.htm",
      "contextRef": "Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.merit.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mmsi-20201013x8k.htm",
      "contextRef": "Duration_10_13_2020_To_10_13_2020_aBxRJHmo7E6tmw2SZDKbig",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merit.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merit.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merit.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merit.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merit.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merit.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merit.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merit.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merit.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merit.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merit.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merit.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merit.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merit.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merit.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merit.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merit.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merit.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merit.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merit.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merit.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.merit.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>21
<FILENAME>0000856982-20-000041-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000856982-20-000041-xbrl.zip
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M9BF;)#+RY01P X97Q&*0I_"*- 6BQ2YC %CV,4X #SSV.>,C#\D:9V.-48%
M0L!@8_,A('&>B 1 DF=P)?DBX 6(,JD(PU2_+@YR'SYHM(#A%VE<$\@A4DI@
M^30:4 9 687)B\.*,> (W<HG(@=JJ.>4LCQ52%#:2 U%F_0?[%F&\BT#Q(#A
M 8NB.$_A)>$P3L:T5?#F=#:>9#%^]5F.]T6"#>4@B660*FHWFDV (O+4ST,.
M,\['<0*K6%EF^/[^L+GM/G<<L2X 7,@ZK?:.QS2MA+T,X: X^T66-HD^[\L,
M)N?#&/_))<OX^)<-^8[8!4 Q &@%@Y1I!KPT8[TX3S(&!ZF8D;D,$(X;_E&
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MM,-N1!FAMD22(FC?JI: M\#H/A O930!^J%WT:HFL))BTV(?7@=S8"#@HTY
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M%;>WFEL+SF)GV-)8#5^$X0'M&VRAQ@LU\'.[FZM< )T%):M6M7X"5>MN(Q<
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MMWKP?@4;<X,Z'NY! /L^\V"/M2\EFY$8$X.Z#@R*3*>XOYI X,[!+J**CZP
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MBN68+'?-I*J$,W)NI8[@-1<(FR>)<;%2?#:&WM(5)]T52%T@$]P[9<'57W3
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M!)!4V-665FZ6J"*Z0;*5Y(S"K\3RX#,YWQ$!EM,;10\UU:DD-]H%K-0)6)X
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M4>L@G7,_E;#UVEPJ,!T[B2/I*XQ"RZLQ8-OWIQ6!P#Y*8ZB5>A9CG?N'<SK
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MDP-V.>$A]=PY.3FO#^-%]$ =<8FAL"^M>2R8_U^)(?FUSJM6%5Z=JG#"IXG
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MY[=[-V]B&=SEW-P8Q,$,_AEEX_#=_P%02P,$%     @ D(M04?^3$8 -O
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M?4PS19D*<LD![2PUM2&W?9#J0];OEAV&\1CD,]AE+-]H"VKQ9(4CM%&ZPAJ
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M"C@O@1CY;A]_"3^ T9Q]:V2#DPW?\H@C9X)Q?IA$2 D:5X0A__KT?Y,3M.?
M;^P>Y1(XFISS0QEKA8?NPD[$Z"Z^\_TDU<+!8XX*<S+#-Y[FG;77W4]=V#*N
MPM^(\<3UIT*8OZ'9]?AW&!<.;+J^A;Y2ZF^0,%XD(\R\/'*UUO*E3HMX+?B:
MX&8#,"K(MY,Q(?7:/\:>]#M]S^H*<#8'<,E:TSHJ,"M:P')]J<,E)D(UDC0D
M:HZR88NO?H11JS""#:/B4W877MG*Y[?OP_P\/U('.?7HL^_N+/7N,%]Z$,$#
M85  -@\<!3%.3D!KM<T.OTWM]41B^)A[LN$SL%BG&-N <\;QM1<_^&&-_4#(
M",?9H37R8SB"_9@2@K:EHV[6O8STB;]Z8A)Q"@MW>!CW1O#8L*><?DR1"QG)
MZ_ECL639;$[53'P',XPCX>&?4UC-(C-;LM9'Z>,K@WNO+!F4#>:==\Q4#YV+
M"YUV.*N*]CU:3?O*/?:)G&%*5C\(9]R%W8([+O#[<2_26X["RR$%EV&7RL"7
MO&8M.7Q60 [SH0D$JWE8_!^"@.-@L8/63E(#CI<#K-AC(T.'Z)04".?DYED;
MHZ(-DN6 6^2@%M9Z\.,"#ZZROG6/YY5Y $\3'5KZ"9RURN<>PN/5\V!YBE);
M//FF+N%AA O/-&S) T'_M/L4Z@OI#T8(T3_A#'0#J:;!MEI\YMG,) T3("J)
MX0@P!#PW_ S. *QJ*&!A; 66D+?*!./A)XZ'-IT$-'3].**Y\-@^;B3^?:C@
M3>PIHC'AMY9/$ZQ:=9QU#BV#*AJ H4[S0NC4]3T<;Y@0_BJ,7?J1OO4>+S%^
MUHTCTO^N,W;6S26<%[%_02Z%$_#MT0[12 _U20X(1']$1K^&C*AG:2G9;/7%
MLW#]":TAKM(S..3\/6%J%(A*K@>)2#O\@6O4$]98T+8*:5\Y(68YN[X=].D#
M,"QZR>?FV#BT'?08OH:VCOK@@-XNO$+S:KHHCD8^^TJP&6P,5KLB-&PS\I=D
M1MC8(DMVR+YAW@V$.*!7+]<([@('8LBXKP)CPJ[KY^PZW%IX,W/W.5X8.5',
MLX;-=RLW'R[)M7_P11U;ZXJ78RI]-8&JY]D1+_(%O\'?3.B\P <RK1324+ =
M</JXH\&)=3@Y0I-SNO+&CO?LN_1+-4><2=TURH(,T=;TSDD%U<[)>FKG<0);
MA4]@F,8_C 5&2.()>@V\>Y48 I_F&>;26D\Z%A".>(:#H>TY_V0I!V9>(*(X
M\&@^Y'5*M4>GF0Z]5DA)*$B9JRTK$?1\7/&T:MD$IP<?B\$G'OT-IJ] 7$IH
MK%(KI?.Z/D@91._)PC-Z*ZWTO.#KL1AWA?H]04>&PJ)@*_SMP<[ \RW_A'NO
MM;(G!586G.*P%S@3>MJ214+=K<R3*EJ9I^L=]Z>1$X!* T4[M6Z4]8!@"ZF(
M<D0 Q2QZ#IZ,@=,S<*JVJPZ<-K42"2$M"+J"I 4=65)$<*[P.*YK715":I2Z
MLX]6WMF739)O9TF^_(25FC493KG9NJ1Z^I)#VNGZ:6/8U%@'"$/)XBYXX+(K
ML&?J&3$D5+T*Z";WVN1>MX+#4*7A:?%G8[81E."$E" :>M+(-;#&IJ68"0E0
M?$)66>#78RDI$U]\[_K+S3[FY\#W#<%$?0$CTP,-2;K0L"0I_#$=X_NR,;*O
M1DKLSG+*A3:4>=J2_=4Y3?1LE0RPLW7#?#GN_QRK2X?WC'B(X7K(6,J44TO2
MU>%4J@QQX\^,M"D&NC1X%O9QZ4A9)PJ%.]A'9#O.A=)39BS""%'8^=&7M:;8
M*3!%&=UYO2[0*RI[*K?N*8^7X^[]'[>?KIYN[[X^EE?]M#K8L-+UVS#YDXNL
MK&>I)HL,5-4G*>VQ[7B1C0(MO[;1CI(ZS134UQ)<JXL@U5>E7&<*4HZ30K*R
M-:L4&04+R>(Y8OLG#NE,O2YM)J-.]SWF.5!9?E#X*AF1B^?/9PX&:OUI6@MO
MM_ZX7VP,/)*.35:BX*-U*OED=TGE(-VAG(!/"?&>N66EI=>5GA^EY<$EU1ML
MK4"M@*V=H$J=.1LG+Y(U>]8I>+70'&Q;_P##&;3*9:IV+:< LW3LBZGZ[ E#
MOO((!]B%9<\A5R>JZU3.)"GT%[DT!^IZ76&*C L27"=)"#B=P?E[ST'3/A$L
M"?Z4!P@(=R;AJN[4(FX5N.'($0/KAHD7GI.[IN&K/ 2ZWUW!8 :!@#X_Z",&
M09 SCJ,IGI5K/_; Y\ K^08?X3JOY\!7^@:!0OA2?AK]<3ZGCE!$$^25"$NF
M>1WVQGHVOD<,&826*X;DJ.N;A?$$L\L(O\A\.= (5EQ_!I8N77$]+Q<-EZ!%
M[IP?1Z6[0Q3D8-E;QSSQ*ZL1-*#_6RX2G&0K!.UZ50A*=(P"TCAP%$EZ$=A&
M,K2T4O0L3->"(@$A0^!5P&@,"A8>L;'DT3&9%$,@*BD)%HT8KBBK$C73T2)R
M)+SHXX>K*M3]Y2NUVA0IFF\D$1WIG<N;_$R&NDJO82PM//0*I>%.A&%>Q72W
M7O)P;/\@T4=@?Z=G[8$9Y H[C*S_B>T #KP[W9>6'&+FAG9 N1%#YHWM2)+G
MR8(*9>A=Q7TG2CQL97G.^MD)8&<O\YM]PQ9$>Y1 @_#()'ZE?>E[51 X^?'R
MVDA'JDU1;W+.^Y-E+%A_ ]Z2XM^3=/ :%QSE6K@&109OI3GWT*]Z;/?ACL^V
MXY(L8Z(-*P;C6,$AWU5A)?.KS6KSV@W$6:XJ/$V EJ7KPH9BY'4JS%[-%*;O
M.:"T5/5CWY["0Q_ ?TR=F*#=P4D8VD,F24U0:=4266>U8AMA2\$.K1>! ;)0
MQG-4]:7))*=:E"0$<E5XI$5)@SJ\ *8(7>Q ;4EK+,4C[80%IIE5D21VU:&T
MQN0:'.WKP]$>-SC:!D?[VG"T\] C"EA[BOY#.F%\!5882###"/[3[\[FV>9&
M"!+77^%M">P3AY&D"X'=@^C8),:^(,I@\TI1TP3),4/&>LQSB"-7-2XHE_2\
MG@3],%EPU<[FL/.GDKL<ET'4-/'<<T4ZYDQ'6&D;*GX&!V^"+V3NZZ<<+W&\
M*MJ?0 ]"N=D7/W9A3U N_N=>OR=Z(@SM@+['<B7F;C+\!F-?< 86/B"RZ6X<
M.HCH-B$"%#JSY63+V$9K:XL=%L_.($QF>SU4BC9E37B)#EQN$F!B+06 Z-O.
M  HRD=06!6TM;($RCL>JN$',$\$)#9@L6\T'>N0?H%3*TZ1?W2L/U2?:PS:A
MOA8N?4L]@U"@$YH@J'?QC/P'?=V(AUBC\#B'5FB[F/TUF#8(WM'2U1H@BFPG
M"-^HOPW>"]VOAG@2^+H,28+!TM"R1M3P![[WXX"X'&P,B[>(#]O#JF+X.AZ
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MT*X-VK4^:-=\GT["5A.G;J>XS83BKUJPS3]7A6V.,:+/WLN>&<QG^&YHNW9
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M>&57C@W5E%;V5!>O59-5=G5Z6',@\%H.U-G+.#CJ%+2M\EEC$Z98UP8G31_
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MOF.#G^_V&OV?]*Z4XZ[B9)G1 NHLE$VQM%(YEI9I;"O6<XYZT"VM9WQW4W8
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M&Z$X3?:Y17MD%;=W'O\0MMV0Y6/98=,%9"!T.6$M^X%0""]\6VK )17,+R<
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M.BV/^N)9N/XDTQ';MD!:>TQ:S68!_CXC%F<Z)VC+88#0H\6]J1ETE!TQ5<]
M:!)5=9!7;T!%&DGAYEP4G.,A(6> "*6)C4URJF &U[V5 D/_T%[T^F]\+ @9
MHN&V9X<&R&^?LLLZTFQ$H$.+2K^J\&PYG1?J]"+XC"QM-K0E=^EH9=VXJY*-
MA@W]U5=M7#95&TW51GVJ-E[G/)>VK=O4M//=KI-VJB3FU7E=.Z,2^P7H#9>[
M-ND*ZRH8EG6GDTF*U*LPOYK[%/[@[4)_XF1[^9>&&G(C\OSDLDKR?,^I5Y;8
M3%,Q0^UL].NGTE-&H69>I*OZG-OUTA4Z:-BB6LO8C13/";.;#(0X&/CP@%AR
MV4N1C,%/9IK8&L-Q8U?9J ?6*+(=C[G)9(-762$7MAAD8$\U-QWM""9=#[E6
MDK=4SQ^/8T^W#1P$_K@*RUISWO4Q=4\/PB6\ZYV.*B]MV#(;79:ORVJJS$P%
M@V7X(@0YA"F?,0<ZJW!N:ZYH9GN<4(\XI#QP1.H-,*G7XIQ9E5,FM9+]["<N
M8;\_)9=M*RY.X^/\FGJA9HHAET&D5]D.'+42.9X?9?MM-"*E$2E%1<IS_26*
MCHF(@S$WC--NM]$'2!JI52RGJ5LP=UDYS?%)@C!L7-Q&[N3(G9J)'18> A-"
M&-L+%1S[+I<T;T"<U1DAA8%!NS="YVP8.WTA(W(R:E2%@SXKE2YKY1N31;2D
M7< Y&7E5%DRK8;9+(=0\2LW?.M4<[Z777TQ6K+XX7K/Z0@&6\<1]I-[V!_%D
ME2J,!WG>,4:>94GO,L.=XTH62X[#,W$E]S75U3]W@X'3PS0 X5H)@LR_P,B8
MC.:LQT9Y4HB-,B&@+[>>H;/866AT=)Z.5BT[JJ&BORQ#R,15D?SKMP!Y,+EB
M'\ST*.?9K*_PHWL"F\//,8 =[_"Y5^SHL_YR6+M]OLT]2-)\BWNW[+HS4/*[
MJO5Q.=5P&-;QZS5Q434_$TD"TN(6*<1?T4IA'+"X3Q<%4=]U\PB"X,3WV^>V
M)#.E.0/2W/2!*G!,,N7<K$0FW[$2V$BQ&Y>]TSU)A@%=A2W?1S8\"RF;5/=W
MHQ2(>Y;CK=.M8BK*0[LQFS!+]WN:K?^N@%&X'KWZ=0+3N#)VBBDZEIN'3[PQ
M89:\G^U(G@M!;0%#WBUH]4G@1R@#4W I5\-EH!^AM5=>QRO1'K9;)!$7/A9"
M3AQ/F<MPBB6-A7J$ENYY)\]]YHCA]\KQA45NF8<RLL,?TC]6C.,@(/JPP_U@
M"J:>'?3I VOD]Y+/S;%Q:#OHC:0!S7\<D*@@_N_D2CN.1GX0CIQ)^F/9O4\"
M<QP/+'2L,.97QBQ'04IZ<"VBAR]SOV6%<6^]NNBSHG71I9KHJX/AF[JJIJYJ
M-W551X=-75535_5*ZY5D$QV+\ZF&"-31IT ,1!!PP ETF<#6PJ%UK;5MV+:D
M/7\IS7D9MDYL^7[6EB^CL\)27=/$@RI6,C43#:H95X4,[! UE'$>N&$W>K0S
M#;AUCTS5RV9AZ^A6=<EM:Y6R,3R#W"[;!H&6WX4?*L2Z'\@(NR'JS/>L120.
MA51A<-AD(,&VT-((J,$0)]_ZY+ <8(MVY/* U0G N=%=WQW<&K#(8XY,V B@
MQ." AVU>Q420=VH-;"<X&%-)A87]:"NZ.XYJM3W@];C3T%F6U#M>T/*@@4%5
M5K55)M51LV+@&Z-EMFI%C1VH-?$2_'\/F=*Z<7](,18F7R)I%DY$SQE@2'//
MX;[,W3ATJ!VU)T2?9"O+7@ILA9$SIL"*%X^[(D +DH'EBFHND;I& (4#I$;X
M%*;G]WIQ8#:+2Z*YV/J-P[*.L\]3PHEC.&<,+E6D] +,'8,SGG%3%?BI@ORJ
MN2Y.7E=;.@2&]IUD*#CA;7!(G%N*<R1?Y[4IS_R,K'T#"I?1_@M;5KIY9!AW
M0ZP2@448^_T,7:X< [NM*^(P(GN* _ 0R2X3L ?D9H)]?9T;^ ]EE)"#@W!
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M@B%5:1=[DDG4DLMB>FX<XDD8B][(]IP0HYY@M@Q'\G+)$N@'(;BS4_4GUE_
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M>Z/RIRR7[?6&J;-XT-.MD6+*)/XFR<MFF"*3Y#H&OL [,]K 9HY(Z=P,.42
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M5I5*+N#O7J1.C1T$MC?D!G=*0O">E>W:U"1"GF&.G=7^F?>"JT'66<Y;H6G
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M[X+T8#GW3?KL<K;@ EA&E227Y\F(W]+A#@10%[%HHK:\&C*E'60$62V\1;3
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MPMGA$ ')=4@> OA)WUOY.NBS(#G%$X4]0>RF0S7WE3P.ELJ5&_]&Q@0PZQV
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MHRK[RS*&23?6 5V;0KS0*"SPRKZX5#C EG>X:6#K1(-04G/T>U32W C2^H5
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MMF1F[_@X5DFC8I;2:['W$B!A3R F.JE]@6==OQ52'!+P+PU2=N6#XLKE,51
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M=*ZI=;TC[3"U31Q-;.+H[;5='&T71]O%4=QC?&X71WH .K##S^T.^$#'H(X
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MK"R)6T)5+U,[4N.+#$+("24,GY"Y'C:?3^&$HL!GHD.V_T9ZS7LC5*%Z6LL
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M<^L2Y;JQ35.9>S6J/[19?PY^5T%&M$F,$?A3=9I@#;(L;/T@V (_::M6L#K
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M,CJ8;8S?IFO)CZ]AL&'MA?0>V:(DC $:XU1[B_7J@^V($YP2LJ@(2;*6>!7
MRD_*I)A!Z.12D:J)&M:_DTY#R:\==8\C\8-,-Q(Z/*,VD$DB\4KI#Y <:*\
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MJ_J,XQ"S;JFNQ,32(+,J4%>WN:)5U$C8U[3R\(=XU=EO>!04+3"#-D:X*;'
M8FLNPM?0&XF'\@G5JN30=_1;2Y&7LS%P/YS=N!G,Y)9CX5RU)+IG R13WA$#
MBSV-4"LE:ET#4)\A=HA\9MOFN0J$(5JU>S&---NFLT=.&U*FIK[+7O ,A^*V
MC$K85S%LTS418"E$S74'-J>Y01D?L =SWEXJ@VWNED(=A(4J>[P;W5(-GA*R
M:PAC7GHD&FJ@["P8R\N4Z34W,XF:M^X^8 K:H%(WX0[CONI:9E[%2_@\O?I
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MU/YG0]R!GQX,MOG/%F_MF;\8= 1](GM/M9F 3,JDM\1W2R&/]%#O27Z'OXG
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M+Q+YH&OP3^0J=7%* 7 /"XRU)*4D647I@XYOQAF;(TO@]XRT5*)H1D()Y/A
M&%*@KSN!7VJ:3\R8A**$5A4IM@(YPS'#T.N?$\]&'.D3Y/NT48V.8M0'CP!R
M1WQ"3;(=KB2%D!;&_.WKYI=1B$8<\J^8Z-^:&W&)WYMT(DEX:\)DK&U34F>^
M;PG&&^M9&V3 *7F\E[MD?9_J;5A/(!X9"E\O9H,?9;R_H:,^M6$=<EM+^6BC
MQAH'K-E$;Q"H,>,J6*PZ@;:Q(50@&\1\FUK-2%36;#P,QG=<LL]LYH(J$SX8
MUJ\.N,#G71P$,*3H/'8O5.6$PG56VX\4KHVPDR:S002'KY=;S-;[)-;/#LJ#
MYJ@_X;ZC40"O+FN5\F65G+M.RZ4=,0SAGP.+S1&;R_@=%_27+7P<\\\EQ6F>
M=3M&VYA)-O-JEI%,Z9K#=_$I*U8J*_XH85$)JXTB1_!9"X.RGU)C)JFA?K11
MSR,U.+<%MIXPC)8>_(XY:+3P5\=!/Y#]L+9]%4V1!V#XD9]@V*(.@T<:R/8F
MV-$;PM? #(N;\6+K+EC"6,L$"%V<F-ED+N@!L, -SB<][N_P/!.#4CK;B'T=
MQ&"/S'*Z@D/$=[V@B_NWA:!F1B#V$X!BT<)8&G>_ "(":#GP(D20"N],-W#U
M-EKNV$,4:*M$ >/0:0)O0"<^>FM()W0RP3T=O@C6/\;@^&YSKO(TF<%5F^$/
MHCH18D8WJ6LRW)%NDT?3L88V/I=MWTP=F?H#S@QW/P4^H"&CDFNI+E4D(I(%
ME+0JTU1>6]>^B+'KE+M-L LOT!*.EB9@EQ'=HF;'2VR^V^.W*^)V60<,II7A
M3Z3S:I&L Z-M!BY/KS"8I[NF)KP:(K%ADLZ?4-$J6%01VE<<G ,_TK_0C0,\
MW1N\#E<V,_E7@#:I,01_8/D8P[1,*A85(ID[7D!E'/& $6!$7'P [8@>M'[,
M73C%\@,(Q:AQ9@*[B<3/C$]GS,)#]3,.X/5R<1+]?<[B.QG1VO9US&S0N>P-
MTJ&F<8UH$7,O<I?V827[CB^LQ/]5"ANR+.,_TK4"#Q,8W$"XY8#'>#YINDY'
M>&H+H:,6'=G$#<]JEJ5\]M_(J8'#V$%GR)1,@'1.^_@SR:J&0 Z?(XM!(>4)
MV+(;JB)@6^? 14!]@6&8O C&>$S!=HB%42KD2X.0AIJ/-"/DZO^K;N2+DSN&
M/C4FN@_&$>VA08TC3[C*QU#,/9LB!,+5,&2H)I88B])"$$PLX,&''[%-;@JS
M>% C/%Z:3R\7BD7L:GU"]P#_9H<^"%&,XCTA'R=,Q43L=ET31 &*?^C/"-#C
M[K/8G)^YTQ )%+'G>(COOD"F!FP)_?@!D\AU%[IR<<>#B-9,"T(,>TBF1"-<
MY'>H1E&"@1HK*281/^CA$.M!4@FL?PO'$0ID#]Z%$?X,^ &[V Q)2?J@'.1/
MY(FX2G@. $QP@&03$M1T2A2,P# ]U(D$+XPBA%07FV=I"ZX\H8VW<#G: Y[*
M20ULJ@VR>U ><V>UZ6/((OAZCH)82=*,8GV@57JF(517P6OQJ6X^FA9J9ZBS
MV3R%C1MZ'1BA3]U^0FN#-[EVS]^=P#FVYF0<0U;C,X,*4<>;"' %WL((7:@@
MAB]OB?':@K^C(I_D$Z-FP:!N45*U?M:[P37J@2;-BRF%_DN8)1Z,'8#>HXA+
M'I+$\"QHM(^8!*B#).!AV "8$N\>@09;RD6JX/A%>C#!=! ,J3\Z/2$&/,8>
M>!C6$;T:PU//>QH6"M"_"+*[;"/\#010?/K4WI#M0Y+&#V>B%,/@7)]O3A0>
MO^'= (+XH%SAK?G<&VKPSRZ5S^E\LQ'A5@MD@7:8^QMK+CR+)4CRQ$'^"JSC
M#O5!\? V(BX:[?WDZ<DACQMDHL0\,4QSGIT'-9_A,QOH'QAW-$X+Z0-/:@)+
M3/49=5]@W3$6N(_RZD56;W:ZH#-Z(B_;%/XL$(PFR!D8QT98>Y#_BB(]/A4(
M1@!LT4//JA!NR->'Z^1YD1.D$N671TI![#7G8C"A6&J,V0B24"_0X_'R"%SV
M,S!=]%51 +P5<OEXEL=\@.OF%W@*:.7J";\M!D[.>*5B=V/X+C_]#CH#Q&@.
M=0V>J [$SZ.',0X2*L\$Y]H NP/ $O<&9!'J49CK$R3H98M@=(4 $5- K]<F
MKJ,%GC_4!R]RA7: R,2*_'YHIS#F/T>._)6]W7*$2FX]\$_"-T-'),!MTU98
M%R5)".*#"4!B2AAR=V)WCYC3UH)>T/[ U=]EG 5$&$V>Z(9PZT+BHHD-.H03
MM-IQR\FZCA?EU+U! G-!*JC3,YBSQ4$&,V8=?V8P?\0,YL4H)FO;T5K=$ O5
M\\:7;<*#D4RKC.K7B5?YZF"XXSU*ED23 '17OOQBK\I&O"83VV>@XV'O?U-X
MHWG?'IA]GN-Z;;,+5V&<@J_S-IA((JR.>\S 0.""%KD%K.Z8<Z,2;7H//!+C
M>>*.'?K!<!CA,@Y'CR\/<3<Z@0=R\0Q2PP/;4P.#!'@H?P]>-&W=%6F0278L
M!#]\,#)!->;WN'Q!2Y%:(B;BH0)A<>@F15^$K86?@>\(68B61)2.&?-\]L@B
M%'7;?0_C)['=[,4F@_DB;21"F(!FH)*X"L?73?,#*&7C\/\9JN;5!&G3I*:%
M!,HE%>YJ$\H7DM=KC&[="2PCLCTQAA>Y)T!* F%&HCVIRH@$Y5 E-5ZAAR[!
M[38F"18Q 7\.$0$78RT'IT8X6+JAICP][B"6_V#JGZ,AG-N? <#>-.,0J.FB
M+0%J';0,'4F8[3\4\ @K$TWX>D1SHL4+23%"J4<@XEP8Z@WO4YX)57,;ZZ'B
M]AO)BQ&;A>&^%<#SY<U$ (MD(S34>-XBZ#N8'"ZD;71B<IB39/)0,\]GP!J'
MJUC\O^VI&-O2]'9;1%>\94V5Y/0[V+)6 =4J\J50L@M\!'3.O7B/]EFB+#Y/
MC$C<B*KBHV&=VJ$6-P_K;;1&RZZ+/I<HK$#)X+2+SYUO'T^JF;:H%2$<]CY*
M.4R.UD A#ZD 23HLF"K)"M82H*X1;:^:*G@F!#WYP0T)QI;D:,)9QNN2#+['
MU]$'T7,^>9_@?87WL5WWC+L2J]RV^V1+'XDMS;0A-VE*F5B^&A,:AK=*4MN&
MWG7!J'AJ'FE34:,$MW/B"XG<AZ%$X:7NJA4)D/('";[]B115'MI@.YZ,FZ2B
MA6\.^/T\_6+QMW9WK6W' T%+PWO9V%A"Y'L.UA?55S%M_I)F.?K#$%D,'./Q
M[IIQY R^/T]IQ,_XPV?\8?&UF2>=9SC8!3.KHE6<I&B]U.'KO1T#NY&G0'9B
MIWG(EKSY %F\-O4"V;R9,KY0SI9\?7B&5KK]"AG+-.(DZ\;@? S^8T A*T#J
MXO>7/GMB@9@>$,EJ-CQN(.HT49YL;:8"NTI.4J:?*IR5,M%F7"G<C9O@:8F/
M822M:3F]:/C1-9^?DI!"/1CPB\P_?DXUGI4#/"+<&#LL!A)2<N9BPH6T5)A:
M*ODCC36L)#\*FRHIV>5-_#($;SH_4BGPA>K. WWTU$$-<8Y*TG-/_I+&.UY+
M^G48&#M78(0:TCFI^.&(X85"VR)*\_XG?5A0T*A/+(J;@A&B45YB8AJWUDC;
MQ;*[G8YGIM#/H,A*FCW!_WE=HRJ5VGYGKFCZ2L7QY UK&WQGBC'!A:*)O&Z1
M>3>^PP6LXS*OQ4OC>A9^6V1RS5C ;'*1#I&IAU?CY3JB8AIGM?W4P4$]+G@V
M;QF/L)M$%X-2&XLOXT'645\8!/ 2.[^&L!1UO)5T.X@LE4J;NIC5<BB16\=J
M;I 3:5>*@;H4FP>2Y4CBB3#=*$\?75HN0^\%((C+N$2. %V-1CO/D0-_%:]4
M_QI>J1;D(@5]^)WSRA?2(5Y@FE$^6IBMC<QJ-,,GN?1F#,=)?_$:$4[-)?D7
M7_[\J[G8ZE9S!?K57),<XZ F+X.DCV,!B[E85)K%-&UFWOMB/N<N^TOALI^^
M>#&7RL=->:%<':[JNA<&AK"C>!=*'!;:CS<^2J$<'I6M<Q\L]D%6)M#"QQ->
MKRY"H^,\$W381SM)38]4 M=%K?,RS"*VXYJK&^%)&[[(V:MQ3QZYV[D\'L_C
MHAX9I(PIJW0TOD(M^[,H./-)P?-3\!(R;Q9(HDL\KFK"@2.BY1S'0_PIH4,\
MLV$L=,AO?JS0X4<)%LYRR%V]MG]:OKJ^K-:7DWNQ* 7YC9)"SA.G"XE-Q8.M
MD3,>FK;!JPET^&E(&Y-.4#*P$%!<%,WTH@U&HFR.!\"*:FTFK^7"G4=A C^/
MN(8-,-DBP+Q'WMW C[/($]G>3:0L6<9PIK.]I>Q \D:G>_-[PZQD]@.^L[*D
MO.FYL',:EH!<O/EM35V;97B9HE28JK6H@UJ42QKI2?6R=D5.JKNU2OF8U+_7
MKZHG]0V1ZU8[K4CSJ)@?>MIFF2I)^<,&E,5#LC_&B#[)[Y/\_A#R6P%;WZ4^
M*PV<:3GA3%L@Q:U@##O]TNLH:B0?X+G#$5<[HDUOD^RXN%-]7R+'EM,W/OG;
M'\_?9CVG<\6+ZY,,_RXR?#-*J[1-UB3'O&QI6/!)9$_$L5PPZUU>>>&-SK9_
M)XG%"W%V)0]'69H';ZK72<T,R"DDJ>Q"':M)=T3HTAQR2 S?B]V8X_Y8/,MP
M\E&X@WQ1S3'Z\*/M=ZSM_P=02P,$%     @ D(M048/2DTCQ)@  J"D  !<
M  !M;7-I+3(P,C Q,#$S>#AK,# Q+FIP9\UZ=U13W[;N1D140 1!%(%(#45
MFB M@E+]T870$1 I$5!ZCZB 1#H"2E5::*'W%NF"]!8ZTGMO(83DQG/.O>>\
M<<]XX[[WQQMO9:RQQZI[S94YO_FMM2=QC/@;N*ZNK*8,D%T  #+2#R!. H^!
MRY<N45ZBN$Q)27GERN6KU PTU%14U+?I;] RL#*#V%B965CN<@F![W+<XV1A
MX97DNW=?1%Q<' 1^*"<E*BLD)B[Z9Q*R*U>N4%-1WZ*AN27*SL(N^G^<B#\
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M!R91V(#1K\]5X9)W-SM288HK\_BBE[JS6N.OE25%?H-Z2^;W#B4]<F\V9'7
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M",0E'O9P$AY50HZVTW"7<X[D>&A4E!,T^6]*:N1'SLGE1Y2.'A$!JLGP!T1
M-?6(X]0RE<6O2]J6RZ/MBJ]D#A+\*7O84_-XO]38QW!-U@15&)K>R7'@*KS]
M6VM'A CP5(>;*#G>:&&6GF*9UO"),7VX;E@Z.IJ2O9[*@[$<.<JWAMG#>AK*
MW,'#A)>U6G2KT1LXV?A7DR#V!?AV\6+ -^WYY:2S$,V"^Z5!,D?UB7BFG\-:
M1[!#1IJV\*S)2S45P592EY[01/96YSO3>24H!;TJ.GQ8.,%>81MRZ[4TFVHN
M>DYJ!+YJV$A""WA[T81*;LAP/MA+8L.=8*MW'IY%!/H?#!'P15B=?RU !8G
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MDCC^'U!+ 0(4 Q0    ( )"+4%$^/'C>1@,  +(+   1              "
M 0    !M;7-I+3(P,C Q,#$S+GAS9%!+ 0(4 Q0    ( )"+4%$1N\Q":04
M &8\   5              "  74#  !M;7-I+3(P,C Q,#$S7VQA8BYX;6Q0
M2P$"% ,4    " "0BU!1SSAE78L$   I)P  %0              @ $1"0
M;6US:2TR,#(P,3 Q,U]P<F4N>&UL4$L! A0#%     @ D(M0460Y9^@0+
M\WD! !P              ( !SPT  &UM<VDM,C R,#$P,3-E>#$P,3=C8F$R
M82YH=&U02P$"% ,4    " "0BU!1_Y,1@ V\  !=0 @ '
M@ $9.@  ;6US:2TR,#(P,3 Q,V5X,3 R.# Y83DY+FAT;5!+ 0(4 Q0    (
M )"+4%%5B8?I.0\  .(R   <              "  6#V  !M;7-I+3(P,C Q
M,#$S97@Y.3%F.3-A9C0N:'1M4$L! A0#%     @ D(M0498>7UG5(   &^<
M !0              ( !TP4! &UM<VDM,C R,#$P,3-X.&LN:'1M4$L! A0#
M%     @ D(M048/2DTCQ)@  J"D  !<              ( !VB8! &UM<VDM
H,C R,#$P,3-X.&LP,#$N:G!G4$L%!@     (  @ *@(   !. 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
